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C
erebral white matter lesions and asymptomatic brain infarcts are common in elderly 
people.1-3 These brain lesions are thought to result from cerebral small vessel dis-
ease, and their presence and severity increase with age and the presence of arterial 
hypertension.2-4 There is widespread belief that cerebral small vessel disease plays a role in 
the aetiology of dementia. Small vessel disease is commonly regarded as the primary pa-
thology in subcortical ischemic vascular dementia, one of the subtypes of vascular demen-
tia.5-7 Furthermore, vascular factors, including cerebral small vessel disease, are increasingly 
recognized to be involved in the aetiology of Alzheimer’s disease.8 However, there is hardly 
any evidence from prospective population-based studies to support these notions.
The vascular depression hypothesis implies that there is a subtype of depression occur-
ring in late-life that is characterized by a distinct clinical presentation and an association 
with cerebrovascular disease.9 According to this hypothesis, small vessel disease may also 
be involved in the aetiology of depression in older people.10,11 Again, this relationship has 
hardly been studied prospectively in the general population.
The objective of this thesis was to provide evidence for an aetiologic role of small vessel 
disease in dementia and depression. For this goal we prospectively investigated the asso-
ciation of both presence, severity and progression of small vessel disease with the develop-
ment of cognitive decline, dementia and depression in the Rotterdam Scan Study, a large 
population-based MRI study in elderly people.2 In chapter 2, we ﬁ rst study the relationship 
between cerebral small vessel disease on MRI and decline in executive function and memory 
(chapter 2.1). Second, we assess the association between asymptomatic brain infarcts and 
the risk of dementia and cognitive decline (chapter 2.2), and the association between cer-
Figure 1. Lacunar infarct (arrow) in the 
right putamen.
Figure 2. Cerebral white matter lesions in 
the periventricular and subcortical region.
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ebral white matter lesions and dementia (chapter 2.3). We also investigate the association 
between homocysteine, a risk factor for cerebral small vessel disease, and cognitive function 
(chapter 2.4). Whether brain infarcts and white matter lesions increase the risk of depression 
is evaluated in chapter 3. Chapter 4 focuses on the assessment and relevance of progression 
of white matter lesions. We compare different methods for the measurement of progression 
of white matter lesions (chapter 4.1). Next, we investigate the rate of progression of white 
matter lesions, and determine risk factors for this progression (chapter 4.2). Finally, we ex-
plore whether  progression of white matter lesions is related to the risk  of stroke, cognitive 
decline, dementia and depression (chapter 4.3). In chapter 5, we reﬂ ect on our main ﬁ ndings 
and discuss several methodological and conceptual issues related to the topic of this thesis, 
and speculate on the implications of our results.
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72.1
Cererebral small vessel disease
and decline in information
processing speed and memory
Cerebral small vessel disease is common in elderly people and may contribute to the development of 
dementia. The objective of the present study was to evaluate the relationship between measures of cer-
ebral small vessel disease on MRI and rate of decline in speciﬁ c cognitive domains in 832 participants 
from the prospective, population-based Rotterdam Scan Study. Participants were 60 to 90 years of age 
and free from dementia at baseline in 1995 to 1996. White matter lesions (WML), cerebral infarcts and 
generalized brain atrophy were assessed on baseline MRI. We performed neuropsychological testing 
at baseline and repeatedly in 1999 to 2000, and in 2001 to 2003. We used random-effects models for 
repeated measures to examine the association between quantitative MRI measures and rate of decline 
in global cognitive function, information processing speed, and memory. There were a total of 2266 as-
sessments for the 832 participants in the study, with an average time from the initial to last assessment 
of 5.2 years. Periventricular WML, brain infarcts, and generalized brain atrophy on MRI were associ-
ated with the rate of decline in cognitive function. These structural brain changes were speciﬁ cally as-
sociated with decline in information processing speed. The associations between MRI measures of cer-
ebral small vessel disease and cognitive decline did not change after additional adjustment for vascular 
risk factors or depression. After exclusion of participants with an incident stroke, the associations of 
periventricular WML and brain infarcts with information processing speed were no longer signiﬁ cant, 
which may indicate that stroke plays an intermediate role in the relationship between cerebral small 
vessel disease and cognitive decline. Our results suggest that in elderly people cerebral small vessel 
disease may contribute to the development of dementia by affecting information processing speed.
Abstract
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INTRODUCTION
There is increasing evidence that cerebral small vessel disease contributes to the develop-
ment of cognitive decline and dementia.1,2 Cerebral small vessel disease can be visualized 
on MRI as white matter lesions (WML) and lacunar infarcts.3,4 Generalized brain atrophy on 
MRI is a characteristic ﬁ nding in AD,5,6 but is also associated with vascular risk factors and 
small vessel disease.7 Both the presence of brain infarcts, and severity of WML and general-
ized brain atrophy on MRI, are associated with an increased risk of dementia.8,9 A diagnosis 
of dementia is often preceded by a preclinical phase of many years.10 During this phase, 
people already perform less well on psychometric tests.11,12 A sharp decline in psychometric 
performance is observed at the time that the ﬁ rst clinical changes in cognitive functioning 
and behavior start to interfere with activities of daily living.13
Establishing the temporal relationship between cerebral small vessel disease and cogni-
tive decline in the general population may provide evidence for a causal role of cerebral 
small vessel disease in the etiology of dementia. It will also help answering the question 
whether small vessel disease differentially affects information processing speed, since the 
typical cross-sectional ﬁ ndings in individuals with WML and lacunar infarcts are sugges-
tive of disconnection of fronto-subcortical structures.14,15 The objective of the present study 
was to evaluate the relationship between measures of cerebral small vessel disease on MRI 
and rate of decline in speciﬁ c cognitive domains in a large sample of community-dwelling 
elderly.
METHODS
Participants
The Rotterdam Scan Study is a prospective, population-based cohort study, designed to 
study causes and consequences of age-related brain changes on MRI in the elderly. The 
characteristics of the 1077 participants have been described previously.15 All participants 
were free of dementia at baseline. Baseline examination in 1995 to 1996 comprised a struc-
tured interview, neuropsychological tests, physical examination, blood sampling, and all 
participants underwent an MRI scan of the brain. Each participant gave informed consent 
to protocol, which was approved by the medical ethics committee of the Erasmus Medical 
Center Rotterdam.
In 1999 and 2000, we reinvited 973 participants for a second examination with a protocol 
similar to that of the baseline examination; of those invited 787 participated (81%). The re-
maining 104 participants were not reinvited for the following reasons: 82 had died, 17 had 
been institutionalized, 4 had moved abroad, and 1 could not be reached. In 2001 and 2003, 
we reinvited 844 participants for a third examination that comprised an interview, physical 
examination, and neuropsychological tests; of those invited 653 participated (response 79%). 
NP21.indd   8 09-02-2004, 12:14:53
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The remaining 233 participants were not reinvited for the following reasons: 187 had died, 
29 had been institutionalized, 11 had moved and could not be reached, and for 6 participants 
the invitation was postponed for logistical reasons. The present study is based on 832 par-
ticipants who had at least one follow-up neuropsychological assessment. 
Magnetic Resonance Imaging procedure
We made axial T1-, T2-, and proton density weighted scans on 1.5-Tesla MRI scanners (MR 
Gyroscan, Philips, Best, the Netherlands and MR VISION, Siemens, Erlangen, Germany). 
The slice thickness was 5 or 6 mm (scanner dependent) with an interslice gap of 20%.16 WML 
severity was graded for periventricular and subcortical areas separately. Periventricular 
WML were scored semiquantitatively (range: 0 to 9). For subcortical WML, a total volume 
was approximated, based on number and size (range: 0 to 29.5 ml).17 Cerebral infarcts were 
deﬁ ned as focal hyperintensities on T2-weighted images, 3 mm in size or larger, and with 
a corresponding prominent hypointensity on T1-weighted images.8 Generalized brain atro-
phy was scored on T1-weighted images. Cortical atrophy was rated on a semiquantitative 
scale (range 0 to 15) using reference scans. Subcortical atrophy was measured by the ventri-
cle-to-brain ratio (range: 0.21 to 0.45).18
Cognitive decline
Participants underwent the following neuropsychological tests at the baseline and follow-
up examinations: the Mini-Mental State Examination,19 the Stroop test,20,21 the Letter-Digit 
Substitution Task,22,23 a verbal ﬂ uency test (animal categories),24 and a 15-word verbal learn-
ing test (based on Rey’s recall of words).25 We used parallel versions of the same tests at the 
follow-up examinations. For each participant, we calculated z scores (individual test score 
minus mean test score divided by the standard deviation) for the tests at baseline and follow-
up using the mean and standard deviation of the baseline tests. We constructed compound 
scores for global cognitive function (Cognitive Index), information processing speed, and 
memory. The compound score for global cognitive function was the average of the z scores 
of the Stroop test (sum of the reading, color naming and interference subtask), the Letter-
Digit Substitution Task (number of correct digits in one minute), the verbal ﬂ uency test 
(number of animals in one minute), and the immediate and delayed recall of the 15-word 
verbal learning test. The compound score for information processing speed was the average 
of the z scores for the Stroop test (sum of the reading, color naming and interference sub-
task) and the Letter-Digit Substitution Task (number of correct digits in one minute). The 
compound score for memory was the average of the z scores for the immediate and delayed 
recall of the 15-word verbal learning test. 
Ascertainment of dementia
All participants were free of dementia at baseline. We screened all participants for de-
mentia at follow-up with the Mini-Mental State Examination (MMSE)19 and the Geriatric 
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Mental State Schedule.26 Screenpositive subjects were evaluated using the Cambridge Men-
tal Disorders of the Elderly Examination (CAMDEX) diagnostic interview.27 Participants 
who were suspected of having dementia based on their CAMDEX performance were exam-
ined by a neurologist, and underwent additional neuropsychological testing. In addition, 
we continuously monitored the medical records of all participants at the general practition-
ers ofﬁ ce, and at the Regional Institute for Outpatient Mental Health Care (RIAGG) to obtain 
information on interval cases of dementia until April 1st 2002.8
Other baseline measurements
The following baseline variables were used as possible confounders: age (continuously per 
year); sex; educational status,28 disturbances of mood (deﬁ ned as a Center of Epidemiologic 
studies Depression Scale (CES-D) score of 16 or higher),29 Apolipoprotein E (APOE) geno-
type,30 (dichotomized into carriers and non-carriers of the APOE ε4 allele). Incident stroke 
during follow-up was assessed through self-report and checking of medical records, and 
veriﬁ ed by a neurologist.8
Data analysis
To examine the association between quantitative MRI measures and rate of cognitive decline 
we used random-effects models for repeated measures (PROC MIXED with residual maxi-
mum likelihood method; SAS Systems for Windows release 6.12; SAS Institute, Cary, NC). 
Random-effects modeling of longitudinal data can be conceptualized as a method in which 
regression coefﬁ cients to account for within-subject change of scores across time are simul-
taneously estimated for all individuals in the sample, and in the same analysis, between sub-
ject predictors of these within-subject change indices are evaluated.31 This approach utilizes 
all available data and accounts for within-person correlation across time, which results in 
increased statistical power for estimating effects.32,33 We included random-effect terms to ac-
count for differences between participants in cognitive performance at baseline and in rate 
of cognitive decline. To account for effects on baseline cognitive performance we included 
terms for age, sex, and education. Age was the only demographic variable that was related 
to cognitive decline in preliminary analyses, so we included a term to account for the effect 
of age on rate of cognitive decline.
First, we evaluated the association between MRI measures and cognitive performance 
at baseline and rate of cognitive decline, by adding terms individually to the models. We 
analyzed periventricular and subcortical WML, and subcortical and cortical brain atrophy 
in quintiles of their distributions to study the shape of the associations, and continuously 
per standard deviation. Brain infarcts were analyzed as present versus absent. Second, we 
adjusted for incident stroke, vascular risk factors and depressive symptoms. Third, we stud-
ied the association of the MRI measures with cognitive decline, conditional on other MRI 
measures, by entering all MRI measures jointly in the same model. Fourth, we examined 
possible interaction of MRI measures with APOE in relation to cognitive decline, by in-
NP21.indd   10 09-02-2004, 12:14:55
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cluding effects for the interaction of the MRI measures with presence versus absence of the 
APOE ε4 allele in the models. Finally, we repeated the analyses on the association between 
MRI measures and cognitive decline after exclusion of participants with incident dementia 
during follow-up.
RESULTS
Table 1 gives the baseline characteristics of the study population. People without a fol-
low-up examination were older, less educated, performed worse on the Mini-Mental State 
Examination, and had more severe periventricular WML and cortical atrophy at baseline, 
compared to people with a follow-up examination (table 1). Two hundred thirty partici-
pants (28%) had two neuropsychological assessments, and 602 (72%) had three assessments, 
contributing to a total of 2266 assessments. Average time from the initial to last assessment 
was 5.3 years (SD 1.2; range 2.8 - 7.9). The mean annual decline on the Cognitive Index was 
0.022 points (95% conﬁ dence interval 0.029 to 0.014), on the MMSE 0.031 points (95% conﬁ -
dence interval 0.057 to 0.005), in information processing speed 0.053 points (95% conﬁ dence 
Table 1. Characteristics of the study population
Characteristic
People with a
follow-up
examination
n= 832
People without a 
follow-up
examination
n= 245
P-value for 
difference*
Age, yr 71 76 <0.01
Women, % 53 48 0.12
Primary education only, % 32 44 0.03
Systolic blood pressure, mmHg 146 (21) 150 (23) 0.46
Diastolic blood pressure, mmHg 79 (12) 78 (12) 0.91
Hypertension, % 48 62 0.07
Diabetes, % 6 11 0.07
Depression, no CES-D positive, % 7 9 0.44
MMSE score 28 (2) 27 (3) <0.01
APOE ε4 carriers, %† 27 26 0.74
Periventricular WML, score 2.2 (2.1) 3.2 (2.4) 0.02
Subcortical WML, ml 1.2 (2.5) 2.1 (4.0) 0.16
Subcortical atrophy, VBR 0.31 (0.035) 0.33 (0.036) 0.53
Cortical atrophy, score 5.2 (2.7) 6.8 (3.0) 0.01
Cerebral infarcts, % 23 29 0.92
Values are unadjusted means (SD) or percentages; *age and sex adjusted difference in mean or 
percentage; †APOE genotype was not determined in 79 of the 832 people with a follow-up exami-
nation and in 27 of the 245 people with a follow-up examination.
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interval 0.062 to 0.045), and in memory 0.024 points (95% conﬁ dence interval 0.012 to 0.037). 
Higher age was associated with a higher rate of cognitive decline. For each year increase 
in age, the annual rate of decline on the Cognitive Index increased with 0.004 points (95% 
conﬁ dence interval 0.003 to 0.005), and decline on the MMSE increased with 0.012 points 
(95% conﬁ dence interval 0.009 to 0.016). Age was also associated with decline in information 
processing speed and memory (table 2). Increasing severity of WML and generalized brain 
atrophy, and the presence of brain infarcts were associated with decline on the Cognitive 
Index (ﬁ gure). Per standard deviation increase in periventricular WML severity the annual 
rate of decline on the MMSE increased with 0.035 points (95% conﬁ dence interval 0.003 to 
0.066). Annual decline on the MMSE for people with brain infarcts was 0.085 points (95% 
conﬁ dence interval 0.02 to 0.15) larger than for people without brain infarcts on MRI. Other 
MRI measures were not associated with decline on the MMSE (data not shown). Periven-
tricular WML, brain infarcts, and subcortical and cortical atrophy were associated with 
annual decline in information processing speed, but not with decline in memory (table 
2). Additional adjustment for vascular risk factors or depressive symptoms did not change 
the estimates (data not shown). During follow-up 42 participants developed a stroke. After 
exclusion of participants with an incident stroke, the associations of periventricular WML 
and brain infarcts with change in information processing speed were no longer signiﬁ cant 
(regression coefﬁ cient per standard deviation increase in periventricular WML -0.007 (95% 
conﬁ dence interval -0.016 to 0.002), for presence of brain infarcts -0.006 (95% conﬁ dence 
interval -0.025 to 0.014)), whereas the associations of generalized brain atrophy with change 
in information processing speed remained (regression coefﬁ cient per standard deviation 
Table 2. Association of age and MRI measures with decline in information processing speed 
and memory.
Variable
Information processing speed Memory
Estimate 95% CI Estimate 95% CI
Age (per year increase) -0.006 (-0.007; -0.004) -0.002 (-0.004; -0.000)
Periventricular WML (per 
SD increase) 
-0.015 (-0.024; -0.006) -0.003 (-0.018; 0.012)
Subcortical WML (per SD 
increase) 
-0.008 (-0.018; 0.003) -0.003 (-0.019; 0.013)
Brain infarcts (yes vs. no) -0.020 (-0.040; 0.000) 0.009 (-0.022; 0.040)
Subcortical atrophy (per 
SD increase)
-0.014 (-0.023; -0.005) 0.000 (-0.013; 0.014)
Cortical atrophy (per SD 
increase)
-0.030 (-0.040; -0.020) 0.007 (-0.009; 0.022)
Estimates are regression coefﬁ cients (95% conﬁ dence interval) for annual decline in z score. All 
models are controlled for age, sex, education, and the interaction of age with time.
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increase in subcortical atrophy -0.010 (95% conﬁ dence interval -0.019 to -0.002), and per 
standard deviation increase in cortical atrophy -0.023 (95% conﬁ dence interval -0.032 to -
0.014)). When MRI measures were analyzed conditional on each other, the association with 
information processing speed remained signiﬁ cant for periventricular WML, subcortical 
atrophy, and cortical atrophy. The associations of periventricular WML, brain infarcts, sub-
cortical and cortical atrophy with information processing speed attenuated, but remained 
signiﬁ cant after exclusion of participants who developed dementia (n=23) during follow-up. 
No statistically signiﬁ cant interactions were present between MRI measures and presence of 
the APOE ε4 allele, in relation to cognitive decline (data not shown).
DISCUSSION
In this large population-based study, we found that periventricular WML, brain infarcts, 
and generalized brain atrophy on MRI, were associated with the rate of decline in cognitive 
function. These structural brain changes on MRI, which are thought to be caused by small 
vessel disease, were speciﬁ cally associated with decline in information processing speed.
Several methodological issues should be addressed. This study was performed in a 
large number of elderly participants from the general population, who were nondemented 
at baseline, and followed for ﬁ ve years on average. The use of random-effects models in 
combination with the large sample size has lead to precise estimates. However, people who 
participated in this study were younger, more educated, had a higher MMSE score at base-
line, and had less severe periventricular WML and cortical atrophy, compared to people 
who did not undergo a follow-up examination. This attrition is likely to have resulted in 
an underestimation of the association between structural brain changes on MRI and rate of 
cognitive decline. This should be taken into account when generalizing our results to the 
general population at large.
Previously, other population-based studies reported on the relationship between 
indicators of cerebral small vessel disease on MRI and cognitive decline. Garde and col-
leagues reported on the relationship between WML severity and decline in intelligence.34 
We previously reported on the association between WML and decline on the Mini-Mental 
State Examination,35 and between silent brain infarcts and decline in cognitive function.8 
The Cardiovascular Health Study reported that subcortical brain atrophy was associated 
with cognitive decline, whereas brain infarcts, high WML grade, and high sulci width, were 
not.36 They deﬁ ned cognitive decline as a decline of ﬁ ve points or more on the Modiﬁ ed 
Mini-Mental State examination in three years, and used this as a dichotomous variable in 
the analyses. This will have reduced statistical power, and may explain the absence of a 
statistically signiﬁ cant relation with cerebral infarcts, WML, and sulci width. Furthermore, 
WML were analyzed as severe versus non severe, and no distinction was made between 
WML severity in the periventricular and subcortical region. Our observation that WML and 
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infarcts in particular affect speed of information processing is in line with previous ﬁ ndings 
from studies in nondemented older people relating WML and infarcts to cognitive function 
and decline.15,37-39
None of the structural MRI measures were associated with rate of decline in memory. 
Memory decline is a pivotal symptom in dementia, and is particularly related to medial tem-
poral atrophy.40 We previously reported that (silent) brain infarcts, periventricular WML, 
and subcortical brain atrophy increase the risk of dementia.8 The present results suggest that 
WML, infarcts, and generalized brain atrophy contribute to dementia mainly by affecting 
non-memory related cognitive function. However, selective drop out of participants with 
memory decline should also be taken into account. Of the 832 people who participated in 
the present study, 23 (3%) developed dementia during follow-up, compared to 25 (10%) of 
the 245 people who did not participate.
Different pathophysiological mechanisms may underlie the associations of periventricu-
lar WML, cerebral infarcts, and generalized brain atrophy with cognitive decline, and more 
speciﬁ c, decline in information processing speed. In our study, the vast majority (89%) of 
brain infarcts was lacunar, and were located in the basal ganglia and subcortical region.41 
Both lacunar infarcts and WML are thought to result from arteriolosclerosis. Occlusion of 
the arteriolar lumen leads to lacunar infarcts, while critical stenosis of multiple medullary 
arterioles leads to hypoperfusion and widespread incomplete infarction of the cerebral 
white matter.3,42 Lacunar infarcts and WML are thought to interrupt prefrontal subcortical 
loops, which leads to impaired prefrontal lobe functioning, including impaired informa-
tion processing speed.42-44 We observed that adjustment for incident stroke attenuated the 
association of WML and brain infarcts on MRI with cognitive decline, which suggests that 
new infarcts play an intermediate role.8 Furthermore, progression of WML may mediate the 
association between WML and cognitive decline, since WML severity is a strong predictor 
of WML progression.45 Apart from having a direct effect on cognitive function, lacunes and 
WML may also be an indicator of AD encephalopathy. WML and lacunes are frequently 
found in patients with AD, and evidence suggests that these lesions interact with typical AD 
pathology, such as amyloid plaques and neuroﬁ brillary tangles.2 Generalized brain atrophy 
may result from both AD and cerebrovascular disease.5,31 Neuronal loss in cortical associa-
tive areas, as well as cerebrovascular damage to white matter ﬁ ber tracts connecting these 
areas, may explain cognitive decline associated with generalized atrophy.
In conclusion, we showed that measures of cerebral small vessel disease on MRI in non-
demented elderly people are associated with decline in cognitive function, and particularly 
affect information processing speed. Our results contribute to increasing evidence for an 
etiologic role of cerebral small vessel disease in cognitive dysfunction and dementia.
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2.2
Silent brain infarcts
and the risk of
dementia and cognitive decline
Background – Silent brain infarcts are frequently seen on magnetic resonance imaging (MRI) in healthy 
elderly people and may be associated with dementia and cognitive decline. 
Methods – We studied the association between silent brain infarcts and the risk of dementia and cog-
nitive decline in 1015 participants of the prospective, population-based Rotterdam Scan Study, who 
were 60 to 90 years of age and free of dementia and stroke at baseline. Participants underwent neu-
ropsychological testing and cerebral MRI at baseline in 1995 to 1996 and again in 1999 to 2000 and were 
monitored for dementia throughout the study period. We performed Cox proportional-hazards and 
multiple linear-regression analyses, adjusted for age, sex, and level of education and for the presence 
or absence of subcortical atrophy and white matter lesions. 
Results – During 3697 person-years of follow-up (mean per person, 3.6 years), dementia developed in 
30 of the 1015 participants. The presence of silent brain infarcts at baseline more than doubled the risk 
of dementia (hazard ratio, 2.26; 95 percent conﬁ dence interval, 1.09 to 4.70). The presence of silent brain 
infarcts on the baseline MRI was associated with worse performance on neuropsychological tests and 
a steeper decline in global cognitive function. Silent thalamic in farcts were associated with a decline 
in memory performance, and nonthalamic infarcts with a decline in psychomotor speed. When par-
ticipants with silent brain infarcts at baseline were subdivided into those with and those without ad-
ditional infarcts at follow-up, the decline in cognitive function was restricted to those with additional 
silent infarcts. 
Conclusions – Elderly people with silent brain infarcts have an increased risk of dementia and a steeper 
decline in cognitive function than those without such lesions. 
Abstract
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INTRODUCTION
Dementia is a major health problem in Western countries. Dementia will develop in one 
in four 55-year-olds,1 and the number of patients with dementia will rise as life expectancy 
increases. Evidence has accumulated that vascular abnormalities have a role in the develop-
ment of dementia. Patients with stroke are at increased risk for both vascular dementia and 
Alzheimer’s disease.2-4 People who were found at autopsy to have lacunar cerebral infarcts 
were more likely to have had dementia than those without infarcts, and fewer pathological 
ﬁ ndings of Alzheimer’s disease were needed in persons with such infarcts for clinical symp-
toms of dementia to be present.5,6 Patients with Alzheimer’s disease more frequently have 
asymptomatic (i.e., silent) brain infarcts on magnetic resonance imaging (MRI) than do con-
trol subjects without dementia.7,8 The prevalence of silent brain infarcts is also high in elderly 
populations without dementia,9-11 but little is known about their prognostic relevance. We 
therefore examined the relation between silent brain infarcts and the risk of dementia and 
cognitive decline in the general population.
METHODS
Participants 
The Rotterdam Scan Study is a prospective, population-based cohort study designed to 
study the causes and consequences of brain changes in the elderly.12 In 1995 to 1996, we ran-
domly selected 1717 participants 60 to 90 years of age, with stratiﬁ cation according to age 
(in ﬁ ve-year groups) and sex, from two ongoing population-based studies.13,14 A total of 1077 
elderly people without dementia participated (63 percent). Participants were signiﬁ cantly 
younger and more highly educated and performed better on the Mini–Mental State Exami-
nation than nonparticipants.15 The medical ethics committee of the Erasmus Medical Center 
approved the study, and each participant gave written informed consent.
The baseline examination in 1995 to 1996 comprised a structured interview, physical 
examination, blood sampling, and neuropsychological tests at the research center, as well 
as a cerebral MRI scan. For the present study we excluded 62 participants with a history of 
stroke before the baseline evaluation (Fig. 1).16 We monitored all 1015 participants through-
out the study by reviewing medical records from their general practitioners after baseline 
for death and major complications, including cognitive problems, dementia, stroke, and 
transient ischemic attack. In 1999 to 2000, we reinvited 914 of the 1015 participants for a 
second examination, of whom 739 participated (81 percent) (Fig. 1). The remaining 101 par-
ticipants were not reinvited, for the following reasons: 75 had died, 15 had been institution-
alized for dementia, 7 had already been examined in 1999 as part of the regular examination 
for the Rotterdam Study,14 3 had moved abroad, and 1 could not be reached.
People who were ineligible or who declined to undergo the second examination were 
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signiﬁ cantly older, were less highly 
educated, and performed worse on the 
neuropsychological tests at baseline than 
participants in the second examination. 
People who declined to undergo the 
second examination did not differ sig-
niﬁ cantly from those who participated 
with respect to the presence or absence of 
silent brain infarcts at baseline, whereas 
ineligible participants had a nonsigniﬁ -
cantly higher prevalence of silent brain 
infarcts than participants (absolute age- 
and sex-adjusted difference, 5 percent; 
95 percent conﬁ dence interval, -3 to 14 
percent). Thirteen of the 739 participants 
were ineligible to undergo a second MRI 
of the brain because of a contraindication 
to MRI, and 97 declined to undergo the 
procedure. In total, 629 of the 901 eligible 
participants (70 percent) underwent a sec-
ond MRI in 1999 to 2000.
Cerebral infarcts and other MRI 
measures
All 1015 participants underwent MRI of 
the brain at baseline in 1995 to 1996. We 
made axial T1-weighted, T2-weighted, 
and proton-density-weighted scans on 
1.5-Tesla MRI scanners (MR Gyroscan, Philips, or MR VISION, Siemens).11 In 1999 to 2000, 
629 participants underwent a second MRI with use of the MR VISION scanner and the same 
sequences.
The presence of brain infarcts was rated similarly at baseline and follow-up. We deﬁ ned 
brain infarcts as areas of focal hyperintensity on T2-weighted images that were at least 3 mm 
in diameter. Proton-density scans were used to distinguish infarcts from dilated perivas-
cular spaces. Areas of hyperintensity in the white matter also had to have corresponding 
prominent hypointensity on T1-weighted images, in order to distinguish them from cerebral 
white matter lesions. A single trained physician who was unaware of the patients’ history 
of stroke and transient ischemic attack scored infarcts on both the baseline and second MRI 
with respect to their location and size. An intrarater study for detecting infarcts (110 images 
randomly selected from both scanners) showed good agreement (κ=0.80).
Figure 1. Flow diagram of the study population.
The various study samples are indicated by 
double-lined boxes. MRI denotes magnetic reso-
nance imaging.
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We obtained information on any history of stroke and transient ischemic attack from the 
participants themselves and by checking medical records of all participants, independently 
of their MRI results. An experienced neurologist subsequently reviewed the participants’ 
medical history and scans and categorized infarcts as silent or symptomatic. We deﬁ ned 
silent brain infarcts as evidence on MRI of one or more infarcts, without a history of a (cor-
responding) stroke or transient ischemic attack. If a prior stroke or transient ischemic attack 
did correspond with a lesion, the latter was deﬁ ned as a symptomatic infarct. The intrarater 
reliability for the classiﬁ cation of infarcts as silent or symptomatic was excellent (κ=1.0). If 
participants had both symptomatic and silent infarcts, they were included in the group with 
symptomatic infarcts.
White matter lesions and subcortical atrophy of the brain were rated on the baseline 
MRI scans.12 White matter lesions were considered present if they were hyperintense on 
proton-density and T2-weighted images, without prominent hypointensity on T1-weighted 
scans. The severity of periventricular white matter lesions was determined by adding three 
region-speciﬁ c scores (grades ranged from 0 to 9, with higher grades indicating greater 
severity). The volume of subcortical white matter lesions was approximated on the basis 
of the number and size of lesions (volume range, 0 to 29.5 ml). The severity of subcortical 
atrophy of the brain was estimated by calculating the ratio of ventricle to brain (the average 
of assessments at the frontal and occipital horns and the caudate nucleus) on T1-weighted 
images.17 Both intrareader and interreader studies (100 of each) showed good-to-excellent 
agreement.12
Dementia
All participants were free of dementia at baseline. We screened all participants for demen-
tia at follow-up using the Mini–Mental State Examination and the Geriatric Mental State 
Schedule.1 Participants who were positive at screening underwent additional cognitive 
testing with the Cambridge Mental Disorders of the Elderly Examination. People who were 
then thought to have dementia were examined by a neurologist and underwent extensive 
neuropsychological testing. In addition, we continually monitored the medical records of 
all participants at their general practitioners’ ofﬁ ces and the Regional Institute for Ambula-
tory Mental Health Care to obtain information on newly diagnosed dementia until March 
1, 2000. Dementia and its subtypes were diagnosed by a panel that reviewed all available 
information according to standardized criteria.18-20 The onset of dementia was deﬁ ned as the 
date on which the clinical symptoms allowed the diagnosis of dementia to be made. We had 
complete follow-up data for dementia on all participants through our system of monitoring 
general practitioners.
Cognitive decline
Participants underwent the following neuropsychological tests at the baseline examination: 
the Mini Mental State Examination, the 15-word verballearning test, the Stroop test, the Pa-
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per-and-Pencil Memory Scanning Task, and the Letter–Digit Substitution Task.15 We used 
alternative versions of the same neuropsychological tests at the second examination. For 
each participant, we calculated z scores (individual test score minus mean test score divided 
by the standard deviation) for the neuropsychological tests at baseline and at follow-up us-
ing the mean and standard deviation of the baseline tests. We constructed compound scores 
for memory performance by averaging the z scores of the total of three immediate recall tri-
als and the delayed-recall trial of the 15-word verbal-learning test. The compound score for 
psychomotor speed was the average of the z scores for the reading subtask of the Stroop test, 
the one-letter subtask of the Paper-and-Pencil Memory Scanning Task, and the Letter–Digit 
Substitution Task. The compound score for global cognitive function was constructed by 
calculating the average of the z scores for all the above tests.15 Cognitive decline was calcu-
lated by subtracting the z scores for memory performance, psychomotor speed, and global 
cognitive function at baseline from the z scores at follow-up.
Statistical analysis
First, we used Cox proportional-hazards regression analysis to examine the relation be-
tween the presence of silent brain infarcts at baseline and the risk of subsequent dementia 
in the 1015 participants who were free of dementia and stroke at baseline. The duration of 
follow-up was calculated from the date of the MRI at baseline until death, the diagnosis of 
dementia, or the end of follow-up, whichever came ﬁ rst. We also investigated the associa-
tion of white matter lesions and subcortical atrophy of the brain with dementia and whether 
these structural changes in the brain affected the relation between silent brain infarcts and 
dementia. Second, we estimated the association between the presence of silent brain inf-
arcts at baseline and subsequent cognitive decline by multiple linear-regression analysis in 
the subsample of 739 participants who underwent neuropsychological tests at follow-up. 
We also investigated whether this relation with cognitive decline differed between silent 
in farcts in the thalamus and infarcts elsewhere, because thalamic nuclei are involved in 
storage and short-term memory.21,22 Third, we examined the contribution of newly detected 
silent infarcts to the rate of cognitive decline. This analysis was based on 619 participants 
without symptomatic infarcts on the second MRI (Fig. 1).
We adjusted all analyses for age, sex, and level of education. In the analyses of cognitive 
decline, we also adjusted for the interval between the two sets of neuropsychological tests.
RESULTS
During 3697 person-years of follow-up (mean per person, 3.6 years), dementia developed 
in 30 participants (3 percent), 26 of whom had Alzheimer’s disease (1 with cerebrovascular 
disease), 2 vascular dementia, and 1 multisystem atrophy; in 1, the subtype was unknown. 
Four patients with dementia died, but no autopsy was performed.
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Table 1. Baseline characteristics of all participants who were free of dementia and stroke in 
1995 to 1996, those who underwent the second neuropsychological examination, and those 
who underwent the second MRI scan in 1999 to 2000.*
Characteristic
All
participants
(N=1015)
Participants
who underwent
2nd examination
(N=739
Participants 
who underwent 
2nd MRI
(N=619)
Age — yr 72.1±7.4 70.9±7.0 70.7±7.0
Women — no. (%) 526 (52) 390 (53) 320 (52)
Primary education only — no. (%) 357 (35) 235 (32) 191 (31)
MMSE score† 27.4±2.2 27.6±2.1 27.6±2.0
Hypertension — no. (%) 517 (51) 357 (48) 291 (47)
Diabetes mellitus — no. (%) 66 (7) 42 (6) 33 (5)
Use of aspirin — no. (%) 109 (11) 71 (10) 49 (8)
Use of oral anticoagulants — no. (%) 41 (4) 24 (3) 20 (3)
APOE e4 carriers — no. (%)‡ 267 (29) 206 (30) 171 (30)
Silent brain infarcts — no. (%) 217 (21) 148 (20) 116 (19)
Thalamic 32 (3) 20 (3) 14 (2)
Nonthalamic 185 (18) 128 (17) 102 (16)
White-matter lesions
Periventricular — grade 2.3±2.2 2.1±2.1 2.0±2.1
Subcortical — ml 1.3±2.8 1.1±2.4 1.1±2.5
Ratio of subcortical brain atrophy 0.32±0.04 0.31±0.04 0.31±0.04
* Plus–minus values are unadjusted means ±SD. MRI denotes magnetic resonance imaging.
† The score on the Mini–Mental State Examination (MMSE) can range from 0 to 30, with higher 
scores indicating better cognitive function.
‡ The apolipoprotein E (APOE) genotype was not determined in 97 of the 1015 participants, 63 of 
the 739 who underwent the second examination, and 55 of the 619 who underwent the second 
MRI.
Table 1 shows the baseline characteristics of the participants. Eleven of the 217 partici-
pants with silent brain infarcts at baseline had cortical infarcts, 202 had lacunar infarcts – 171 
in the basal ganglia and 31 in the subcortex – and 4 had infarcts in the cerebellum or brain-
stem. Fourteen of the 30 participants in whom dementia developed had one or more silent 
brain infarcts present on the baseline MRI, 7 of whom had multiple infarcts.
The presence of silent brain infarcts at baseline more than doubled the risk of dementia, 
and this result remained largely unchanged after adjustment for the severity of white matter 
lesions and subcortical atrophy (Table 2). A greater severity of periventricular white mat-
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Table 2. Relation between the presence of silent brain infarcts at baseline, the severity of 
periventricular and subcortical white matter lesions, and the risk of dementia.
Variable
Hazard ratio (95% conﬁ dence interval)
Adjusted for age, 
sex, and level of 
education
Adjusted for age, sex, 
level of education, 
and MRI measures*
Silent brain infarcts (yes vs. no) 2.26 (1.09–4.70) 2.03 (0.91–4.55)
Severity of periventricular white matter lesions
(per SD increase)
1.59 (1.13–2.25) 1.47 (0.92–2.35)
Severity of subcortical white matter lesions
(per SD increase)
1.21 (0.96–1.53) 0.92 (0.65–1.29)
* The magnetic resonance imaging (MRI) measures adjusted for were presence or absence of silent 
brain infarcts, severity of periventricular and subcortical white matter lesions, and severity of sub-
cortical brain atrophy.
ter lesions was also associated with an increased risk of dementia (Table 2), as was greater 
severity of subcortical atrophy of the brain hazard ratio per increase of 1 SD in severity, 1.78; 
95 percent conﬁ dence interval, 1.26 to 2.51).
There was no signiﬁ cant difference in risk between participants with Mini–Mental State 
Examination scores below 26 and those with a score of 26 or above at baseline or between 
carriers of the apolipoprotein E ε4 allele and noncarriers. The exclusion of participants who 
used aspirin or oral anticoagulants at baseline did not materially change the results. Nine-
teen of the 30 participants in whom dementia developed underwent a second cerebral MRI 
or computed tomographic scan; a symptomatic infarct was found in 3 (16 percent) and a 
new silent brain infarct was found in 4 (21 percent). This rate was higher than that among 
the 618 participants without dementia at follow-up, of whom 8 (1 percent) had a sympto-
matic brain infarct and 71 (11 percent) a silent brain infarct on the second MRI scan.
Global cognitive function was signiﬁ cantly worse in participants with silent brain in-
farcts on the baseline MRI than in those without such infarcts (adjusted mean difference 
in z score, -0.11; 95 percent conﬁ dence interval, -0.20 to -0.01). The presence of silent brain 
infarcts at baseline was associated with a steeper decline in cognitive function (Table 3). 
The presence of multiple silent infarcts showed a stronger relation with cognitive decline 
than the presence of single silent infarcts (adjusted mean difference in z score for multiple 
infarcts, -0.34; 95 percent conﬁ dence interval, -0.51 to -0.17; and for single infarcts, -0.07; 95 
percent conﬁ dence interval, -0.20 to 0.06). Silent infarcts in the thalamus were associated 
with a greater decline in memory performance, whereas infarcts located elsewhere resulted 
in a greater decline in psychomotor speed (Table 3). There was no association between the 
presence of silent brain infarcts at baseline and a decline in the Mini–Mental State Examina-
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Table 3. Association between the presence of silent brain infarcts on magnetic resonance 
imaging in 1995–1996 and subsequent cognitive decline.*
Variable
Silent brain infarcts
All Thalamic Nonthalamic
decline in z score (95% CI)
Memory performance -0.01 (-0.16 to 0.15) -0.50 (-0.87 to -0.13) 0.06 (-0.10 to 0.23)
Psychomotor speed -0.19 (-0.34 to -0.04) -0.11 (-0.36 to 0.13) -0.20 (-0.36 to -0.05)
Global cognitive
function
-0.15 (-0.27 to -0.02) -0.28 (-0.50 to -0.06) -0.13 (-0.26 to 0.001)
* Values are the mean differences in the z scores between follow-up and baseline, with 95 percent 
conﬁ dence intervals (CIs) between those with and those without silent brain infarcts, adjusted for 
age, sex, level of education, and interval between neuropsychological tests. A positive value indi-
cates an increase in the z score.
tion score (adjusted mean difference in the score, -.01; 95 percent conﬁ dence interval, -0.44 
to 0.33).
When participants were subdivided into four groups according to the presence or ab-
sence of silent brain infarcts on the baseline and follow-up MRI, the decline in cognitive 
function was restricted to those with new silent brain infarcts on the follow-up scan, regard-
less of whether they had silent infarcts at baseline (Fig. 2). Memory performance improved 
for all participants, as expected owing to the learning effect. There were no signiﬁ cant 
changes in scores on the Mini–Mental State Examination among the various groups.
DISCUSSION
We found that the presence of silent brain infarcts on MRI at baseline in the general popula-
tion doubled the risk of dementia. People with silent infarcts had a steeper decline in cogni-
tive function than those without silent infarcts, but this decline was conﬁ ned to people who 
had additional silent brain infarcts after baseline.
The strengths of this study are the large number of elderly participants and its popula-
tion-based design. Furthermore, we had no losses to follow-up for the analyses of dementia. 
Notwithstanding good-to-excellent intrareader agreement, we still may have incorrectly 
identiﬁ ed brain infarcts or misclassiﬁ ed infarcts as silent or symptomatic. However, be-
cause silent brain infarcts were identiﬁ ed and classiﬁ ed in a blinded fashion from data on 
dementia and neuropsychological tests, any misclassiﬁ cation would have resulted in an 
underestimation of the associations.
The dementia diagnoses in our study were clinical diagnoses. We intentionally refrained 
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Figure 2. Mean change in memory per-
formance, psychomotor speed, and global 
cognitive function among participants with 
and those without silent brain infarcts on 
magnetic resonance imaging at baseline 
(1995 to 1996) and at follow-up (1999 to 
2000), after adjustment for age, sex, level 
of education, and interval between neu-
ropsychological tests.
Bars are 95 percent conﬁ dence intervals. P 
values are for the comparison with partici-
pants who did not have infarcts at baseline 
or follow-up.  
from analyzing subtypes of dementia, 
because a distinction based on clinical 
information is hard to make, especially 
in elderly people, in whom dementia 
often is a heterogeneous disorder. There 
is increasing evidence that vascular fac-
tors may contribute to the development 
of Alzheimer’s disease.23,24 After a stroke, 
dementia, including Alzheimer’s disease, 
develops in approximately 30 percent of 
patients with symptomatic infarcts.2-4 We 
found that silent brain infarcts increase 
the risk of dementia, the majority of cases 
of which in our study were of the Alzhei-
mer’s subtype. Furthermore, we showed 
that a greater severity of periventricular 
white matter lesions, also thought to re-
sult from small vessel disease, was associ-
ated with an increased risk of dementia.
Our ﬁ ndings of a large number of new 
infarcts in the participants in whom de-
mentia developed and a steeper decline 
in cognition in those with a new infarct 
support the notion that people with silent 
brain infarcts are at high risk for additional infarcts, both silent and symptomatic,25 which 
may contribute to dementia. Perhaps an infarct in a brain already affected by Alzheim-
er’s disease–related abnormalities further impairs cognition, leading to clinically evident 
dementia. This notion is supported by autopsy ﬁ ndings showing that fewer plaques and 
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tangles led to clinical Alzheimer’s disease in the presence of lacunar in farcts.5 Alternatively, 
silent brain infarcts may trigger the development of senile plaques and neuroﬁ brillary 
tangles or reﬂ ect cerebral vulnerability or a certain vascular risk proﬁ le that enhances the 
abnormalities associated with Alzheimer’s disease. However, several clinicopathological 
studies found that patients with Alzheimer’s disease who had infarcts had a similar amount 
of plaques and tangles or even fewer than those without in farcts.26-29
We found that silent brain infarcts – those without relevant stroke symptoms – are as-
sociated with worse cognition, conﬁ rming the results of a cross-sectional study.9 Recently, 
we reported that the presence of periventricular white matter lesions is associated with a 
steeper cognitive decline,30 and we have now found that this is also true for silent brain 
infarcts. That the relation between infarcts and cognitive decline was stronger for multiple 
infarcts than for single infarcts strengthens these ﬁ ndings. Furthermore, we found that this 
decline in cognitive function was conﬁ ned to persons with incident silent infarcts, which 
may suggest a stepwise decline after an infarct occurs.
The reason that we found no relation between a decline in the score on the Mini–Mental 
State Examination and the presence of silent brain infarcts is probably that this test, al-
though useful as a screening tool for dementia, is not a very sensitive means of detecting 
subtle changes in cognitive function. The Cardiovascular Health Study did ﬁ nd an associa-
tion between evidence of infarcts on MRI and a decline in a modiﬁ ed Mini–Mental State 
Examination score, which comprised 100 rather than 30 questions and examined a broader 
range of cognitive function.31 Furthermore, we found that the decline in different cognitive 
domains varied with the location of silent brain infarcts on MRI. Strategic infarcts in the 
thalamus, which is involved in storage and short-term memory,21,22 were associated with a 
worse performance in memory tasks.
Our ﬁ nding that in both participants with and those without silent brain infarcts memo-
ry performance improved at the second examination may be explained by a learning effect.32 
This learning effect does not seem to have a major role in tests speciﬁ c for psychomotor 
speed. The presence of silent infarcts that were not in the thalamus resulted in a decline in 
psychomotor speed. These infarcts probably interrupt various connecting ﬁ bers in the white 
matter that are involved in these psychomotor tasks.
In conclusion, the presence of silent brain infarcts on MRI identiﬁ es persons at increased 
risk for dementia, probably because these people continue to have additional brain infarcts, 
both silent and symptomatic, that decrease their cognitive function.
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2.3
Cerebral white matter
lesions and the risk of
dementia
Objective – To study the association between white matter lesions (WML) in speciﬁ c locations and the 
risk of dementia. 
Design – The Rotterdam Scan Study, a prospective population-based cohort study. We scored peri-
ventricular and subcortical WML on MRI, and followed participants until January 2002 for incident 
dementia.
Setting – General population.
Participants – 1,077 elderly people aged 60 to 90 years, who were non-demented at base line.
Main outcome measure – Incident dementia by DSM III-R criteria.
Results – During a mean follow-up of 5.2 years, 45 participants developed dementia. Higher severity 
of periventricular WML increased the risk of dementia, whereas the association between subcortical 
WML and dementia less prominent. The adjusted hazard ratio of dementia for each standard deviation 
increase in periventricular WML severity was 1.67 (95% CI 1.25 - 2.24). This increased risk was inde-
pendent of other risk factors for dementia and partly independent of other structural brain changes 
on MRI.
Conclusions – WML, especially in the periventricular region, increase the risk of dementia in elderly 
people.
Abstract
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INTRODUCTION
Cerebral white matter lesions (WML) in elderly people are thought to result from small-ves-
sel disease, and are considered to be a risk factor for dementia.1 Evidence relating WML to 
dementia is mainly derived from studies in stroke patients and from cross-sectional studies 
in patients with dementia. WML increase the risk of post-stroke dementia, and together 
with lacunar infarcts, WML are considered the primary type of brain lesions in subcortical 
ischemic vascular dementia.1,2 Small-vessel disease may also contribute to the development 
of Alzheimer’s disease (AD), since patients with AD were found to have more WML than 
controls.3
WML are also frequently seen on MRI of non-demented elderly, but only few studies 
investigated the extent to which WML increase the risk of dementia in the general popula-
tion.4,5 We investigated the risk of dementia for WML in speciﬁ c locations in the Rotterdam 
Scan Study. Furthermore, we assessed whether the association between WML and demen-
tia is independent of other risk factors for dementia and other structural brain changes on 
MRI. 
METHODS
Study population
The Rotterdam Scan Study is a prospective, population based cohort study, designed to 
study causes and consequences of age-related brain changes in the elderly. The character-
istics of the 1077 participants have been described previously.6 All participants were free of 
dementia at base line.5 Base line examination in 1995 to 1996 comprised a structured inter-
view, neuropsychological tests, physical examination, blood sampling, and all participants 
underwent an MRI scan of the brain. In 1999 to 2000, 787 of the 973 participants who were 
alive and eligible were re-examined at the research center similar to the baseline examina-
tion (response 81%). All participants were continually monitored for mortality, dementia 
and stroke until January 1st 2002.
MRI procedure 
Details of the MRI examinations in the Rotterdam Scan Study have been published.6 We 
considered WML to be in the periventricular region if they were directly adjacent to the 
ventricle; otherwise we considered them subcortical. Periventricular WML were scored 
semiquantitatively for locations at the frontal and occipital horns, and the lateral walls of 
the ventricles, in order to obtain a total periventricular score (range: 0 to 9). For subcortical 
WML, a total volume as appearing on hardcopy was approximated, based on number and 
size of lesions in the frontal, parietal, temporal and occipital lobes (range: 0 to 29.5 ml).6 We 
rated cortical atrophy on a semiquantitive scale (range 0 to 15), and assessed subcortical 
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atrophy by the ventricle-to-brain ratio (range: 0.21 to 0.45). Cerebral infarcts were deﬁ ned 
as focal hyperintensities on T2-weighted images, 3 mm in size or larger, and with a corre-
sponding prominent hypointensity on T1-weighted images if located in the white matter.5
Ascertainment of incident dementia
Participants with dementia were carefully excluded at base line.5 We screened all partici-
pants for dementia at follow-up with the Mini-Mental State Examination (MMSE)7 and the 
Geriatric Mental State Schedule8 Screen positives were subsequently evaluated using the 
Cambridge Mental Disorders of the Elderly Examination (CAMDEX).9 Participants who 
were then thought to have dementia were examined by a neurologist, and underwent 
extensive neuropsychological testing. In addition, we continually monitored the medical 
records of all participants at their general practitioners’ ofﬁ ce, and at the Regional Institute 
for Outpatient Mental Health Care (RIAGG) to obtain information on newly diagnosed de-
mentia until January 1st 2002.5 A panel that reviewed all available information diagnosed 
dementia and its subtypes according to standardized criteria.10,11,12 We deﬁ ned the onset of 
dementia as the date on which the clinical symptoms ﬁ rst allowed the diagnosis of dementia 
to be made.
Other baseline measurements
The following variables assessed at baseline were used as possible confounders: age, sex, 
educational status,13 hypertension, diabetes mellitus, smoking, APOE genotype,14 history of 
stroke and incident stroke.5
Data analysis
We assessed the association between WML and measures of generalized brain atrophy with 
Pearson’s correlation coefﬁ cient, and the association between WML and presence of cerebral 
infarcts with linear regression analysis. To examine the relationship between WML and the 
risk of dementia and AD, we used Cox’ proportional hazards regression models.15 We ana-
lyzed periventricular and subcortical WML in categories of severity to analyze the shape of 
the relationship, and as a continuous variable (per standard deviation). Adjustments were 
made for age and sex, and analyses were repeated with possible confounders and measures 
of other structural brain changes added to the models. Additionally, we excluded partici-
pants with a history of stroke at baseline, and participants with a baseline MMSE score of 25 
or lower. We examined possible effect modiﬁ cation by APOE genotype through stratiﬁ ed 
analysis.
RESULTS
Characteristics of the participants are shown in table 1. Periventricular and subcortical WML 
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Table 1: Baseline characteristics of participants of the Rotterdam Scan Study
Characteristic N=1077
Age, years 72.2 (7.4)
Sex, % female 51.5
Education, % primary education only 34.8
Mini-Mental State Examination (score) 27.4 (2.2)
Hypertension, % 52.0
Diabetes, % 5.8
Current smoking, % 15.7
Periventricular white matter lesions (score) 2.4 (2.2)
Subcortical white matter lesions (ml) 1.4 (2.9)
Cortical brain atrophy (grade) 5.6 (2.9)
Subcortical brain atrophy (ventricle-to-brain ratio) 0.316 (0.036)
Cerebral infarcts, % 24.0
APOE genotype* N=971
ε2/ε2 or ε2/ε3 or ε3/ε3, % 70.9
ε2/ε4 or ε3/ε4 or ε4/ε4, % 29.1
Values are unadjusted means (standard deviation) or percentages.
*The APOE genotype was not determined in 106 of the 1077 participants
were positively correlated with cortical brain atrophy (Pearson correlation coefﬁ cient 0.40, 
p<0.01 and 0.25, p<0.01) and subcortical brain atrophy (Pearson correlation coefﬁ cient 0.21, 
p<0.01 and 0.14, p<0.01). Presence of cerebral infarcts was associated with a higher severity 
of periventricular and subcortical WML (age and sex adjusted mean difference in periven-
tricular WML severity 1.6 points, 95% CI 1.3 to 1.9 points; in subcortical WML severity 2.0 
ml, 95% CI 1.6 to 2.4 ml). 
During 5,572 person-years of follow-up (mean per person 5.2 years), 45 participants 
developed dementia (incidence rate 8.1/1000 person-years). AD was diagnosed in 34 (76 
%) patients, vascular dementia in 6 (13%), and another 5 (11%) were diagnosed with other 
types of dementia (Parkinson’s disease dementia (3), multiple system atrophy (1), and un-
speciﬁ ed dementia (1)). One-hundred-seventy-four participants died. The risk of dementia 
increased linearly with severity of periventricular WML (ﬁ gure 1 and table 2). Increasing 
severity of subcortical WML tended to increase the risk of dementia, but this association 
was less strong (ﬁ gure 1 and table 2). The hazard ratio for dementia per standard devia-
tion increment in periventricular WML score remained largely the same after exclusion of 
participants with a history of stroke (n=58) (hazard ratio for dementia 1.66, 95% CI 1.22 to 
2.27), and after adjustment for incident stroke (hazard ratio for dementia 1.63, 95% CI 1.21 to 
2.19). After exclusion of participants with a baseline MMSE score of 25 or lower (n=173) the 
association remained (hazard ratio for dementia 1.50, 95% CI 1.04 to 2.16).
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Figure 1. Relation between white matter lesion (WML) severity in the periventricular and subcor-
tical region, and the risk of dementia.
Severity of white matter lesions (WML) is divided in three categories based on the distribution of 
periventricular WML scores. The risk of dementia is expressed as age and sex adjusted hazard 
ratios. The number of dementia cases and total number of participants in consecutive periven-
tricular WML severity categories were 16 and 749 (grade 0-3), 18 and 261 (grade >3-6), 11 
and 66 (grade >6-9), and in consecutive subcortical WML severity categories 24 and 763 (0-1 
ml), 10 and 244 (>1-6 ml), 10 and 65 (>6-29.5 ml).
Table 2: Relation between the severity of periventricular and subcortical white matter lesions 
(WML) and the risk of dementia.
Periventricular WML Subcortical WML
Variables adjusted for
Hazard 
ratio
95%CI
Hazard 
ratio
95% CI
Age and sex 1.67 (1.25-2.24) 1.20 (0.98-1.46)
Age, sex and education 1.67 (1.25-2.23) 1.20 (0.98-1.46)
Age, sex, hypertension, diabetes and 
smoking
1.69 (1.25-2.29) 1.21 (0.99-1.48)
Age, sex and APOE genotype 1.66 (1.23-2.25) 1.18 (0.97-1.44)
Age, sex and cerebral infarcts 1.60 (1.17-2.18) 1.13 (0.91-1.40)
Age, sex and generalized brain atrophy 1.51 (1.13-2.03) 1.15 (0.93-1.41)
Age, sex, cerebral infarcts and
generalized brain atrophy
1.42 (1.04-1.94) 1.08 (0.86-1.35)
Age, sex, and WML in other location* 1.91 (1.31-2.78) 0.90 (0.68-1.19)
Numbers are hazard ratios and 95% conﬁ dence intervals per standard deviation (SD) increment in 
periventricular white matter lesion score (range 0 to 9; SD 2.2), and subcortical white matter lesion 
volume (range 0 to 29.5; SD 2.9).
*Periventricular WML conditional on subcortical WML and vice versa.
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Participants who developed dementia during follow-up had on average more severe 
WML at baseline in all locations within the periventricular and subcortical region (ﬁ gure 2). 
Periventricular WML also increased the risk of AD (hazard ratio for AD 1.41, 95% CI 1.01 to 
1.98). The association of periventricular WML and AD was similar for those with and with-
out an APOE ε4 allele (data not shown).
COMMENT
Higher severity of periventricular WML increased the risk of dementia, whereas the associa-
tion between subcortical WML and dementia was less prominent. The association between 
periventricular WML and dementia was independent of possible confounders, and partly 
independent of other structural brain changes on MRI. The strengths of this study are the 
large number of participating elderly, its population-based design, and the fact that we had 
a complete follow-up for dementia through our monitoring system. Another important fea-
ture is the distinction between WML in the periventricular and subcortical region. 
A preclinical phase of many years often precedes a diagnosis of dementia, especially in 
the case of AD.16 It is therefore likely that our study population contained participants with 
a preclinical stage of dementia that remained below detection at base line. The association of 
periventricular WML and the risk of dementia did not change after exclusion of participants 
Figure 2. Relation between white matter lesion (WML) severity and incident dementia for differ-
ent locations of WML in the periventricular and subcortical region.
Bars represent age and sex adjusted mean white matter lesion severity (standard error) at base-
line for participants without (n=1032) and participants with (n=45) incident dementia during 
follow-up.
NP23.indd   36 09-02-2004, 12:18:07
Cerebral white matter lesions and the risk of dementia
37
with a low MMSE score at baseline, which suggests that the association is not conﬁ ned to 
participants with a preclinical stage of dementia.
Our results are in line with those from previous studies on the relationship between 
WML and dementia. Cross-sectional case-control studies reported positive associations 
of the severity of WML on MRI with AD and vascular dementia.3,17 In the Cardiovascular 
Health Study, participants with more severe WML had a two-fold increased risk of demen-
tia.4
Several potential mechanisms may underlie the observed associations between WML 
and dementia. Histopathological studies demonstrated that irregular and conﬂ uent WML 
correspond to ischemic tissue damage including infarction, gliosis and rarefaction and loss 
of myelin.18 This tissue damage is likely to cause disconnection of functionally related corti-
cal and subcortical structures that are important to cognitive functioning.19 It has been sug-
gested that periventricular WML are just an epiphenomenon of brain atrophy, and are not 
independently related to disease.20,21 We found that the association between periventricular 
WML and the risk of dementia was partly independent of generalized brain atrophy. Fur-
thermore, we found that the association between periventricular WML and incident de-
mentia was largely independent of presence of cerebral infarcts, of which in our study the 
majority was lacunar, and was not mediated by incident stroke. 
 Subcortical WML were not as strongly associated with dementia as periventricular 
WML, which is in line with previous reports.3 Several possible pathophysiologic mecha-
nisms may explain this ﬁ nding. Firstly, WML close to the ventricles may interrupt bundles 
of cholinergic ﬁ bers, which extend from the nucleus basalis to the cerebral cortex, resulting 
in cholinergic denervation.22 Secondly, the white matter in the periventricular region has a 
high density of long association ﬁ bers, whereas subcortical white matter has a high density 
of U-ﬁ bers. Diffusion tensor MRI studies found that white matter pathology in patients with 
AD selectively involved ﬁ ber tracts connecting cortical association areas, such as the cingu-
late bundles and the corpus callosum.23,24 Periventricular WML may reﬂ ect vascular damage 
to these ﬁ ber tracts, or alternatively, represent wallerian degeneration of these tracts. 
Extensive WML alone is sufﬁ cient for a diagnosis of vascular dementia,12 and this leads 
to circularity when associations between WML and subdiagnoses of dementia are studied. 
However, the observed association between periventricular WML and AD suggest that 
WML may contribute to clinical AD. This is compatible with the view that most elderly peo-
ple with dementia have mixed disease.25 Because of the small number of cases with vascular 
dementia, we cannot provide reliable estimates for the association between WML and the 
risk of vascular dementia. In conclusion, we found that higher severity of periventricular 
WML is independently associated with an increased risk of dementia. Longer follow-up 
with repeated MRI is needed to gain insight in whether, and to what extent, progression of 
WML increases the risk of dementia.
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2.4
Homocysteine and
cognitive function
in the elderly
Background – Elevated plasma total homocysteine (tHcy) concentrations are associated with AD and 
vascular dementia, but the relation with cognitive performance in nondemented elderly people is not 
known.
Objective – To examine the association of tHcy and cognitive function in the elderly, and assess 
whether this may be mediated by structural brain changes on MRI.
Methods – The Rotterdam Scan Study is a population-based study of 1,077 nondemented elderly. 
Cognitive performance was assessed, and compound scores were constructed for psychomotor speed, 
memory function, and global cognitive function. Cerebral infarcts, white matter lesions, and general-
ized brain atrophy were measured on MRI. The cross-sectional relationship between tHcy levels and 
neuropsychological test scores was assessed by multiple regression.
Results – Mean tHcy level was 11.5 µmol/L (SD 4.1). Increasing tHcy levels were associated with lower 
scores for psychomotor speed, memory function, and global cognitive function, and this was largely 
due to the association with tHcy levels in the upper quintile (>14 µmol/L). Adjusted differences be-
tween test scores of participants in the upper quintile as compared with the lower four quintiles of tHcy 
were -0.26 (95% CI: -0.37; -0.14) for psychomotor speed, -0.13 (95% CI: -0.27; 0.01) for memory function, 
and -0.20 (95% CI: -0.30; -0.11) for global cognitive function. These associations were not mediated by 
structural brain changes on MRI.
Conclusion – Elevated tHcy levels are associated with decreased cognitive performance in nonde-
mented elderly people, and the relation was most marked for psychomotor speed. This association 
was independent of structural brain changes on MRI.
Abstract
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INTRODUCTION
Homocysteine is a sulfur-containing amino acid derived from methionine. Plasma total 
homocysteine (tHcy) concentrations are increased in patients with AD and vascular demen-
tia.1,2 In a large longitudinal study, increased tHcy was a risk factor for the development of 
dementia and AD.3 Previous studies in nondemented elderly have reported that higher tHcy 
levels are associated with worse cognitive performance4-6 and with cognitive decline,7 but 
many of these studies have been small or the instruments used to measure cognitive func-
tion were unspeciﬁ c to assess these associations reliably.
The adverse effects of tHcy on cognitive function may arise as a consequence of direct 
neurotoxicity8 or indirectly through cerebrovascular disease.9 The relevance of structural 
brain changes as assessed by MRI, such as cerebral infarcts, white matter lesions (WML), 
and generalized brain atrophy, as possible intermediates in the association of tHcy with 
cognitive function has not been previously studied. We investigated the relation between 
elevated tHcy levels and cognitive performance in a nondemented elderly population and 
assessed the extent to which any association may be mediated by structural brain changes 
on cerebral MRI. 
SUBJECTS AND METHODS
Subjects
The Rotterdam Scan Study was designed to study the causes and consequences of age-re-
lated brain changes in the elderly.10 Participants were recruited from the Rotterdam Study11 
and the Zoetermeer Study,12 which are ongoing prospective cohort studies. In 1995 through 
1996, 1,904 elderly aged 60 to 90 years were randomly selected after stratiﬁ cation by sex 
and by age in 5-year age groups. Among the invited subjects, 187 were excluded (owing 
to presence of dementia, a contraindication for MRI scanning, or blindness). Assessment 
of dementia was performed by using a stepped approach. All participants were initially 
screened with the Mini-Mental State Examination (MMSE)13 and the Geriatric Mental Sched-
ule (GMS), organic section.14 Subsequently, participants who scored below a cutoff of 26 on 
the MMSE or above 0 on the GMS were further evaluated using more extensive neuropsy-
chological tests, including an informant interview, and review of medical records. Of the 
1,717 eligible participants, 1,077 completed all examinations (overall response 63%). Each 
participant gave informed consent to protocol, which was approved by the medical ethics 
committee of the Erasmus Medical Center, Rotterdam.
Total plasma homocysteine level
We collected nonfasting blood samples from participants into Vacutainers (Becton-Dickin-
son, Oxford, UK) containing sodium citrate in 1995 through 1996; these whole blood sam-
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ples were put on ice immediately and centrifuged within 60 minutes, and aliquots of plasma 
were stored at -80°C. Plasma total tHcy concentrations were determined, 3 years after stor-
age, by ﬂ uorescence polarization immunoassay on an IMx analyzer (Abbott Laboratories, 
Chicago, IL). This method has an intralaboratory imprecision of less than 5%.15 Blood sam-
ples were unavailable for tHcy measurement in 39 participants, either owing to inability to 
collect the blood sample or loss of samples after collection. Seven participants whose tHcy 
levels were greater than 45 µmol/L were excluded.
Neuropsychological testing
Neuropsychological tests were administered in 1995 through 1996. We used the follow-
ing three tests to assess executive function: an abbreviated Stroop test,16,17 the Letter-Digit 
Substitution Task (a modiﬁ ed version of the Symbol Digit Modalities Test),18 and a verbal 
ﬂ uency test.19 A Paper-and-Pencil Memory Scanning Task consisting of four subtasks was 
used to measure attention.20,21 We assessed memory function by means of a 15-word verbal 
learning test (based on Rey’s recall of words),22 which consists of three immediate recall tri-
als and a delayed recall of words. An average or compound cognitive test score was made 
by transforming individual test scores into standardized Z-scores (Z-score = test score 
– mean test score/SD). Compound scores were estimated for psychomotor speed, memory 
performance, and global cognitive function.23 Compound scores for psychomotor speed 
were calculated by averaging the Z-scores of the reading subtask of the Stroop test, the one 
letter subtask of the Paper-and-Pencil Memory Scanning Test, and the Letter-Digit Substi-
tution Task. Compound scores for memory function were calculated by averaging the Z-
scores of the total of three immediate recall trials and the delayed recall trial of the 15-word 
verbal learning tests. Compound scores for global cognitive performance were calculated 
by averaging the Z-scores of the reading subtask of the Stroop test, the one letter subtask 
of the Paper-and-Pencil Memory Scanning Test, the Letter-Digit Substitution Task, and the 
immediate and delayed recall of the 15-word verbal learning test. The MMSE13 was used as 
a general indicator of cognitive function.
MRI procedure
Cranial MRI scanning was performed in all participants with 1.5-Tesla scanners at two cent-
ers to assess the presence of cerebral infarcts, WML, and generalized brain atrophy, as previ-
ously published.23,24 Cerebral infarcts were deﬁ ned as focal hyperintensities on T2-weighted 
images, 3 mm or larger. Lesions in the white matter also had to have corresponding promi-
nent hypointensities on T1-weighted images. WML were considered present if visible as hy-
perintense on proton density and T2-weighted images, without prominent hypointensity on 
T1-weighted images. WML were scored for periventricular and subcortical areas, resulting 
in a total periventricular score (range 0 to 9) and an index for total subcortical WML volume 
(range 0 to 29.5). Generalized brain atrophy was scored on T1- weighted images. Subcortical 
atrophy was measured by the ventricle-to-brain ratio (range 0.21 to 0.45) and cortical atro-
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phy was rated on a semiquantitative scale (range 0 to 15) using reference scans.
Duplex ultrasonography
Both the right and left carotid arteries were examined for the presence of plaques in the 
common carotid artery, the bifurcation, and the internal carotid artery using a 7.5 MHz 
linear array transducer and a Duplex scanner (ATL Ultra-Mark IV, Advanced Technology 
Laboratories, Bethel, WA).25 Plaques per region were deﬁ ned as being present or absent, and 
the data were used to estimate a carotid plaque score of 0 to 6.
Other measurements
The following variables were considered as possible confounding variables in the relation-
ship between tHcy and cognition: age, sex, the highest level of education achieved (accord-
ing to the United Nations Educational, Scientiﬁ c, and Cultural Organization [UNESCO]),26 
disturbances of mood (determined with the Center of Epidemiologic Studies Depression 
Scale [CES-D]),27 serum creatinine level (enzymatic assay),28 and use of cigarettes (pack-
years) and alcohol (units/day).
Data analysis
Among the 1,077 study participants, 1,031 had tHcy levels within the reliable 5 to 45 µmol/L 
range. All neuropsychological data were missing in four participants. Of the remaining 
1,027, data on one or more tests were incidentally missing or incomplete due to physical 
handicap, insufﬁ cient motivation, or technical problems. The association of tHcy level with 
cognitive performance, as assessed using neuropsychological test scores, was assessed us-
ing multivariate linear regression, treating tHcy as a continuous variable. To assess whether 
the relationship between tHcy and cognitive performance was linear, we analyzed this re-
lationship using tHcy categorized into quintiles of its distribution. Limits in tHcy level for 
the different quintiles were as follows: ﬁ rst quintile <8.54 µmol/L (median 7.57 µmol/L, n = 
203), second quintile 8.55 to 9.87 µmol/L (median 9.12 µmol/L, n = 207), third quintile 9.88 
to 11.44 µmol/L (median 10.54 µmol/L, n = 208), fourth quintile 11.45 to 13.95 µmol/L (me-
dian 12.47 µmol/L, n = 208), ﬁ fth quintile >13.96 µmol/L (median 16.34 µmol/L, n = 201). 
Because of an apparent threshold, tHcy was also dichotomized into the lower four quintiles 
versus the upper quintile (>14.0 µmol/ L). Analysis of covariance was used to obtain ad-
justed mean cognitive performance by quintiles of tHcy and adjusted mean difference in 
cognitive performance between tHcy levels of 14.0 µmol/L or lower and tHcy levels >14.0 
µmol/L. All analyses were adjusted for age, sex, educational level, depression (CES-D score 
of 16 or higher), and serum creatinine to exclude confounding, and analyses were also ad-
justed for current alcohol use (units/day) and cigarette smoking (pack-years). To elucidate 
whether and to what extent the observed associations of tHcy with cognitive performance 
might be explained by structural intermediates, further analyses also adjusted for WML, 
cerebral infarcts, generalized brain atrophy, and carotid atherosclerosis.
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RESULTS
Selected characteristics of the study participants are shown in table 1. The mean plasma to-
tal tHcy level was 11.5 (SD 4.1) and values varied from 5.1 µmol/L to 40.1 µmol/L. Plasma 
tHcy levels increased with age (1.5 µmol/L increase per 10 years, 95% CI 1.2 to 1.9), and 
were higher in men then in women (mean difference 1.2 µmol/L, 95% CI 0.7 to 1.7). Increas-
ing tHcy levels were associated with lower neuropsychological compound scores. Each SD 
(4.1 µmol/L) increase in tHcy level was associated with a decrease in compound scores for 
psychomotor speed by 0.06 points (95% CI 0.02 to 0.11), for memory function by 0.03 points 
(95% CI -0.02 to 0.08), and for global cognitive performance by 0.05 points (95% CI 0.01 to 
0.09). With increasing tHcy, participants had more WML, more cerebral infarcts, and more 
cortical atrophy, after adjustment for age and sex.29
The ﬁ gure shows the relationship between tHcy in quintiles and compound scores for 
psychomotor speed, memory function, and global cognitive function, adjusted for age, sex, 
education, depression, and serum creatinine. There was an apparent threshold in the re-
lation of cognitive performance between the lowest four quintiles and the upper quintile 
(>14.0 µmol/L) of tHcy. The association of tHcy and test scores for individual neuropsy-
chological tests showed a similar pattern. We therefore performed subsequent analyses 
with tHcy dichotomized into the top quintile and the lower four quintiles. Table 2 shows 
the relation between neuropsychological tests and tHcy level dichotomized at the upper 
Table 1. Characteristics of the study population.
Characteristics All participants (n = 1,077
Age, y, mean (SD) 72.2 (7.4)
% Female 51.5
tHcy, µmol/L, mean (SD) 11.5 (4.1)
Education, % primary education only 34.8
Serum creatinine, µmol/L, mean (SD) 88.9 (18.5)
Alcohol use, units/d, median (interquartile range) 0.3 (0.0; 2.0)
Smoking, pack-years, median (interquartile range) 10.0 (0.0; 31.5)
Depression, % CES-D positive 7.4
Cerebral infarcts, % 24.0
White matter lesions, mean (SD)
Periventricular, grade 2.4 (2.2)
Subcortical, mL 1.4 (2.9)
Generalized brain atrophy, mean (SD)
Cortical atrophy, grade 5.6 (2.9)
Ventricle-to-brain ratio 0.314 (0.035)
Carotid plaque score, median (interquartile range) 1 (0; 3)
tHcy = plasma total homocysteine; CES-D = Center for Epidemiologic Studies Depression Scale.
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Figure. Relation between plasma total homocysteine (tHcy) in quintiles and cognitive function 
(expressed as mean Z-scores [+SEM]) adjusted for age, sex, education, depression, and serum 
creatinine.
Mean Z-scores are plotted at the median tHcy levels of the different quintiles. Limits in tHcy 
level for the different quintiles were as follows: ﬁ rst quintile <8.54 µmol/L, second quintile 8.55 
to 9.87 µmol/L, third quintile 9.88 to 11.44 µmol/L, fourth quintile 11.45 to 13.95 µmol/L, ﬁ fth 
quintile >13.96 µmol/L. 
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Table 2. The relation between total plasma tHcy and neuropsychological test outcome.
Neuropsychological test n Mean (SD)
Difference (95% CI) 
upper quintile vs lower 
four quintiles of tHcy
Mini-Mental State Examination (score)* 1,027 27.5 (2.1) -0.29 (-0.62; 0.05)
Stroop test†
Reading (part 1 in sec) 1,019 18.6 (5.2) 0.83 (0.02; 1.64)
Naming (part 2 in sec) 1,015 25.5 (7.0) 1.34 (0.24; 2.44)
Interference (part 3 in sec) 995 58.1 (23.2) 4.68 (1.08; 8.28)
Letter Digit Substitution Task*
No. of letters/min 995 26.7 (6.9) -1.64 (-2.64; -0.65)
Verbal ﬂ uency*
No. of animals/min 1,021 20.4 (5.1) -1.53 (-2.32; -0.75)
Paper and Pencil Memory Scanning Task†
1 letter (sec) 1,000 31.7 (9.7) 2.97 (1.52; 4.42)
2 letters (sec) 1,000 46.1 (15.4) 3.71 (1.35; 6.07)
3 letters (sec) 997 57.6 (18.0) 2.46 (-0.34; 5.26)
15-word verbal learning test*
Total in three trials (no. of words) 1,016 20.1 (5.4) -0.67 (-1.47; 0.14)
Delayed recall (no. of words) 1,014 5.9 (2.7) -0.33 (-0.74; 0.08)
Values are mean test scores (SD) and mean adjusted differences (95% CI) in test score between 
upper quintile (>14 µmol/L) and lower four quintiles of plasma total homocysteine (tHcy). Adjust-
ments were made for age, sex, education, depression, and serum creatinine.
* Lower scores indicate worse performance.
† Higher scores indicate worse performance.
quintile (>14.0 µmol/L) compared with the lower four quintiles. Individuals with elevated 
tHcy levels in the upper quintile had worse performance on all individual neuropsychologi-
cal tests, although this difference in test performance was not signiﬁ cant for the MMSE, the 
three-letter subtask of the Paper-and- Pencil Memory Scanning Test, and the immediate and 
delayed recall of the 15-word verbal learning test. Further adjustment for use of alcohol and 
for smoking did not alter these associations (data not shown).
Table 3 shows the relation between tHcy and neuropsychological compound scores after 
further adjustment for cerebral infarcts, WML, and generalized brain atrophy. The differ-
ence in neuropsychological compound scores between people with tHcy levels in the upper 
quintile compared to the lower four quintiles was only slightly attenuated after adjustment 
for these radiologic variables. Furthermore, the relation of tHcy with cognitive performance 
was unaltered by further adjustment for carotid artery plaques (data not shown).
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Table 3. The inﬂ uence of structural brain changes on the association of tHcy and neuropsy-
chological compound scores.
Difference in cognitive performance (95% CI) for people in the upper 
quintile vs lower four quintiles of tHcy
Compound score Model 1*
Adjusted for cerebral 
infarcts and WML†
Adjusted for general-
ized brain atrophy†
Speed -0.26 (-0.37; -0.14) -0.24 (-0.36; -0.12) -0.24 (-0.35; -0.12)
Memory -0.13 (-0.27; 0.01) -0.10 (-0.24; 0.05) -0.12 (-0.26; 0.02)
Cognitive Index -0.20 (-0.30; -0.11) -0.18 (-0.28; -0.08) -0.19 (-0.29; -0.09)
Values are adjusted mean differences in compound score between the highest quintile (>14.0 
µmol/L) of total plasma homocysteine (tHcy) and the lower four quintiles and 95% CI.
* Adjusted for age, sex, education, depression, and serum creatinine.
† Additional to model 1.
DISCUSSION
Elevated plasma tHcy levels were signiﬁ cantly associated with adverse cognitive function 
in this large population-based study of elderly people. The associations of tHcy were strong-
est for psychomotor speed, but were also present for memory function. There was an appar-
ent threshold for tHcy of about 14 µmol/L, above which it was signiﬁ cantly associated with 
adverse cognitive performance. This association of tHcy with cognitive function appeared 
to be independent of the presence of cerebral infarcts, WML, or generalized brain atrophy 
on MRI.
Using a cross-sectional study design for these analyses, the current report cannot refute 
the possibility that high tHcy levels were a consequence of cognitive impairment rather 
than being causally related to cognitive impairment. It is possible that dementia can lead to 
a deterioration of diet, resulting in insufﬁ cient intake of folate and vitamin B
12
 and elevated 
tHcy levels. Because people with dementia were excluded from our study, we consider it 
unlikely that cognitive dysfunction may have caused elevation in tHcy levels. A large fol-
low-up study found that increased tHcy levels were strongly and independently related to 
the development of dementia and AD,3 suggesting that high tHcy levels may be causally 
related, rather than being a consequence of impaired cognitive function.
The use of a single tHcy measurement to classify persons may have underestimated the 
strength of any associations due to regression dilution by 15 to 30%.30 Furthermore, we 
could not assess the relative importance of vitamin status (such as vitamin B
12
 and folate) or 
free thyroxine levels for cognitive function.
The overall response rate to invitation to participate in this study was 63%. Nonpartici-
pants were older and had a higher frequency of hypertension, and had lower MMSE scores 
than participants.23 Consequently, the proportion of people with cognitive impairment may 
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have been underestimated in our study. However, we have no reason to believe that the as-
sociation of tHcy with cognitive function may be materially different between participants 
and nonparticipants.
The results of the current analyses conﬁ rm the ﬁ ndings suggested by the results of previ-
ous studies on the association of high tHcy levels with cognitive dysfunction and demen-
tia.1-6 We found a threshold effect in the relation between tHcy and cognitive function above 
tHcy levels of 14 µmol/L.31 The possibility that tHcy levels under 14 µmol/L may affect cog-
nitive function cannot be excluded, but the extent that this occurs remains below threshold 
of detection using the neuropsychological tests used in this report. We found that partici-
pants with high tHcy levels tended to have lower MMSE scores, although this association 
was not signiﬁ cant. We previously reported a lack of association between tHcy and cogni-
tive impairment (deﬁ ned as a MMSE score of 25 or lower) and cognitive decline (deﬁ ned as 
a drop in MMSE of more than one point per year) in a random sample of participants from 
the Rotterdam study.32 These ﬁ ndings may be explained by a low sensitivity of the MMSE 
to detect subtle differences in cognitive function in healthy elderly populations, and a short 
follow-up period with a mean of 2.7 years. Another study with a longer follow-up and older 
subjects did ﬁ nd a signiﬁ cant association between tHcy and decline in MMSE.7
There are several plausible biological mechanisms that may explain the relationship 
between tHcy levels and cognitive function. Elevated tHcy is an independent risk factor for 
cerebrovascular disease,33 which in turn is a risk factor for cognitive decline and dementia.34 
We recently reported on the association of tHcy and silent brain infarcts and WML in the 
Rotterdam Scan Study.29 Previously we reported on the association of WML and cognitive 
function.23 In the current study we found that the association between tHcy and cognitive 
function was not mediated by cerebral infarcts, WML, or generalized brain atrophy. Al-
though we cannot exclude that measurement error involved in the assessment of structural 
brain changes was associated with a failure to establish such an intermediate role, we sug-
gest that other mechanisms play a role in the association of tHcy and cognitive function. 
tHcy may have a direct neurotoxic effect.8 Additionally, high tHcy levels may be a marker 
of impaired methylation reactions in brain tissue, which play an important role in the pro-
duction of neurotransmitters, phospholipids, and myelin.35 Finally, high tHcy may promote 
β-amyloidpeptide mediated toxic effects on neuronal cells.36
Further prospective and intervention studies are needed to conﬁ rm whether the associa-
tion between high tHcy levels and cognitive dysfunction is causal, and whether lowering of 
the plasma tHcy level reduces the risk of cognitive decline and dementia.  
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Cerebral small vessel disease
and depression
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Brain infarcts,
white matter lesions
and the risk of depression
in the general population
Background – Cerebrovascular pathology may contribute to late-life depression. Whether brain in-
farcts and white matter lesions increase the risk of depressive disorders in the general population has 
not been studied longitudinally.
Methods – The Rotterdam Scan Study is a prospective, population-based cohort study among 1,077 
non-demented elderly people. The presence of brain infarcts and severity of white matter lesions were 
scored on cerebral MRI scans obtained at baseline in 1995-1996. We assessed depressive disorders dur-
ing follow-up by re-examination of the cohort in 1999-2000, and by monitoring medical records. We 
used logistic regression analysis to estimate relative risks of depressive disorders associated with the 
presence of brain infarcts and severity of white matter lesions.
Findings – During a mean follow-up of 3.6 years, 48 participants had an incident, and 30 participants 
a chronic (recurrent or persistent) depressive disorder. Brain infarcts were associated with a three-fold 
increased risk of chronic depressive disorders (all infarcts: odds ratio 2.9, 95% conﬁ dence interval 1.1-
7.6, asymptomatic infarcts: odds ratio 3.2, 95% conﬁ dence interval 1.2-8.9). Severe subcortical white 
matter lesions more than doubled the risk of incident depressive disorders (odds ratio 2.2, 95% conﬁ -
dence interval 1.1-4.5). Periventricular white matter lesions were not related to depressive disorders.
Interpretation – In elderly people, both symptomatic and asymptomatic brain infarcts are associated 
with chronicity of depressive disorders, whereas severe subcortical white matter lesions are associated 
with an increased risk of incident depressive disorders. Our ﬁ ndings suggest that cerebral small-vessel 
disease plays a role in the pathophysiology of late-life depression.
Abstract
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INTRODUCTION
There is a convergence of evidence suggesting a causal link between cerebrovascular disease 
and depression in late life.1 This has led to the ‘vascular depression’ hypothesis, which im-
plies that there is a subtype of depression arising in later life that is characterized by a dis-
tinct clinical presentation and an association with cerebrovascular disease.2 About a third of 
hospitalized stroke patients develop a depressive disorder.3 The question remains whether 
in these patients depression is a direct consequence of vascular brain damage, or is a psy-
chological reaction to physical disability or perceived disease. Epidemiological and neu-
roimaging studies suggest that also asymptomatic brain infarcts and white matter lesions, 
which typically result from cerebral small vessel disease, are related to depression in elderly 
people.4,5 We previously showed that white matter lesions on MRI are associated with the 
presence of depressive symptoms.6 One longitudinal population-based study examined the 
relationship between cerebral small vessel disease and self-reported depressive symptoms 
over time. This study showed that cerebral small vessel disease was associated with worsen-
ing and persistence of depressive symptoms, but not with incident depressive symptoms.7 
Whether cerebral small vessel disease increases the risk of clinical depressive disorders in 
the general population has not been studied prospectively. We therefore examined the as-
sociation of asymptomatic and symptomatic brain infarcts and white matter lesions with the 
risk of depressive disorders in a population-based follow-up study among elderly people. 
Since the risk of depression may be related to lesion location, we additionally investigated if 
relationships were different for speciﬁ c locations of cerebral small vessel disease.3
METHODS
Participants
The Rotterdam Scan Study was designed to study causes and consequences of brain changes 
in the elderly. The study design has been described in detail.8 In 1995-1996, we randomly se-
lected participants aged 60 to 90 years in strata of age (5 years) and sex from two large ongo-
ing population-based studies, the Zoetermeer Study and the Rotterdam Study.9,10 A total of 
1,077 non-demented elderly participated in our study (overall response 63%). The medical 
ethics committee of the Erasmus Medical Center approved the study, and each participant 
gave written informed consent.
Baseline examination in 1995-1996 comprised a structured interview, screening for de-
pressive symptoms, physical examination, blood sampling, and neuropsychological tests at 
the research center, as well as a cerebral MRI scan. In 1999-2000, we re-examined 787 of the 
973 participants who were alive and eligible (not institutionalized, not moved abroad) at the 
research center with a protocol similar to that used at the baseline examination (response 
81%). Compared to participants in the second examination, people who were ineligible or 
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who declined to undergo the second examination were signiﬁ cantly older (mean age dif-
ference 4.2 years), and were less educated (percentage primary education only 56% versus 
32%). The percentage of people with depressive symptoms at baseline did not differ among 
participants and non-participants. 
We monitored all 1,077 participants throughout the study by reviewing medical records 
from their general practitioners and from the Regional Institute for Ambulatory Mental 
Health for death and major complications, including depression and dementia. Follow-up 
for depression was virtually complete until March 1st, 2000 (99.4%; for 7 participants we had 
no information on depression). 
Cerebral infarcts and white matter lesions
All participants underwent MRI of the brain in 1995-1996. We made axial T1-weighted, T2-
weighted, and proton-density-weighted scans on 1.5 Tesla MRI scanners (for participants 
from Zoetermeer: MR Gyroscan, Philips, Best, the Netherlands and for participants from 
Rotterdam: MR VISION, Siemens, Erlangen, Germany). The slice thickness was 5 or 6 mm 
with an interslice gap of 20%. 
Infarcts were deﬁ ned as focal hyperintensities on T2-weighted images, 3 mm in size 
or larger. Proton-density scans were used to distinguish infarcts from dilated perivascular 
spaces. Lesions in the white matter also had to have corresponding prominent hypointensi-
ties on T1-weighted images, in order to distinguish them from cerebral white matter lesions. 
A single trained physician scored infarcts both on baseline and second MRI, including their 
location and size. An intrarater study (n=110) for detecting infarcts showed good agreement 
(κ=0.80).11 An experienced neurologist subsequently reviewed the medical history and scans 
and categorized the infarcts as asymptomatic or symptomatic. We deﬁ ned asymptomatic 
brain infarcts as evidence of one or more infarcts on MRI, without a history of a (correspond-
ing) stroke or TIA. Participants with both symptomatic and asymptomatic infarcts were 
categorized in the symptomatic infarct group.
White matter lesions were considered present if visible as hyperintense on proton-den-
sity- and T2-weighted images, without prominent hypointensity on T1-weighted scans. 
Two raters scored periventricular and subcortical located white matter lesions independ-
ently. Both intrarater and interrater studies (n=100) showed a good to excellent agreement 
(κ=0.79-0.90, r=0.88-0.95). A detailed description of the scoring method has been reported 
previously.8 Severity of periventricular white matter lesions was rated semi-quantitatively 
in three regions (grade range 0-9). A total volume of subcortical white matter lesions was 
approximated based on number and size of lesions in the frontal, parietal, occipital, and 
temporal lobes (volume range 0-29.5 ml).
Assessment of depressive disorders
We assessed whether participants had a psychiatric history in 1995-1996 by interview and 
by checking medical records and indications of prescribed drugs in all 1,077 participants. 
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A history of depression was deﬁ ned as a depressive episode before the baseline examina-
tion lasting for more than two weeks. We also assessed presence of depressive symptoms 
at baseline with a validated Dutch version of the original Center for Epidemiologic Studies 
Depression (CES-D) scale (range 0-60).12 
We acquired information on depression during follow-up in two ways. Firstly, we 
administered the CESD in all participants but one who were re-examined in 1999-2000 
(n=786). Participants with a CES-D score of 16 or more were considered screen-positive.12 To 
ascertain a Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) 
diagnosis,13 a psychiatrist interviewed screen positives with a semi-structured psychiatric 
interview, a Dutch version of the Present State Examination.14 Secondly, as mentioned 
previously, we continually monitored the medical records of all 1,077 participants at the 
general practitioner’s ofﬁ ces and the Regional Institute for Ambulatory Mental Health for 
depressive episodes. Prevalent depressive symptoms were deﬁ ned as depressive symptoms 
(CES-D score >16) or the use of antidepressant medication for the indication of depression 
at baseline. We deﬁ ned incident depressive disorders as depressive disorders at follow-up 
without prevalent depressive symptoms (CESD <16) at baseline. Chronic (persistent or re-
current) depressive disorders were deﬁ ned as depressive disorders at follow-up in persons 
with prevalent depressive symptoms (CESD >16) at baseline.
Other measurements
The following variables assessed at baseline were used as possible confounders: age (con-
tinuously per year); sex; educational status (deﬁ ned as the highest education according to 
UNESCO, and dichotomized into primary education only, and more than primary educa-
tion);15 cognitive function (deﬁ ned as score on the Mini-Mental State Examination (MMSE) 
(score range 0-30).)16 All participants were followed for the development of dementia, which 
was diagnosed according to standardized criteria.17
Data analysis
In order to estimate the relative risks of depressive disorders associated with the presence of 
brain infarcts and the severity of white matter lesions, we used multiple logistic regression 
analysis to calculate odds ratios and 95% conﬁ dence intervals. We excluded participants 
of whom we had no information on depression (n=7), those who were screen-positive but 
received no psychiatric work-up (n=7), and those who were diagnosed with a psychiatric 
disorder other than a depressive disorder during follow-up (n=8), leaving 1,055 partici-
pants in the analyses. We studied incident depressive disorders in 968 participants without 
prevalent depressive symptoms, and chronic depressive disorders in 87 participants with 
prevalent depressive symptoms at baseline. 
In the analyses we adjusted for age, sex, education and baseline MMSE score. We used 
separate models for presence of asymptomatic brain infarcts, and for severity of periven-
tricular and subcortical white matter lesions. For the analyses with brain infarcts, the ref-
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erence group comprised participants without brain infarcts and no distinction was made 
between participants with one or multiple infarcts. Periventricular and subcortical white 
matter lesions were analyzed both continuously per standard deviation, and as presence 
versus absence of severe white matter lesions (ﬁ ve points or more for periventricular white 
matter lesions; two milliliter or more for subcortical white matter lesions).8 In order to in-
vestigate the risk of incident late-onset depression, we excluded all participants with a his-
tory of early-onset depression (n=21). Early-onset depression was deﬁ ned as a depressive 
episode with an onset before the age of 60 years. Additionally, we excluded participants 
with any history of depression. We repeated the analyses after exclusion of participants 
who became demented during follow-up (n=34), because depressive symptoms may be a 
prodrome of dementia, and this might confound the associations of interest. Finally, we 
examined whether the relationship between severity of subcortical white matter lesions and 
the risk of depressive disorders was different for white matter lesions in different locations. 
In order to evaluate this, we used multiple linear regression modeling to compare the white 
matter lesion severity in the frontal, parietal, occipital, and temporal lobes, between partici-
pants with and without incident depression during follow-up. 
Table 1. Baseline characteristics of all participants.
Participants
All
n=1055*
No depressive 
symptoms at 
baseline
n=968
Depressive 
symptoms at 
baseline
n=87
Age, years 72.2 (7.4) 72.1 (7.4) 73 (7.8)
Women 542 (51%) 477 (49%) 65 (75%)
Primary education only 366 (35%) 325 (34%) 40 (47%)
History of depression 66 (6%) 37 (4%) 29 (33%)
Use of antidepressant medication 19 (2%) 0 (0%) 23 (26%)
CES-D score, range 0-60 5.8 (6.1) 4.6 (4.3) 18.9 (7.7)
CES-D score > 16 74 (7%) 0 (0%) 74 (85%)
MMSE score, range 0-30 27.4 (2.2) 27.5 (2.2) 27.0 (2.4)
Brain infarcts on MRI:
Symptomatic
Asymptomatic
252 (24%)
39 (4%)
213 (20%)
220 (23%)
33 (3%)
187 (19%)
32 (37%)
6 (7%)
26 (30%)
Periventricular white matter lesions, 
grade, range 0-9
2.4 (2.2) 2.3 (2.2) 2.9 (2.0)
Subcortical white matter lesions,
volume, range 0-29.5 ml
1.4 (2.9) 1.4 (2.9) 1.6 (2.8)
Values are unadjusted means (standard deviation) or number of participants (percentages).
*Excludes participants without information on depression (n=7), screen-positives without a psychi-
atric work-up (n=7), and participants who were diagnosed with a psychiatric disorder other than a 
depressive disorder during follow-up (n=8).
NP3.indd   59 09-02-2004, 12:20:48
Chapter 3
60
RESULTS
The baseline characteristics of the study population are shown in Table 1. During a mean 
follow-up of 3.6 years, 78 of the 1,055 participants (7.4%) were diagnosed with a depressive 
disorder. The mean age of these 78 participants was 72.1 years, and 55 (71%) were women. 
Of the 968 participants without prevalent depressive symptoms at baseline, 48 (5.0%) had an 
incident depressive disorder. Thirty (34%) of the 87 participants with prevalent depressive 
symptoms had a chronic (recurrent or persistent) depressive disorder. 
The presence of brain infarcts, including asymptomatic infarcts, at baseline was associ-
ated with a three-fold increased risk of a chronic depressive disorder, whereas brain infarcts 
were not associated with incident depressive disorder (Table 2). Severe subcortical white 
matter lesions more than doubled the risk of incident depressive disorders (Table 2). Severe 
periventricular white matter lesions tended to increase the risk of incident depression, but 
this association was less strong (Table 2). White matter lesions were not associated with 
chronic depression (Table 2). Exclusion of participants with early-onset depression in his-
tory (n=21) did not change any of the results, nor did exclusion of participants with any 
history of depression (data not shown). Exclusion of participants who developed dementia 
during follow-up (n=34), of whom 6 were diagnosed with a depressive disorder before the 
dementia diagnosis, did not change the association between infarcts and chronic depressive 
disorders (age, sex, education and MMSE adjusted OR 2.9, 95% CI 1.0-7.9), nor between se-
vere subcortical white matter lesions and incident depressive disorders (age, sex, education 
and MMSE adjusted OR 2.5, 95% CI 1.2-5.0).
Table 2. Association between presence of asymptomatic brain infarcts and severity of white 
matter lesions and the risk of incident or chronic (recurrent or persistent) depressive disorder, 
estimated by odds ratios (OR) with 95% conﬁ dence intervals (CI).
Incident depressive 
disorder
OR* (95% CI)
Chronic depressive 
disorder
OR* (95% CI)
Infarcts (present/absent)
All infarcts 1.0 (0.5-2.1) 2.9 (1.1-7.6)
Asymptomatic infarcts 1.0 (0.4-2.1) 3.2 (1.2-8.9)
White matter lesions 
Periventricular (per SD†) 1.2 (0.9-1.7) 1.2 (0.7-2.1)
Severe periventricular (present/absent) 1.4 (0.7-2.9) 0.9 (0.3-2.8)
Subcortical (per SD†) 1.2 (1.0-1.7) 0.9 (0.6-1.6)
Severe subcortical (present/absent) 2.2 (1.1-4.5) 0.6 (0.2-1.9)
*Adjusted for age, sex, education and baseline Mini-Mental State Examination (MMSE) score
† Standard deviation
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The ﬁ gure shows the age and sex adjusted baseline severity of white matter lesions at 
different locations in the subcortical region for participants with and without incident de-
pression. Participants who developed depression during follow-up had on average more 
severe subcortical white matter lesions at all locations. The largest difference was found for 
subcortical white matter lesions in the frontal lobe (adjusted mean difference 0.53 ml, 95% 
conﬁ dence interval 0.02-1.05). 
DISCUSSION
In this prospective study in community dwelling elderly people, we found that the pres-
ence of brain infarcts was associated with a three-fold increased risk of chronic depressive 
disorders, but was not associated with incident depressive disorders. In contrast, subcorti-
cal white matter lesions were associated with incident depressive disorders. This was most 
marked for white matter lesions in the frontal lobe. White matter lesions did not increase the 
risk of chronic depressive disorders. 
The strengths of this study are the large number of participating elderly people, and 
its prospective population-based design. Furthermore, follow-up for depressive disorders 
was nearly complete. A potential methodological limitation of our study is misclassiﬁ cation. 
Participants tend to underreport depressive symptoms, and physicians probably under-
diagnose depressive disorders, which may have resulted in an underestimation of the true 
Figure. Relationship between white matter lesions and incident depression for different locations 
of white matter lesions in the subcortical region.
Bars represent age and sex adjusted mean white matter lesion severity (standard error) at base-
line for participants without (n= 920) and with (n=48) incident depression during follow-up.
*The mean white matter lesion severity in the frontal region was signiﬁ cantly higher (p-value 
0.04) in participants with incident depression, compared to participants without incident depres-
sion.
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number of events. In addition to information from medical records, we actively screened 
participants for the presence of depressive symptoms, which will have reduced this un-
derestimation. Another issue that needs to be addressed is that, in order to study incident 
depression, we excluded participants with a CES-D score of 16 or higher at baseline. This 
cut-off represents clinically signiﬁ cant depressive symptoms and has a very high sensitivity 
for major depression in elderly subjects.12 Exclusion of participants with a CES-D score of 16 
or higher may have led to an underestimation of the incidence of depressive disorders, and 
possibly to an attenuation of the associations between brain infarcts, white matter lesions 
and depression.   
In the present study, we found that the presence of brain infarcts, of which the majority 
is asymptomatic (85%), was associated with chronicity of depressive disorders. As in other 
studies, we found that the prognosis of depression was poor.18 Thirty-four percent of par-
ticipants who had signiﬁ cant depressive symptoms at baseline were diagnosed as depressed 
during follow-up. This was particularly the case for participants with a brain infarct on MRI 
who were three times as likely to have persistent depression. However, brain infarcts were 
not associated with de novo occurrence of depressive disorders.
We report an association between increasing severity of subcortical white matter lesions 
and the incidence of depressive disorders in elderly people. This is consistent with our ear-
lier cross-sectional ﬁ ndings, and with those from the Cardiovascular Health Study.6,7 We 
found that the association between subcortical white matter lesions and depression was 
most marked for white matter lesion localization in the frontal lobe. This is in agreement 
with neuropathological evidence for ischaemia in frontal-subcortical areas in the brains of 
elderly people with depression.19 However, in clinical stroke patients, the risk of depression 
seems to be unrelated to the location of the brain lesions,20 which suggests that other mecha-
nisms play a role in depression following a large vessel stroke. 
The observation that infarcts and white matter lesions are related to depression in a 
distinct way, i.e. white matter lesions are related to incident, whereas infarcts are related 
to chronic depression may be explained by the difference in pathogenesis of these vascular 
lesions. Infarcts are acute events, and therefore a depressive disorder may develop directly 
after the infarct has occurred, due to disconnection in neural circuits involved in mood 
regulation.21 Participants with an infarct on MRI are therefore more likely to be depressed 
at baseline, which may become chronic during follow-up. White matter lesions on the other 
hand, may represent a more gradual process of brain damage, which might result in a de-
pressive disorder after the damage has reached a certain threshold. This is in line with the 
Cardiovascular Health Study that reported that MRI infarcts were associated with persist-
ence of depressive symptoms, whereas white matter lesions were associated with worsen-
ing of depressive symptoms.7
Depressive disorders are frequently found in patients with dementia.22 Brain infarcts 
and white matter lesions are thought to be risk factors for dementia,17,23 and the association 
between these lesions and depression may therefore be explained by the coexistence of de-
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mentia. In our study, the risk increase of depressive disorders with the presence of brain le-
sions remained largely unchanged after exclusion of participants who developed dementia 
during follow-up. This suggests that in the present study the associations of brain infarcts 
and white matter lesions with depression are not conﬁ ned to participants who developed 
dementia during follow-up. However, there is evidence that late-onset depression is often a 
prodromal disorder for dementia, and people who developed a depressive disorder in our 
study may be predisposed to the later development of dementia.24
Several mechanisms have been proposed for the association between cerebrovascular 
disease and depression.25 First, depressive disorders may be a direct consequence of ischem-
ic brain damage. Second, depressive disorders may be a reaction to deﬁ cits associated with 
serious cerebrovascular disease such as stroke. Third, it has been suggested that depression 
may contribute to the evolution of vascular risk factors and may increase the risk of cer-
ebrovascular disease. We found an increased risk of depressive disorders for people with 
brain infarcts and subcortical white matter lesions. These associations were independent of 
a history of depression, suggesting that cerebral small vessel disease precedes the depres-
sive disorder, rather than being a consequence of depression. Furthermore, asymptomatic 
brain infarcts and white matter lesions, reﬂ ect mainly small vessel disease.11,26 This indicates 
that in elderly people depression may be a direct consequence of vascular brain damage, 
and is not only a psychological reaction to physical disability or perceived disease. Ischemic 
damage of striatal and prefrontal cortical systems may disrupt neurotransmitter circuitry 
involved in mood regulation.19,21
In conclusion, we found an increased risk of depressive disorders in elderly people with 
brain infarcts and white matter lesions in the general population. This supports that vascu-
lar brain damage plays an important role in depression in elderly people. It also suggests 
that prevention of cerebral small vessel disease may diminish the number of depressive 
disorders in elderly people.
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4.1
Measuring progression of cerebral
white matter lesions on MRI;
visual rating and volumetrics
Objective – To evaluate the concordance of  a volumetric method for measuring white matter lesion 
(WML) change with visual rating scales.
Methods – We selected a stratiﬁ ed sample of 20 elderly people (mean age 72 years, range 61-88 years) 
with an MRI examination at baseline and at 3-year follow-up from the community based Rotterdam 
Scan Study. Four raters assessed WML change with four different visual rating scales: the Fazekas 
scale, the Scheltens scale, the Rotterdam Scan Study scale, and a new visual rating scale that was de-
signed to measure change in WML. We assessed concordance with a volumetric method with scatter 
plots and correlations, and interobserver agreement with intraclass correlation coefﬁ cients.
Results – For assessment of change in WML, the Fazekas-, the Scheltens- and periventricular part of the 
Rotterdam Scan Study scale showed little correlation with volumetrics, and low interobserver agree-
ment. Our new WML change scale and the subcortical part of the Rotterdam Scan Study scale showed 
good correlation with volumetrics. After additional training, the new WML change scale showed good 
interobserver agreement for measuring WML change.
Conclusions – Commonly used visual rating scales are not well suited for measuring change in white 
matter lesion severity. Our new white matter lesion change scale is more accurate and precise, and may 
be of use in studies focusing on progression of white matter lesions.
Abstract
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INTRODUCTION
Cerebral white matter lesions (WML) are thought to result from small vessel disease, and 
their presence and severity increase with age and the presence of arterial hypertension.1-3 Al-
though the clinical signiﬁ cance of these lesions remains to be fully understood, WML have 
been associated with dementia, depression and stroke.4-6 In healthy elderly people, WML 
are associated with adverse cognitive function and the presence of depressive symptoms.7-9 
Patients with Alzheimer’s disease, vascular dementia and depression have more severe 
WML than controls.4,5 It has been suggested that WML progress gradually over time, and 
may ultimately lead to subcortical vascular dementia and vascular depression or contribute 
to the clinical expression of Alzheimer’s disease.10 Studies that have determined progression 
of WML over time are limited, and comparison of their ﬁ ndings is difﬁ cult due to the use of 
different visual rating scales for the assessment of WML progression.11-13 Evaluation of WML 
progression is of clinical importance, since it is needed to determine the natural course of 
these lesions, and to study the effect of intervention studies. Visual rating scales have prov-
en their value in cross-sectional studies, but very little is known about the sensitivity and 
reliability of these scales for measuring change in WML over time. Volumetric methods may 
provide the most objective assessment method, but are often time consuming, and therefore 
not always feasible in large studies. The objective of the present study was to evaluate three 
commonly used visual rating scales, the Fazekas scale,14 the Rotterdam Scan study scale,3 
and the Scheltens scale,15 in terms of accuracy and precision in measuring change of WML 
in a deﬁ ned population. We compared the degree of concordance with a volumetric method, 
and the reproducibility of these scales. In addition, we introduce a simple visual rating scale 
that was designed to measure change in WML over time. We compared the performance 
of this WML change scale with the other three visual rating scales, and with the volumetric 
method.
METHODS
Subjects
The scan material used in the present study originates from subjects participating in the Rot-
terdam Scan Study, a population based study that was designed to study causes and conse-
quences of age related brain changes in elderly people.7 In 1995 through 1996, 1,077 nonde-
mented elderly people aged 60 to 90 years underwent a baseline examination that included 
a cranial MRI scan. In 1999 through 2000, 787 of the 973 participants who were alive and 
eligible (not institutionalized, not moved abroad) were re-examined (response rate 81%). Of 
these participants, 668 underwent a second MRI (response rate 69%). We selected scan pairs 
from 10 participants, in a non-random manner, to serve as a training set. Additionally, we 
randomly selected 20 participants who had a baseline and follow-up scan, in three strata of 
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baseline subcortical WML severity, as assessed with the Rotterdam Scan Study scale.3 We 
selected seven participants from the ﬁ rst tertile of subcortical WML severity, seven from the 
second tertile, and six from the third tertile to cover the whole range of the WML distribu-
tion. The mean age of participants was 72 years (range 61-88 years), 10 (50%) were women 
and 8 (40%) had hypertension. The mean time between the ﬁ rst and second MRI was 3.3 
years (range 2.9-4.0 years).
MRI scanning and white matter lesions
Axial T1-, T2-, and proton-density(PD)-weighted cerebral MR scans were made on a 
1.5-Tesla scanner (Siemens, Erlangen, Germany). The following pulse sequences were ap-
plied: T1 (700 ms/14 ms/ 2 [TR/TE/excitations]), T2 (2200 ms/80 ms), PD (2200 ms/20 
ms). Slice thickness was 5 mm, with an interslice gap of 1 mm, and a matrix size of 192 x 
256 pixels. MRI protocols were identical at baseline and at follow-up. We deﬁ ned WML as 
hyperintense lesions, located in the cerebral white matter, that are visible on both T2- and 
PD-weighted images, and do not have a hypointense center on PD-weighted images (as in 
lacunes). Lesions were considered being periventricular in location when directly adjacent 
to the ventricles;otherwise we considered them as subcortical. If periventricular lesions 
extended 10 mm perpendicularly from the ventricular border, the extending part was per 
deﬁ nition scored as a subcortical lesion.
Rating scales
We assessed WML severity at baseline and WML progression with four different visual rat-
ing scales. The Fazekas scale rates WML both in the periventricular and subcortical region 
on a 0 to 3 scale.14 The Scheltens scale rates WML in the periventricular region on a 0 to 6 
scale, and in the subcortical region on a 0 to 24 scale, on the basis of the size and number of 
the lesions.15 It also includes ratings for basal ganglia and infratentorial areas, which were 
not used in this report. The Rotterdam Scan Study scale rates WML in the periventricular 
region on a 0 to 9 scale, and for subcortical WML a lesion volume is approximated based 
on number and size of the lesions.3 In addition, we designed and used a new simple scale 
to measure WML change: the WML change scale. In this scale change in WML (-1 decrease, 
0 no change, +1 increase) is scored in three periventricular locations (frontal caps, lateral 
bands, occipital caps) resulting in a periventricular score of -3 to +3, and in four subcortical 
locations (frontal, parietal, temporal and occipital), resulting in a subcortical score of -4 to +4. 
Increase is deﬁ ned as the occurrence of a new focal lesion or the enlargement of a previously 
visible lesion;decrease is deﬁ ned as the reverse (i.e. disappearance or shrinkage).
Visual rating system
All ratings were performed at the VU medical center. The MRI studies were in digital for-
mat. Four raters analyzed WML on baseline and follow-up images, using the four different 
visual rating scales. Raters were blinded to clinical information, but not to name, age and 
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scan year. WML were rated on PD- and T2-weighted images, by direct scan comparison on 
a personal computer, using the viewing program Radworks (version 5.1, Applicare, Zeist, 
the Netherlands). To optimize the comparability of the baseline and follow-up scans, im-
ages had been registered and resliced using the software package Mirit, that uses mutual 
information as optimization criteria.16 After a training session in which the four raters in 
couples assessed ten scan pairs of the training set, a consensus meeting was held among the 
authors to identify and resolve any possible differences in application of the various scales. 
Following this training stage, each rater then individually scored the 20 series of baseline 
and follow-up MRI studies. The rating scales were always applied in the same order: ﬁ rstly 
the Fazekas scale, secondly the Rotterdam Scan Study scale, thirdly the Scheltens scale and 
ﬁ nally our WML change scale. Raters were aware which was the baseline and follow-up 
scan, and this may lead to bias towards ﬁ nding a positive change in WML severity.  In order 
to estimate this potential systematic measurement error, two raters reassessed the 20 series 
with the WML change scale in the native domain, ﬁ rst blinded to scan date, and two weeks 
later not-blinded to scan date.
Volumetric assessments
We used PD images for the volumetric quantiﬁ cation of WML volume on a workstation 
(Sparc 5;SUN, Palo Alto, Calif.). One reader identiﬁ ed lesions on the registered images, 
and then determined the areas of the lesions using home-developed software (Show_Im-
ages, version 3.6.1) in the native domain to avoid artiﬁ cial enlargement of lesion areas due 
to reslicing. We used a seed growing method to determine WML areas on each slice for 
periventricular WML (frontal caps, lateral bands, occipital caps), and subcortical WML 
(frontal, parietal, temporal and occipital).17 WML areas were not recorded separately for the 
right and left hemisphere. By summing the areas of each slice multiplied by the interslice 
distance, we calculated total WML volumes for the different regions. The volumetric assess-
ments were performed twice, with an interval of six months, and the mean value of the two 
assessments was used in the analyses. The intraclass correlation coefﬁ cients reﬂ ecting the 
intrarater agreement for the baseline assessment were 0.84 for periventricular and 0.97 for 
subcortical WML volume respectively, with a standard deviation of the difference between 
the two ratings of 1.4 ml for periventricular and 0.86 ml for subcortical WML.18
Data analysis
For the volumetric assessment, change in WML volume was calculated by subtracting the 
baseline WML volume from the follow-up volume.19 Pearson’s correlation coefﬁ cient was 
used to assess the relation between baseline WML severity and WML change in the pe-
riventricular and subcortical region. For the visual rating scales (Fazekas scale, Scheltens 
scale, Rotterdam Scan Study scale), change in WML score was calculated by subtracting the 
baseline from the follow-up rating for each rater separately. Progression on the visual rat-
ing scales was deﬁ ned as an increase of 1 point or more on the scale. We made scatter plots 
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to visualize the relation between the change in WML assessed with the volumetric method 
(in ml), and the visual rating scales. Furthermore, we assessed concordance between visual 
scales and volumetrics by the nonparametric Spearman’s rho. Spearman’s rho values of 0 
were considered no relationship between the variables;values equal to 1 were considered 
to reﬂ ect perfect correlation. We quantiﬁ ed the interobserver agreement on the visual rat-
ing scales with intraclass correlation coefﬁ cients. The intraclass correlation coefﬁ cient is 
the biological variation between participants divided by the sum of the variation between 
participants and the rater variation. We estimated the possible bias in the visual ratings that 
may have been intoduced by being aware which were the baseline and follow-up images. 
Bias was expressed as the mean difference in scores on the WML change scale between not-
blinded ratings and blinded ratings.18 Furthermore, we assessed the 95% limits of agreement 
between the not-blinded and blinded method.
RESULTS
White matter lesion severity at baseline and change
The median WML volumes as assessed with the volumetric method were 3.3 ml (range 
1.6;10.4) at baseline and 0.7 ml (range -2.1;6.7) increase for the periventricular region, and 
0.2 ml at baseline (range 0;15.2) and 0.1 ml (range -0.4;3.5) increase for the subcortical region. 
Mean increase in the periventricular region was 1.4 (SD 2.2) and in the subcortical region 0.5 
(SD 0.9). This corresponds to a mean WML increase at a rate of 0.42 ml per year in the peri-
Figure 1. WML progression in an 88-year-old woman who participated in our study.
The composite shows a slice from the baseline study (left), and a corresponding slice from the 
follow up study (right). After 3 1/2 years WML progression has occurred (arrows) in the left and 
right occipital cap (periventricular region), extending into the parietal subcortical regions.
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Table 1A. Periventricular WML severity at baseline, change and number of participants with 
progression for the four visual rating scales and for the four raters
Rating scale Rater 1 Rater 2 Rater 3 Rater 4
  Fazekas scale, 0 to 3
    Baseline, median (rg) 2(2;3) 2(1;3) 2(1;3) 2(2;3)
    Change, median (rg) 0(0;1) 0(0;1) 0(0) 0(0)
    Progression, n (%) 2(10%) 3(15%) 0(0%) 0(0%)
  RSS scale, 0 to 9
    Baseline, median (rg) 6(4;9) 5(3;9) 5(3;9) 5.5(3;9)
    Change, median (rg) 0(0;1) 0(0;2) 0(0) 0(0;1)
    Progression, n (%) 6(30%) 6(30%) 0(0%) 6(30%)
  Scheltens scale, 0 to 6
    Baseline, median (rg) 4(3;6) 3(3;6) 3(2;6) 3(2;6)
    Change, median (rg) 0(0;2) 0(0;3) 0(0;1) 0(0;1)
    Progression, n (%) 2(10%) 3(15%) 1(5%) 3(15%)
  WML change scale, -3 to 3
    Change, median (rg) 1(0;3) 1(-1;3) 0(0;3) 0(0;3)
    Progression, n (%) 11(55%) 11(55%) 5(25%) 8(40%)
Values are medians (range) or absolute numbers (percentage).
Progression on the visual rating scales, including the WML change scale, was deﬁ ned as a positive 
change of 1 point or more on the scale.
Table 1B. Subcortical WML severity at baseline, change and number of participants with 
progression for the four visual rating scales and for the four raters
Rating scale Rater 1 Rater 2 Rater 3 Rater 4
  Fazekas scale, 0 to 3
    Baseline, median (rg) 1(0;3) 1(0;3) 1(0;3) 1(0;3)
    Change, median (rg) 0(0;1) 0(0;1) 0(0;1) 0(0)
    Progression, n (%) 3(15%) 3(15%) 2(10%) 0(0%)
  RSS scale, ml
    Baseline, median (rg) 0.2(0;9.8) 0.4(0;6.4) 0.7(0;9.9) 0.6(0;7.0)
    Change, median (rg) 0.2(0;1.4) 0.2(-0.1;3.8) 0.0(-0.2;2.2) 0.6(-0.1;3.4)
    Progression, n (%) 2(10%) 5(25%) 1(5%) 6(30%)
  Scheltens scale, 0 to 24
    Baseline, median (rg) 5.5(0;23) 6(0;20) 4(0;23) 7(1;21)
    Change, median (rg) 1(0;3) 1.5(-2;4) 0(-2;6) 2(-1;12)
    Progression, n (%) 11(55%) 11(55%) 5(25%) 18(90%)
  WML change scale, -4 to 4
    Change, median (rg) 1(0;3) 2(-1;4) 0(-1;3) 1(0;3)
    Progression, n (%) 16(80%) 17(85%) 9(45%) 17(85%)
Values are medians (range) or absolute numbers (percentage).
Progression on the visual rating scales, including the WML change scale, was deﬁ ned as a positive 
change of 1 point or more on the scale.
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ventricular region and 0.15 ml per year in the subcortical region. Figure 1 shows an example 
of WML progression in the periventricular and subcortical region. 
WML volumes at baseline were positively correlated with WML change (Pearson corre-
lation coefﬁ cient 0.70, p =0.001 for periventricular WML;0.90 p<0.001 for subcortical WML). 
Table 1 gives the WML severity at baseline and WML change as well as the number of partic-
ipants with WML progression, as assessed with the different visual rating scales for the four 
raters. Several methods showed on average an increase in WML in both the periventricular 
and subcortical region, but the number of participants showing progression varied largely 
between the different methods applied.
Correlation between volumetric assessment and visual rating scales
We evaluated the concordance between the volumetric WML change and the change as-
sessed with the visual rating scales. This was done separately for the four raters, and after 
averaging the visual rating of the four raters in order to reduce noise due to interobserver 
disagreement. Figure 2 shows the scatter plots of the relationship between WML change 
measured with the volumetric assessment and the visual rating scales (average of four 
raters) in the periventricular and subcortical region. Visual inspection of the scatter plots 
shows comparatively good agreement between the WML change scale and the volumetric 
method, although the WML change scale tends to overestimate lesion change in the sub-
cortical region (ﬁ gure 2 D), and may systemetically underestimate lesion change in the peri-
ventricular region as volume change gets larger (ﬁ gure 2H). Table 2 gives the nonparametric 
Spearman’s rho between the volumetric method and the four visual rating scales on WML 
change. Only the subcortical part of the Rotterdam Scan Study scale and the WML change 
scale showed signiﬁ cant correlation with the volumetric method for raters 1, 2 and 3, and for 
the average of the four raters (table 2).
Interobserver agreement
The intraclass correlation coefﬁ cients for the interobserver agreement on baseline WML 
severity and change for the visual rating scales including our new WML change scale are 
presented in table 3. Values <0.20 were considered to reﬂ ect poor agreement, 0.21-0.40 fair 
agreement, 0.41-0.60 moderate agreement, 0.61-0.80 good agreement, and 0.81-1.00 very 
good agreement.18 The interobserver agreement for the baseline ratings on the Fazekas, 
Scheltens, and Rotterdam Scan Study scales was fair to good for the periventricular region 
and good to very good for the subcortical region (table 3). However, agreement on change 
was poor for the Fazekas and Scheltens scales, fair for the WML change scale and the peri-
ventricular part of the Rotterdam Scan Study scale, and moderate for the subcortical part of 
the Rotterdam Scan Study scale.
The raters had been using the existing rating scales by Fazekas, Scheltens, and the Rot-
terdam Scan Study previously and thus were better acquainted with it. In a post-hoc study 
that was performed using the new WML change scale after additional training, two of the 
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Table 2. Correlation between volumetrics and visual rating of WML change assessed by the 
nonparametric Spearman’s rho test.
Spearman’s rho
Rater 1 Rater 2 Rater 3 Rater 4
Mean
four raters
Periventricular WML
   Fazekas scale 0.29 0.30 N.A. N.A. 0.37
   Rotterdam Scan Study scale 0.42 0.24 N.A. 0.13 0.27
   Scheltens scale 0.29 0.40 0.18 0.11 0.39
   WML change scale 0.55* 0.70† 0.38 0.13 0.62†
Subcortical WML
   Fazekas scale 0.28 0.13 0.43 N.A. 0.40
   Rotterdam Scan Study scale 0.62† 0.59† 0.19 0.50* 0.54*
   Scheltens scale 0.12 0.28 0.25 -0.18 0.27
   WML change scale 0.65† 0.61† 0.60† 0.35 0.79†
*p<0.05
†p<0.01
N.A. not assessed because none of the participants showed change on the visual scale.
Table 3. Interobserver agreement for the visual rating 
scales for baseline and change measurements
Baseline Change
Periventricular WML
   Fazekas scale 0.37 0.08
   Rotterdam Scan Study scale 0.64 0.23
   Scheltens scale 0.56 0.18
   WML change scale 0.39
Subcortical WML
   Fazekas scale 0.84 0.18
   Rotterdam Scan Study scale 0.90 0.47
   Scheltens scale 0.84 0.003
   WML change scale 0.24
Numbers are intraclass correlation coefﬁ cients.
raters rated 200 additional pairs 
of scans. In this second sample, 
the interobserver agreement was 
0.73 for the periventricular region, 
and 0.72 for the subcortical region, 
indicating good agreement.
Effect of blinding to the scan 
date
Mean difference in score on the 
WML change scale between the 
not-blinded and blinded method 
were +0.075 (SD 0.40) points in 
the periventricular region, and 
-0.025 (SD 0.44) in the subcortical 
region. This indicates there is no substantial bias towards higher progression when images 
are scored with knowledge of which are the baseline and which are the follow-up images. 
The 95% limits of agreement between the not-blinded and the blinded method were (-0.71 
to +0.86) for the periventricular region, and (-0.84 to +0.89) for the subcortical region, which 
suggests that for an individual the not-blinded and blinded methods are unlikely to disa-
gree more than one point on the WML change scale.
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DISCUSSION
We evaluated three commonly used visual rating scales, and one new simple visual rating 
scale in terms of their ability to measure change in WML severity on MRI. We assessed the 
concordance of the visual assessments with volumetric change, and quantiﬁ ed the repro-
ducibility of the scales for measuring WML change. In a stratiﬁ ed sample from a deﬁ ned 
population, during a 3-year time period, both the volumetric method and the visual rating 
scales showed, on average, an increase in WML. We found signiﬁ cant correlations with 
volumetric change for the subcortical part of the Rotterdam Scan Study scale and for the 
new WML change scale. The interobserver agreement was moderate for change on the 
subcortical part of the Rotterdam Scan Study scale, and fair for the WML change scale. In a 
post-hoc study, the interobserver agreement for the WML change scale improved to good 
agreement after observers had become familiarized with the scale. The Fazekas, Scheltens, 
and peri ventricular part of the Rotterdam Scan Study scales showed poor correlation with 
volumetric change, and poor to fair interobserver agreement on the change measurements.
Several methodological issues need to be addressed. First, there is currently no gold 
standard for the assessment of WML change, and our volumetric method cannot be in-
terpreted as such. Second, the comparison between volumetric WML change and WML 
change measured with different visual scales is complicated by differences in type of data 
(continuous versus categorical) obtained with the different methods. We used rank correla-
tion to evaluate the relationship between the visual scales and volumetrics. Unlike agree-
ment, correlation is not affected by the scale of measurement, but does depend on the range 
of the quantity of the sample.19 Therefore, the presented correlations cannot be interpreted 
as agreement between the visual scales and volumetrics, although they do allow for com-
parison between the visual scales. Third, visual rating was performed side by side, and 
with knowledge of the time sequence of scans, which may have led to some bias towards a 
higher progression rating. However, we evaluated this possible bias in a post-hoc analysis, 
and found that this effect was very small. Fourth, registration of the follow-up scans on the 
baseline scans may have caused blurring effect, and although this effect was judged to be 
small, it may have contributed to higher progression rating with the visual rating scales.
The Fazekas, Scheltens, and Rotterdam Scan Study scales were designed for cross-sec-
tional assessments of WML. When applied in a cross-sectional fashion these scales show both 
good intra- and interobserver agreement, which largely corresponds to our ﬁ ndings of  fair 
to very good interobserver agreement for the baseline assessments.3,15,20 A previous study re-
ported that visual rating with the Fazekas and Scheltens scales shows signiﬁ cant correlation 
with quantitative volumetric assessments.20 However, visual assessment of WML change 
with these scales is problematic. There are several explanations for the disappointing per-
formance of these scales in measuring WML change. As shown in our and other data sets, 
baseline WML severity is positively correlated with WML change.11 WML that were already 
rated in the highest category at baseline (and which are most likely to progress) cannot con-
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tribute to progression on these scales due to a ceiling effect. Furthermore, new lesions may 
develop or lesions may grow without crossing the limits of the categories of the scales, and 
thereby remain below detection on the visual scales. The subcortical part of the Rotterdam 
Scan study scale performed better in capturing change, most likely because it incorporates 
the number and size of lesions in more detail, thus avoiding a ceiling effect. However, the 
subcortical part of this scale is elaborate and time consuming. Our new WML change scale 
that was designed to measure WML change not only seemed to be valid, but also takes less 
time to apply. Although agreement on progression initially was fair, it approved to good 
agreement after additional training.
We found that during a three-year time period WML volume increased at a mean rate of 
0.42 ml per year in the periventricular region and 0.15 ml per year in the subcortical region. 
These ﬁ gures on rate of change do not directly reﬂ ect the rate of change in the population at 
large because of the way we constructed our sample for this validation study.  The NHLBI 
Twin study reported a mean WML volume increase of 0.38 ml per year in 168 individual 
male twins with a mean age of 72 years,21 which is comparable to the range of our ﬁ ndings 
on rate of change.
When we compare the interobserver agreement on the visual scales for the baseline as-
sessments in the present study to those reported in the literature, interobserver agreement 
was comparable for periventricular WML on the Fazekas scale (0.37 vs. 0.35-0.74) and for 
subcortical WML on the Rotterdam Scan Study scale (0.90 vs. 0.88), higher for subcortical 
WML on the Fazekas scale (0.84 vs. 0.34-0.78) and Scheltens scale (0.84 vs. 0.69), but lower 
for periventricular WML on the Scheltens scale (0.56 vs. 0.71) and Rotterdam Scan Study 
scale (0.64 vs. 0.79-0.90).3,15,20
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4.2
Progression of cerebral white
matter lesions in the population-
based Rotterdam Scan Study
Background and purpose – Cerebral white matter lesions in elderly people are mostly caused by cer-
ebral small-vessel disease and have been associated with an increased risk of stroke, dementia and 
depression. We studied the rate of white matter lesion progression over time, and its relation with 
cardiovascular risk factors.
Methods – Six hundred sixty-eight people, aged 60 to 90 years, underwent repeated MRI scanning 
within a 3-year follow-up, as part of the prospective population-based Rotterdam Scan Study. We 
rated change in periventricular and subcortical white matter lesion severity with a semiquantitative 
scale, and graded progression as no, minor or marked. We assessed risk factors for white matter lesion 
progression with logistic and multinomial logistic regression analysis.
Results – Twenty-seven percent of participants showed any and 9% showed marked progression of 
white matter lesions in the periventricular region. Thirty-two percent showed any and 10% showed 
marked progression in the subcortical region. White matter lesion severity and presence of brain inf-
arcts at baseline, higher age, high blood pressure, and current smoking were positively associated with 
progression of white matter lesions. Women had more marked progression of subcortical white matter 
lesions compared to men.
Conclusion – Approximately one-third of elderly people have progression of white matter lesions in 3 
years. Presence and severity of white matter lesion and brain infarcts, higher age, female sex, elevated 
blood pressure and current cigarette smoking are associated with white matter lesion progression.
Abstract
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INTRODUCTION
Cerebral white matter lesions are frequently seen on magnetic resonance imaging (MRI) 
scans in elderly people.1,2 These lesions mostly reﬂ ect demyelination and axon loss due to 
chronic ischemia associated with cerebral small vessel disease.3-5 People with more severe 
white matter lesions have an increased risk of stroke, dementia, and depression.6-8
Cross-sectional studies reported on the higher prevalence and increased severity of 
white matter lesions with older age. Hypertension is considered the main risk factor, but 
other cardiovascular risk factors may be related to these lesions as well.1,5,9-15 Data on change 
of white mater lesions in community dwelling people are however scarce.16 The Austrian 
Stroke Prevention Study reported progression of white matter lesions within three years 
in 18% of the 273 participants. Diastolic blood pressure and severe white matter lesions at 
baseline were the only predictors of lesion progression.16,17
We investigated in a large population-based sample of elderly people, the rate, location 
and conﬁ guration of change of cerebral white matter lesions. Furthermore, we studied the 
association of age, sex, severity and presence of white matter lesions and brain infarcts at 
baseline, and cardiovascular risk factors with progression of cerebral white matter lesions.
METHODS
Subjects
The Rotterdam Scan Study is a prospective population-based cohort study designed to 
study the causes and consequences of age related brain changes in elderly people.18 We 
randomly selected people 60 to 90 years of age, stratiﬁ ed on age and sex, from two ongo-
ing population based studies, the Rotterdam Study and the Zoetermeer study.19,20 A total of 
1,077 elderly people without dementia participated (response rate 63%). The medical ethics 
committee of the Erasmus Medical Center approved the study, and each participant gave 
written informed consent. The baseline examination in 1995 to 1996 comprised a structured 
interview, physical examination, blood sampling, and neuropsychological tests, as well as 
a cerebral MRI scan.
In 1999 to 2000, we re-invited 951 people who were eligible for a second MRI examina-
tion from the cohort of 1,077 people who had a MRI examination at baseline. In total 668 
participated (response rate 70%). One-hundred-twenty-six participants were ineligible to 
undergo a second MRI for the following reasons: 82 died, 19 were institutionalized, 19 had 
MRI contraindications, 3 moved abroad, and 3 could not be reached. The reasons for refusal 
to participate in the second examination were as follows: claustrophobia developed at the 
baseline MRI (n=98), too much trouble (n=90), no interest (n=77), and other reasons (n=18).
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MRI scanning 
At baseline, we made axial T1-, T2-, and proton-density- (PD) weighted cerebral MR scans 
on a 1.5-Tesla scanner (for participants from Zoetermeer, MR Gyroscan, Philips; for par-
ticipants from Rotterdam MR VISION, Siemens, with comparable pulse sequences).18 In 
1999 to 2000 all second MRI scans were made with the MR VISION scanner and the same 
sequences. 
Lesion rating
We considered white matter lesions to be periventricular if they were directly adjacent to 
the ventricle; otherwise we considered them subcortical. At baseline, we scored white mat-
ter lesions severity on hardcopy as described previously.18 We scored periventricular white 
matter lesions semiquantitatively in order to obtain a total periventricular score (range 0-9). 
For subcortical white matter lesion, we approximated a total volume (range 0-29.5 ml). We 
deﬁ ned infarcts as focal hyperintensities on T2-weighted images, 3 mm in size or larger. 
Lesions in the white matter also had to have corresponding prominent hypointensities on 
T1-weighted images, in order to distinguish them from cerebral white matter lesions. We 
deﬁ ned lacunar infarcts as infarcts sized 3 to 20 mm and located in the subcortical white 
matter or basal ganglia.
To assess change of white matter lesions, we transferred digital images to a Linux PC, 
and used a Matlab software (Mathworks) viewing tool. Two raters independently analyzed 
progression of white matter lesions severity on PD- and T2-weighted images by direct scan 
comparison. We used a new white matter lesions change scale, since commonly used rating 
scales designed for cross-sectional assessments of white matter lesions are not well suited 
for measuring change.21 Baseline and follow-up series were downloaded side-by-side, with 
the baseline and follow-up scan randomly appearing on the right or left side of the screen. 
We assessed the difference in white matter lesion severity between the right and left im-
ages. In the periventricular region, we assessed difference in size of lesions in the frontal 
caps, lateral bands, and occipital caps, in the left and right hemisphere (negative difference 
-1 point, no difference 0 points, positive difference +1 point, resulting in a score of -6 to +6). 
In the subcortical region, we assessed difference in number, size, or conﬂ uence of lesions in 
the frontal, parietal, temporal and occipital lobes of the left and right hemisphere (negative 
difference -1 point, no difference 0 points, positive difference +1 point, resulting in a score of 
-8 to +8). If periventricular lesion change extended beyond 10 mm outside the border of the 
ventricle, we considered the change to have occurred in both the periventricular and sub-
cortical region. Raters were blinded to all clinical information, including scan date, for par-
ticipants derived from the Rotterdam Study. This was not possible for participants derived 
from the Zoetermeer Study due to the change in MRI between baseline and follow-up. If 
raters disagreed one point or less on the scale, we used the mean of the ratings, otherwise we 
held a consensus meeting. The change rating showed good interobserver agreement (intra-
class correlation coefﬁ cient periventricular region 0.79; subcortical region 0.75), and good to 
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very good intraobserver agreement (intraclass correlation coefﬁ cient periventricular region 
0.70-0.89; subcortical region 0.78-0.93). Digital images were not available in 52 participants 
due to technical problems. In these participants, we assessed white matter lesion change on 
hardcopy. We deﬁ ned progression as an increase of 1 point or more between baseline and 
follow-up. Progression was categorized into minor progression (score 1-2.5) and marked 
progression (score 3 or higher).
We evaluated the effect of non-blinding of the scan date.21 The difference between non-
blinded and blinded scores was 0.075 (95%CI -0.71; +0.86) points for periventricular white 
matter lesions, and 0.025 (95%CI -0.84; +0.89) points for subcortical white matter lesions. 
Therefore, non-blinding in the Zoetermeer Study part of our study did not introduce bias.
Cardiovascular risk factors
Blood pressure was measured twice on the right arm with a random-zero sphygmoma-
nometer. The two measurements were averaged. Hypertension was deﬁ ned according to 
WHO-ISH guidelines, as systolic blood pressure of ≥ 160 mmHg, diastolic blood pressure 
of ≥ 100 mmHg, or the use of blood pressure lowering medication.22 Smoking habits were 
classiﬁ ed as never, former and current cigarette smoking. We considered diabetes mellitus 
to be present if the random glucose level was ≥ 11.1 mmol/l or if a person was taking oral 
antidiabetics or insulin. The presence of atrial ﬁ brillation was assessed by MEANS interpre-
tation of a 12-lead ECG (ACTA ECG, ESAOTE).23 Serum total cholesterol and high-density 
lipoprotein were determined with an automated enzymatic procedure (Hitachi analyzer, 
Roche Diagnostics). To determine plasma total homocysteine levels, we used a ﬂ uores-
cence polarisation immunoassay on an IMx analyser (Abbott Laboratories).9 Partial arterial 
oxygen saturation was measured twice, with a pulse oximeter (Andos, Oxycount). The two 
measurements were averaged (range 86-99%).15 Participants underwent ultrasonography 
of both carotid arteries with a 7.5-MHz linear-array transducer and a Duplex scanner (ATL 
Ultra-Mark IV, Advanced Technology Laboratories). We examined the right and left carotid 
arteries for the presence of plaques in the common carotid artery, bifurcation, and internal 
carotid artery and calculated the total number of sites with plaques present (range 0-6). In-
tima-media thickness was measured by longitudinal 2-dimensional ultrasound of the com-
mon carotid artery. We calculated the mean common carotid intima-media thickness as the 
mean of the near and far walls of both the right and left common carotid arteries.13 Apolipo-
protein E (APOE) genotyping was done on coded genomic DNA samples.24 The distribution 
of the APOE genotype in this population was in Hardy-Weinberg equilibrium.
Data analysis
We used age and sex adjusted analysis of covariance to assess whether baseline risk fac-
tors differed between people with and without a second MRI assessment. We calculated 
Spearman’s rho for correlation between periventricular and subcortical white matter lesion 
progression. We used logistic and multinomial logistic regression analyses to study the 
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association of risk factors with any, minor and marked white matter lesion progression. 
People with a negative difference in white matter lesion severity over time were added to 
the group of people with no progression. All analyses were adjusted for age and sex, and 
additionally for cardiovascular risk factors. Baseline white matter lesion severity could con-
found the relation between risk factors and white matter lesion progression. However since 
it could also be an intermediate factor, adjustment for baseline severity may result in over 
adjusted estimates as well. To evaluate these effects we additionally adjusted the analyses 
for baseline white matter lesion severity.
Table 1. Baseline characteristics of people who had a 2nd MRI assessment and for those who 
refused or were ineligible.
People with 
2nd MRI as-
sessment
n=668
People that 
refused 2nd 
MRI assess-
ment
n=283
People 
ineligible for 
2nd MRI as-
sessment
n=126
Age, year
Women
Systolic blood pressure, mmHg
Diastolic blood pressure, mmHg
Use of antihypertensive medication
Hypertension
Current smoking
Former smoking
Diabetes
Atrial ﬁ brillation
Total cholesterol, mmol/l
High-density lipoprotein, mmol/l
Use of lipid-lowering drugs
Total homocysteine, µmol/l
Oxygen saturation, %SpO
2
Intima media thickness, mm
Plaques in carotid artery (range 0-6)
Periventricular white matter lesions (range 0-9)
Subcortical white matter lesions, ml
Brain infarcts
Lacunar infarcts
APOE ε4 allele
71 (7)
52
147 (21)
79 (12)
30
47
16
51
5
3
5.9 (1.0)
1.3 (0.3)
7
11.0 (3.6)
96.4 (1.3)
0.86 (0.15)
1.5 (1.6)
2.2 (2.1)
1.2 (2.5)
22
20
30
74 (7)*
57
149 (22)
79 (12)
42*
57
13
50
8
1
5.9 (1.0)
1.3 (0.4)
8
11.7 (4.2)
96.3 (1.2)
0.87 (0.13)
1.8 (1.6)
2.5 (2.1)
1.5 (3.1)
25
23
30
77 (8)*
41*
146 (23)
75 (12)*
43
58
21*
52
13*
9*
5.7 (1.3)
1.2 (0.3)*
2*
13.9 (5.4)*
96.3 (1.5)
0.93 (0.17)
2.3 (1.7)*
3.5 (2.5)*
2.1 (4.1)
34
28
22
Values are unadjusted means (SD) or percentages
*Age and sex adjusted mean or percentage is signiﬁ cantly different (p<0.05) from people with 
2nd MRI assessment
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RESULTS
People who underwent a second MRI were younger and less often used blood pressure low-
ering medication than people who refused a second examination (table 1). They were also 
younger, healthier and more often female than people who were ineligible for a second MRI 
(table 1). The mean follow-up between the two MRI assessments was 3.3 (SD 0.2) years.
Twenty seven percent of the people had any progression of periventricular white mat-
ter lesions and 32% had any progression of subcortical white matter lesions, whereas 39% 
had any progression of white matter lesions in either region (table 2). Spearman’s rho for 
the correlation between progression in the periventricular and subcortical region was 0.60 
(p<0.001)). Two people had minor regression of white matter lesions in the periventricular 
and 13 in the subcortical region. Within people with periventricular white matter progres-
sion, 17% had progression of the frontal caps, 56% of the bands and 73% of the occipital caps. 
Within the people with subcortical white matter lesion progression, 71% had progression in 
the frontal, 63% in the parietal, 12% in the occipital and 7% in the temporal lobe. The hemi-
spheres were equally affected. Marked subcortical white matter progression predominantly 
consisted of growth and conﬂ uence of lesions, whereas minor progression mostly consisted 
of new small lesions (ﬁ gure 1).
Table 2. Relationship between periventricular and subcortical white matter lesion (WML) 
progression.
Periventricular WML progression
no minor marked totals
S
u
b
c
o
rt
ic
a
l
W
M
L
P
ro
g
re
s
s
io
n no
minor
marked
407 (61)
72 (11)
         9 (1)
38 (6)
59 (9)
23 (3)
6 (1)
19 (3)
35 (5)
451 (68)
150 (23)
67 (10)
totals 488 (73) 120 (18) 60 (9) 668 (100)
Numbers are absolute numbers of people and percentages of overall total.
Figure 1. Conﬁ guration 
of minor and marked 
subcortical white matter 
lesion progression.
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White matter lesion severity and the presence of brain infarcts, of which 90% were lacu-
nar, on baseline MRI were strongly related to progression of white matter lesions (table 3). 
None of the people without lesions at baseline, and three people with only small punctate 
lesions (<3 mm) at baseline, had marked subcortical white matter lesion progression. The 
extent of progression of both periventricular and subcortical white matter lesions was 
strongly related to age (ﬁ gure 2). Women had a higher risk of subcortical white matter le-
sions progression than men, and this difference reached signiﬁ cance for marked subcortical 
white matter lesions (table 4). Systolic and diastolic blood pressure were positively associ-
ated with white matter lesion progression (table 4), which remained after adjustment for 
use of blood pressure lowering medication (data not shown). Current cigarette smoking 
was positively associated with marked white matter lesion progression (table 4). We did not 
observe a relation between atrial ﬁ brillation, carotid atherosclerosis, homocysteine levels, 
oxygen saturation and white matter lesion progression. 
Additional adjustment for baseline white matter lesion severity, strongly diminished the 
strength of the associations between white matter lesion progression and age (odds ratios 
per year increase in age for progression in the periventricular region 1.05 (95%CI 1.02; 1.08), 
in the subcortical region 1.02 (95%CI 1.00; 1.05)), sex (odds ratio of women for marked pro-
Figure 2. Proportions of periven-
tricular and subcortical white lesion 
progression in 10 years age strata.
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gression of subcortical white matter lesions 1.67 (95%CI 0.89; 3.12)), systolic blood pressure 
(odds ratio per standard deviation increase for progression in the periventricular region 
1.09 (95%CI 0.87;1.36), in the subcortical region 1.07 (95%CI 0.88;1.29)), and diastolic blood 
pressure (odds ratio per standard deviation increase for progression in the periventricular 
region 1.17 (95%CI 0.94;1.45), in the subcortical region 1.09 (95%CI 0.91;1.31)). The associa-
tions between current cigarette smoking and marked white matter lesion progression did 
not change after adjustment for white matter lesion severity at baseline. The association of 
blood pressure, hypertension, and smoking with progression of white matter lesions hardly 
changed after additional adjustment for other cardiovascular risk factors (data not shown).
DISCUSSION
We found that approximately 30% of people between 60 and 90 years of age had any pro-
gression and 10% had marked progression of periventricular and subcortical white matter 
lesions within a period of 3-years. Older age, female sex, higher blood pressure, current 
cigarette smoking and high white matter lesion severity and the presence of brain infarcts 
at baseline were associated with progression of white mater lesions. The associations were 
independent of other cardiovascular risk factors.
The strengths of the present study are its large number of participating elderly people 
from the general population, its prospective design, and the assessment of a large number 
of risk factors. Still, several methodological issues should be considered. First, there is a pos-
sibility of selection bias. People who participated were younger and healthier compared to 
those who were ineligible or refused a second MRI scan. Therefore, the progression of white 
matter lesions in our study may be an underestimation of the progression in the population 
at large. The same selection may also have attenuated the estimates for the associations 
between risk factors and progression of white matter lesions. Second, we changed MRI 
scanner in half of our cohort, which made it not possible to blind for study date in that part. 
However, we evaluated the effect of non-blinding and found that it did not cause overesti-
mation of progression in our study.21 Furthermore, the rate of progression and the strength 
of the associations between risk factors and white matter lesion progression were not differ-
ent for the blinded and non-blinded group. Third, adjustment for baseline lesions could in 
theory introduce overestimated risk associations. This results from regression towards the 
mean as a result of measurement error.25 We consider this effect to be small, ﬁ rstly because 
we used a change scale instead of calculated differences between repeated measurements, 
and secondly because none of the risk estimates increased after adjustment for lesions at 
baseline.
It is hard to compare the distribution of white matter lesions between studies, due to dif-
ferences in study population, imaging techniques, lesion rating, lesion categorization and 
risk factor distributions, and the same holds for comparing progression of white matter le-
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sions.26 In the Austrian Stroke Prevention Study,16,17 18% of the participants had any and 8% 
had marked progression within 3 years of follow-up. The lower proportion of progression of 
white matter lesions in this study compared to our ﬁ ndings could be explained by the exclu-
sion of people with cerebrovascular disease, the 10 years lower mean age of the participants 
and the lower response rate.
In cross-sectional studies, older age and higher blood pressure, in particular diastolic 
blood pressure, were strongly associated with white matter lesion severity.2,18 Furthermore, 
women tended to have more severe white matter lesions.2 We observed that these risk 
factors are also associated with progression of white matter lesions. The Austrian Stroke 
Prevention study reported the same associations of age and diastolic blood pressure with 
progression of white matter lesions.16,17 In addition, we found that current cigarette smoking 
was also associated with periventricular and subcortical white matter lesion progression.
Our data conﬁ rm that white matter lesion severity and presence of brain infarcts at base-
line are strongly associated with lesion progression.16,17,27 The association between brain inf-
arcts and progression of white matter lesions can be explained by a shared exposure to risk 
factors and susceptibility for these factors, resulting in a common pathological substrate.27,28 
Baseline white matter lesions and lacunar infarcts reﬂ ect small vessel disease and chronic 
hypoperfusion. Continuation of a state of hypoperfusion could, without additional vessel 
damage, result in lesion progression. We adjusted for baseline white matter lesions to assess 
whether risk factors were associated with progression independent of the severity of small 
vessel damage that was already present. This adjustment strongly diminished the strength 
of the associations between risk factors and progression of white matter lesions, suggesting 
that the effect of age and high blood pressure on white matter lesion progression in a 3-year 
period is for a large part explained by the relation with severity of small vessel disease at 
baseline.
We reported previously on the cross-sectional association between atrial ﬁ brillation,11 
carotid atherosclerosis,12 homocysteine levels,9 oxygen saturation15 and white matter lesions. 
We did not observe an association between these factors and progression of white matter le-
sions. This could be explained by selective follow-up as noted earlier. We repeated the cross-
sectional analyses with these risk factors in the 668 people with a second MRI and found 
no signiﬁ cant associations (data not shown), conﬁ rming selective follow-up. Alternative 
explanations for these distinct ﬁ ndings are the smaller samples size, and the possibility that 
baseline white matter lesion distribution is a more robust measure of small vessel disease 
since it reﬂ ects accumulation of lesions over a longer period of time.
In this study we considered progression of white matter lesions as an increase in number, 
size or conﬂ uence of lesions. This “lesion volume”-based paradigm may not cover the 
complete pathofysiology, since progression could, apart from increase in volume, also be 
increase in tissue damage within existing lesions. Conﬂ uent white matter lesion show his-
topathological similarity to lacunar infarcts, whereas smaller lesions correspond to no or in-
complete infarction.3,4 A prospective study in patients with CADASIL showed progression 
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in tissue damage with diffusion tensor imaging.29 Future studies on the development of pro-
gression of white matter lesions should therefore not only examine change in number and 
size of lesions, but should also take change in integrity of the white matter into account.
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4.3
Progression of cerebral white
matter lesions and the risk of
stroke, dementia and depression
Background and purpose – Cerebral white matter lesions (WML) are common in elderly people and 
mostly reﬂ ect ischemic damage due to cerebral small-vessel disease. We examined whether progres-
sion of WML is associated with the risk of stroke, dementia, cognitive decline, and depressive symp-
toms in the general population.
Methods – In 668 participants from the Rotterdam Scan Study we performed MRI of the brain both 
at baseline in 1995 to 1996 and again in 1999 to 2000. We assessed progression of WML with a semi-
quantitative rating scale by direct scan comparison. At both visits participants underwent a structured 
interview, physical examination and neuropsychological testing. Throughout the study period, we 
monitored participants for stroke and dementia. We used multiple logistic and linear regression analy-
sis to examine the association between WML progression and clinical outcomes.
Results – The mean follow-up period between the ﬁ rst and second MRI was 3.3 years. In this period 
about one third of participants showed WML progression. WML progression was associated with a 
more than three-fold increased risk of stroke and a steeper decline in global cognitive function and psy-
chomotor speed. Marked WML progression increased the risk of dementia and depressive symptoms, 
which was partly explained by the occurrence of stroke during follow-up.
Conclusions – Elderly people with WML progression have an increased risk of stroke, dementia, cogni-
tive decline and depressive symptoms in comparison to those without WML progression.
Abstract
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INTRODUCTION
Cerebral white matter lesions are frequently observed on MRI in elderly people. These 
lesions mostly reﬂ ect incomplete infarction of the cerebral white matter as a result of 
ischemic damage caused by cerebral small vessel disease.1 The presence and severity of 
WML increases with age and the presence of arterial hypertension.2 Although the clinical 
importance of WML remains to be fully understood, evidence accumulates that WML are 
associated with the development of stroke, dementia and depression.3,4 However, most evi-
dence relating WML to clinical outcomes is derived from studies that used a single WML 
measurement. Studying progression of WML over time in relation to clinical outcomes may 
provide stronger arguments for a causal relationship between WML and clinical outcomes. 
The population-based Austrian Stroke Prevention Study reported progression of white mat-
ter lesions in 18% of individuals over 3 years.5 In this study, lesion progression had no inﬂ u-
ence on the course of neuropsychological test performance, and this lack of association asks 
for further exploration. A study in patients with symptomatic carotid artery disease found 
that progression of WML on CT was associated with the occurrence of stroke.6 The purpose 
of the present study was to examine the association between WML progression on MRI and 
the risk of stroke, dementia, cognitive decline, and depressive symptoms in a population-
based follow-up study among elderly people.
METHODS
Subjects
The Rotterdam Scan Study is a prospective, population based cohort study, designed to 
study causes and consequences of age-related brain changes in the elderly. The character-
istics of the 1,077 participants have been described previously.7 All participants were free 
of dementia at baseline. Baseline examination in 1995 to 1996 comprised a structured inter-
view, neuropsychological tests, physical examination, blood sampling, and an MRI scan 
of the brain. In 1999 to 2000, of the 951 participants who were alive and eligible, 668 (70%) 
underwent a second MRI and were re-examined at the research center similar to the base-
line examination.8 All participants were continuously monitored after baseline for mortality, 
dementia and stroke until April 1st 2002.
MRI scanning 
Participants underwent MRI of the brain at baseline in 1995 to 1996. We made axial T1-, T2-, 
and proton density (PD)-weighted cerebral MR scans on a 1.5-Tesla scanner (MR VISION, 
Siemens, MR Gyroscan, Philips).7 In 1999 to 2000, participants underwent a second MRI 
with the use of the MR VISION scanner and the same sequences. Digital data was available 
for 616 participants (92%) of the 668 participants (286 of the 320 participants scanned with 
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the MR VISION at baseline, and 330 of the 348 participants scanned with the MR Gyroscan 
at baseline). 
WML rating scheme
We considered WML to be in the periventricular region if they were directly adjacent to the 
ventricle; otherwise we considered them subcortical. Baseline WML severity was scored 
on hardcopy with a visual rating scale as described previously.7 We scored periventricular 
WML semiquantitatively in order to obtain a total periventricular score (range: 0 to 9). For 
subcortical WML, we approximated a total volume based on number and size of lesions 
(range: 0 to 29.5 ml). 
Two raters independently assessed progression of WML severity on digital T2-weighted 
and PD-weighted images by direct scan comparison, using a semiquantitative scale.8,9 In the 
periventricular region, we assessed change in size (negative change -1 point, no change 0 
points, positive change +1 point) of lesions in the frontal caps, lateral bands, and occipital 
caps, in the left and right hemisphere, resulting in a score of -6 to +6. In the subcortical re-
gion, we assessed change in either number, size, number and size, or conﬂ uence (negative 
change -1 point, no change 0 points, positive change +1 point) in the frontal, parietal, tem-
poral and occipital lobes of the left and right hemisphere, resulting in a score of -8 to +8. If 
periventricular lesion change extended beyond 10 mm outside the border of the ventricle, 
we considered the change in both the periventricular and subcortical region. Raters were 
blinded to all clinical information, including scan date, for the 286 participants (43%) who 
had digital data available and were scanned with the MR VISION at baseline. This was not 
possible for the remaining 382 participants (57%) either because they changed MRI between 
baseline and follow-up, or because digital data was not available. The change rating showed 
good interobserver agreement (intraclass correlation coefﬁ cient periventricular region 0.79; 
subcortical region 0.75), and good to very good intraobserver agreement (intraclass cor-
relation coefﬁ cient periventricular region 0.70-0.89; subcortical region 0.78-0.93). Progres-
sion was deﬁ ned as an increase of 1 point or more between baseline and follow-up. We 
categorized progression into no progression (score<1), minor progression (score 1-2.5), and 
marked progression (score 3 or higher).8 Hyperintensities on PD- and T2-weighted images 
around an incident infarct were not considered as progression of white matter lesions
New brain infarcts on MRI
The presence of brain infarcts was rated similarly at the baseline and second MRI. We de-
ﬁ ned brain infarcts as areas of focal hyperintensity on T2-weighted images that were at least 
3 mm in diameter. Areas of hyperintensity in the white matter also had to have correspond-
ing prominent hypointensity on T1-weighted images, in order to distinguish them from 
WML. We deﬁ ned lacunar infarcts as infarcts sized 3 to 20 mm and located in the subcortical 
white matter or basal ganglia.
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Incident stroke
In 1999 to 2000, we reinterviewed all 668 participants about symptoms of stroke using a 
structured questionnaire. In addition, we continuously monitored the medical records of 
all participants at the general practitioner’s ofﬁ ce to obtain information on the occurrence 
of stroke until April 1st 2002. For all reported strokes, we recorded information about signs 
and symptoms, date of onset, duration and hospital stay. If participants had been hospital-
ized for a stroke, we retrieved discharge letters and radiology reports from the hospital 
where they had been treated. An experienced neurologist assessed the day of onset and clas-
siﬁ ed the stroke by reviewing all available information. Stroke was deﬁ ned as an episode 
of relevant focal deﬁ cits with acute onset, documented by neurological examination, and 
lasting for >24 ours. On the basis of radiological ﬁ ndings strokes were further subdivided 
into hemorrhagic or ischemic stroke subtypes.3
Incident dementia
Participants with dementia were excluded at baseline in 1995 to 1996.10 At the second exami-
nation, we screened all participants for dementia with the Mini-Mental State Examination 
(MMSE) and the Geriatric Mental State Schedule.11,12 Screen positives were subsequently 
evaluated using the Cambridge Mental Disorders of the Elderly Examination (CAMDEX).13 
Participants who were then thought to have dementia were examined by a neurologist, and 
underwent extensive neuropsychological testing. In addition, we continuously monitored 
the medical records of all participants at their general practitioners’ ofﬁ ce, and at the Re-
gional Institute for Outpatient Mental Health Care (RIAGG) to obtain information on newly 
diagnosed dementia until April 1st 2002.10 A panel that reviewed all available information 
diagnosed dementia and its subtypes according to standardized criteria.14-16 We deﬁ ned the 
onset of dementia as the date on which the clinical symptoms ﬁ rst allowed the diagnosis of 
dementia to be made.
Cognitive decline
Participants underwent the following neuropsychological tests at the baseline and second 
examination: the Mini-Mental State Examination,11 the Stroop test,17 the Paper-and-Pencil 
Memory Scanning Task, the Letter-Digit Substitution Task,18 a verbal ﬂ uency test (animal 
categories),19 and a 15-word verbal learning test (based on Rey’s recall of words).20 We used 
alternative versions of the same tests at the second examination. For each participant, we 
calculated z scores (individual test score minus mean test score divided by the standard de-
viation) for the tests at baseline and follow-up using the mean and standard deviation of the 
baseline tests. We constructed compound scores for global cognitive function, psychomotor 
speed and memory. The compound score for global cognitive function was the average of 
the z scores of all the above tests, except the MMSE. The compound score for psychomotor 
speed was the average of the z scores for the reading subtask of the Stroop test, the one letter 
subtask of the Paper-and- Pencil Memory Scanning Task, and the Letter-Digit Substitution 
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Task. The compound score for memory was the average of the z scores for the immediate 
and delayed recall of the 15-word verbal learning test. We calculated the rate of cognitive 
decline by subtracting the scores at baseline from the scores at the second examination, and 
dividing this difference by the follow-up time between the baseline and second examina-
tion.
Incident depressive symptoms
We assessed presence of depressive symptoms at baseline and at the second examination 
with a validated Dutch version of the original Center for Epidemiologic Studies Depression 
(CES-D) scale (range 0-60).21 We used a score of 16 as a cut-off, which indicates clinically 
signiﬁ cant depressive symptoms.22 We deﬁ ned incident depressive symptoms as depressive 
symptoms at the second examination without prevalent depressive symptoms (CESD <16) 
or the use of antidepressant medication at baseline. 
Other baseline measurements
The following variables assessed at baseline were used as possible confounders: age, sex, 
education, hypertension, diabetes, atrial ﬁ brillation, current smoking, serum total choles-
terol, and carotid artery plaques.8
Data analysis
We assessed whether baseline characteristics differed between people with and without a 
second MRI assessment with analysis of covariance. We used Spearman’s rho for the cor-
relation between baseline WML severity and WML progression, and a Chi-square test for 
the association between WML progression and new brain infarcts. To examine the relation-
ship between progression of WML and the risk of stroke, dementia and incident depressive 
symptoms, we used multiple logistic regression analysis. We used multiple linear regression 
analysis to estimate the association between progression of WML and cognitive decline. 
RESULTS
Compared to people with a second MRI examination, people who refused a second MRI 
examination were on average older and less educated, and those who were ineligible for a 
second MRI assessment were less frequent female, on average older, and less healthy (table 
1). The mean follow-up period between the ﬁ rst and second MRI was 3.3 years (standard 
deviation 0.2 years, range 2.5-4.3 years). During this period, 180 participants (27%) showed 
WML progression in the periventricular region, of whom 120 (18%) showed minor and 60 
(9%) showed marked progression. Two-hundred-seventeen participants (32%) showed pro-
gression in the subcortical region, of whom 150 (22%) showed minor and 67 (10%) showed 
marked progression. One-hundred-and-thirty-six participants (20%) had progression in 
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both the periventricular and subcortical region, of whom 36 (5%) had marked progression in 
both regions. Baseline WML severity was correlated with WML progression (periventricu-
lar region: Spearman’s rho 0.55, p<0.001; subcortical region: Spearman’s rho 0.53, p<0.001). 
Ninety-three participants (14%) had a new brain infarct on the follow-up MRI, of whom 79 
(12%) had a new lacunar infarct. Participants with WML progression more often developed 
new infarcts on MRI, in comparison to participants without WML progression (for periven-
tricular WML progression 31% versus 8% (p<0.001); for subcortical WML progression 25% 
versus 9% (p<0.001)).
The mean follow-up time for stroke and dementia was 4.9 years (standard deviation 
0.8 years, range 3.2-6.5 years). During follow-up, 28 participants (3.6%) developed a stroke, 
of whom 25 had a brain infarct. WML progression increased the risk of stroke, which was 
most marked for WML progression in the periventricular region (table 2). This association 
remained after adjustment for WML severity at baseline (table 2). The association between 
Table 1. Baseline characteristics of participants of the Rotterdam Scan Study with and without 
a second MRI assessment.
Characteristic
People 
with 2nd 
MRI as-
sessment 
n=668
People 
who re-
fused 2nd 
MRI as-
sessment 
n=283
p-value 
for dif-
ference*
People in-
eligible for 
2nd MRI 
assess-
ment
n=126
p-value 
for dif-
ference*
Age, years 71 (7) 74 (7) <0.01 77 (8) <0.01
Women, % 52 57 0.20 41 0.02
Primary education only, % 31 42 0.02 39 0.39
Mini-Mental State Examination (score) 28 (2) 27 (2) 0.25 27 (3) 0.12
CES-D score ≥ 16 7 9 0.53 6 0.58
Hypertension, % 47 57 0.12 58 0.45
Diabetes, % 5 8 0.34 13 0.02
Atrial ﬁ brillation, % 3 1 0.14 9 <0.01
Current smoking, % 16 13 0.79 21 0.02
Total cholesterol, mmol/l 5.9 (1.0) 5.9 (1.0) 0.45 5.7 (1.3) 0.13
Carotid artery plaques (0-6) 1.5 (1.6) 1.8 (1.6) 0.16 2.3 (1.7) 0.01
Baseline MRI variables
Periventricular WML (score) 2.2 (2.1) 2.5 (2.1) 0.76 3.5 (2.5) <0.01
Subcortical WML (score) 1.2 (2.5) 1.5 (3.1) 0.78 2.1 (4.1) 0.32
Brain infarcts, % 22 25 0.85 34 0.23
Values are unadjusted means (standard deviation) or percentages
*After adjustment for age and sex
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WML progression and stroke did not change 
after adjustment for stroke risk factors (data 
not shown). Nineteen participants (2.8%) de-
veloped dementia, of whom 17 (90%) were 
classiﬁ ed as Alzheimer’s disease, and two as 
vascular dementia. Participants with marked 
WML progression had a more than three-fold 
increased risk of dementia (table 3). Howev-
er, conﬁ dence intervals were wide due to the 
limited number of dementia cases. In order 
not to over-ﬁ t our models we only adjusted 
for age and sex. The association of marked 
WML progression in the periventricular 
and subcortical region with dementia at-
tenuated after exclusion of participants with 
incident stroke (n=28): odds ratio for marked 
periventricular WML progression 2.9 (95% 
conﬁ dence interval 0.8-10.8), odds ratio for 
marked subcortical WML progression 3.4 
(95% conﬁ dence interval 0.9-12.8). WML pro-
gression, in particular in the periventricular 
Table 2. Association between WML progression and the risk of stroke.
Odds ratio and 95% conﬁ dence interval
Model 1* Model 2†
Periventricular WML
No progression 1 (ref) 1 (ref)
Any progression 5.4 (2.2-13.2) 2.9 (1.1-7.8)
  Minor progression 3.3 (1.1-9.2) 2.0 (0.7-6.2)
  Marked progression 10.7 (3.9-29.5) 5.2 (1.6-16.9)
Subcortical WML
No progression 1 (ref) 1 (ref)
Any progression 3.1 (1.4-6.9) 2.9 (1.2-6.8)
  Minor progression 2.6 (1.0-6.4) 2.6 (1.0-6.5)
  Marked progression 4.1 (1.5-11.3) 3.9 (1.2-12.1)
*Adjusted for age and sex
† Adjusted for age, sex, and WML severity at baseline
Table 3. Association between WML 
progression and the risk of dementia.
Odds ratio* and 
95% conﬁ -
dence interval
Periventricular WML
No progression 1 (ref)
Any progression 1.9 (0.7-5.0)
  Minor progression 1.1 (0.3-4.0)
  Marked progression 3.4 (1.1-10.9)
Subcortical WML
No progression 1 (ref)
Any progression 2.1 (0.8-5.5)
  Minor progression 1.4 (0.4-4.4)
  Marked progression 3.9 (1.2-12.4)
* Adjusted for age and sex
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region, was associated with steeper decline in global cognitive function and psychomotor 
speed, but was not associated with decline in memory (ﬁ gure). At the second examination 
43 people had incident depressive symptoms. WML progression in the periventricular re-
gion increased the risk of depressive symptoms, whereas the association between subcorti-
cal WML progression and depressive symptoms was less strong and not signiﬁ cant (table 
4). These associations did not change after exclusion of participants with incident dementia 
(n=19; data not shown). The association between marked WML progression in the periv-
entricular region and incident depressive symptoms slightly attenuated after adjustment 
for WML severity at baseline and for new brain infarcts on MRI (table 4), and was strongly 
reduced after exclusion of participants with an incident stroke (n=28): odds ratio for marked 
periventricular WML progression 1.9 (95% conﬁ dence interval 0.6-5.7), odds ratio for 
marked subcortical WML progression 1.2 (95% conﬁ dence interval 0.4-3.5).
Figure. Relationship between WML progression in the periventricular and subcortical region 
and decline in MMSE score, Cognitive Index, Psychomotor Speed, and Memory. Bars represent 
age, sex, and education adjusted mean annual change (standard error) in z scores for cognitive 
performance.
* for signiﬁ cant difference (p<0.05) with no progression
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DISCUSSION
We found that WML progression in elderly people increased the risk of stroke more than 
three-fold. People with WML progression showed a steeper decline in global cognitive 
function and psychomotor speed. Marked WML progression increased the risk of dementia 
and depressive symptoms, which was partly explained by the occurrence of stroke during 
follow-up.
The strengths of this study are the large number of elderly people with a follow-up MRI 
measurement, its population-based design, and the fact that we had a complete follow-up 
for stroke and dementia through our monitoring system. Several other methodological 
issues need to be addressed. First, we assessed WML progression with a semiquantita-
tive rating scale. Volumetrics may be more accurate and precise for assessment of WML 
progression. However, our visual method for measuring change showed good correlation 
with volumetrics (Spearman’s rho: periventricular region 0.62, p<0.01; subcortical region 
0.79, p<0.01), and good interobserver agreement.9 Second, although the total number of 
participants was large, the number of cases with stroke, dementia, and incident depressive 
symptoms was relatively small, which has reduced the precision of our estimates. Third, 
selection may have inﬂ uenced our results. Participants were younger and healthier than 
non-participants, which may have led to an underestimation of the percentage of people 
with WML progression, and an attenuation of the estimates for the associations between 
Table 4. Association between WML progression and the risk of incident depressive symp-
toms.
Odds ratios and 95% conﬁ dence interval
Model 1* Model 2† Model 3‡  
Periventricular WML
No progression 1 (ref) 1 (ref) 1 (ref)
Any progression 2.1 (1.1-4.3) 2.0 (0.9-4.4) 2.0 (1.0-4.0)
  Minor progression 1.9 (0.8-4.2) 1.8 (0.7-4.3) 1.8 (0.8-4.0)
  Marked progression 2.7 (1.1-6.6) 2.5 (0.9-7.2) 2.3 (0.9-6.3)
Subcortical WML
No progression 1 (ref) 1 (ref) 1 (ref)
Any progression 1.7 (0.9-3.2) 1.3 (0.6-2.7) 1.6 (0.8-3.0)
  Minor progression 1.5 (0.7-3.2) 1.3 (0.6-2.9) 1.5 (0.7-3.1)
  Marked progression 2.0 (0.9-4.9) 1.3 (0.5-3.6) 1.8 (0.7-4.4)
* Adjusted for age and sex
† Adjusted for age, sex, and WML severity at baseline
‡ Adjusted for age, sex, and new brain infarcts on MRI
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WML progression and clinical outcomes. Fourth, we presented our estimates for the asso-
ciation between progression of WML and the risk of stroke and depressive symptoms both 
unadjusted and adjusted for WML severity at baseline, because baseline WML severity may 
be considered as a confounder. However, since WML severity at baseline and progression 
of WML are both parameters of the same pathofysiological process, adjustment for baseline 
WML severity may lead to overadjusting, which should be kept in mind when interpreting 
our ﬁ ndings.   
Others and we reported previously that WML increase the risk of stroke.3,23,24 In the 
present study we found that progression of WML was associated with the occurrence of 
new brain infarcts on MRI, of which the vast majority was lacunar, and strongly increased 
the risk of clinical stroke, which is in line with ﬁ ndings from a study in patients with carotid 
artery disease and leukoaraiosis on computerized tomography.6 Furthermore, we found 
that this risk increase was partly independent of baseline WML severity, and independent of 
stroke risk factors. These ﬁ ndings emphasize that WML, lacunar infarcts, and stroke share 
common risk factors and pathofysiological mechanisms. 
WML progression predicted dementia and cognitive decline, extending earlier ﬁ ndings 
from studies with a single WML measurement.25-27 WML may directly contribute to the 
development of dementia through disconnection of fronto-subcortical and cholinergic path-
ways.28,29 Furthermore, WML are closely interrelated with lacunar infarcts with respect to 
etiology and clinical presentation. We showed that the risk increase for dementia was partly 
explained by the development of new cerebral infarcts and the occurrence of clinical stroke. 
Stroke may act both as an intermediate and as a comorbid factor in the relationship between 
WML and dementia. The ﬁ nding that WML progression was associated with decline in 
global cognitive function and psychomotor speed, whereas episodic memory was spared, 
is characteristic of the proﬁ le of vascular cognitive impairment.4 In contrast with our obser-
vations, the Austrian Stroke Prevention Study did not demonstrate an association between 
WML progression and decline in cognitive function.5 The reasons for this conﬂ icting result 
may be differences in subject population and assessment of WML progression. Participants 
in the Austrian Stroke Prevention Study were on average 10 years younger (mean age 60 
± 6 years) than in our study (mean age 71 ± 7 years), and they excluded people with a his-
tory of cerebrovascular diseases at baseline. Both age and brain infarcts are related to WML 
progression and cognitive decline, and this will have resulted in less power to demonstrate 
an association between progression of WML and cognitive decline. Furthermore, they made 
no distinction between progression of WML in the periventricular and subcortical region, 
whereas we found that the relationship between progression of WML and cognitive decline 
was most marked for the periventricular region. 
We found that participants with WML progression had a two-fold increased risk of de-
pressive symptoms. Late-onset depression may be a prodromal disorder for dementia, but 
in the present study the association between WML progression and the risk of depression 
could not be explained by the development of dementia during follow-up. Our ﬁ ndings 
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support the vascular depression hypothesis, which implies that vascular brain damage 
plays an important role in depression in elderly people.30
In conclusion, we found that elderly people with progression of WML have an increased 
risk of stroke, cognitive decline and dementia, and depressive symptoms. Further research 
is needed to show if prevention of the development and progression of WML diminishes the 
incidence of stroke, dementia and depression in the elderly.
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INTRODUCTION
The objective of this thesis was to examine the role of cerebral small vessel disease in the 
aetiology of cognitive decline, dementia, and depression. For this purpose, I described a 
number of studies that were performed within the context of the Rotterdam Scan Study, a 
large prospective population-based cohort study. All 1,077 participants underwent MRI of 
the brain at baseline in 1995 and 1996, and 668 participants (62%) had a second MRI at 3-
year follow-up. We measured the severity of white matter lesions and the presence of brain 
infarcts at baseline, and assessed the evolution of white matter lesions and the occurrence 
of new infarcts between the ﬁ rst and second MRI examination. Participants underwent a 
structured interview, physical examination, neuropsychological testing, and an assessment 
of depressive symptoms at both the baseline and follow-up examinations. Furthermore, we 
followed all participants for mortality and for the development of dementia, depression 
and stroke until April 1st 2002. This design enabled us to relate both the severity of cerebral 
small vessel disease at baseline and the progression of small vessel disease over time with 
the development of cognitive decline, dementia and depression.
 In the previous chapters I described each speciﬁ c study in detail. In this chapter, I take 
a more general viewpoint to discuss several issues related to the topic of this thesis. First, I 
summarize the main ﬁ ndings of the research described in this thesis. Second, I focus on sev-
eral methodological issues that are speciﬁ cally related to our study design. The third part 
addresses several considerations regarding the pathology underlying our determinants, 
white matter lesions and brain infarcts on MRI, and also reﬂ ects on our outcome measures, 
namely cognitive decline, dementia and depression. Fourth, I speculate on the implications 
of our ﬁ ndings and provide recommendations for future research.
MAIN FINDINGS
Cerebral small vessel disease affects cognitive function
People with more severe periventricular white matter lesions and people with brain infarcts 
showed a steeper decline in cognitive function (chapter 2.1 and 2.2). These brain changes 
were particularly associated with decline in information processing speed. The association 
with cognitive decline was also present for asymptomatic infarcts: silent thalamic infarcts 
were associated with decline in memory, and non-thalamic silent infarcts with decline in in-
formation processing speed (chapter 2.2). Furthermore, progression of white matter lesions 
was associated with decline in global cognition and information processing speed in a dose 
dependent manner (chapter 4.3). 
Although the presented associations were signiﬁ cant, the size of the effects was mod-
est, and may not be regarded as clinically relevant. I shall provide several explanations for 
the modest effect sizes when I discuss the methodological issues related to the assessment 
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of cognitive decline. For now, I would like to argue that, despite the size of the effects, our 
ﬁ ndings are relevant from an etiological point of view, and may be regarded as a proof 
of principle. One way to appreciate our ﬁ ndings is to look at the effects in relative terms. 
People with marked periventricular white matter lesion progression decreased almost four-
times faster on the MMSE compared to people without marked progression. Another way 
to view our ﬁ ndings is to compare the effects with those of age. We showed that each stand-
ard deviation increase in severity of periventricular white matter lesions had the same effect 
on change in information processing speed as being 2.5 years older, and that the effect of a 
brain infarct on MRI was comparable with being 3.3 years older. 
Elevated plasma homocysteine concentrations are a risk factor for cerebral small vessel 
disease and have also been associated with cognitive impairment.1,2 Therefore, we studied 
cross-sectionally whether this relationship may be mediated by small vessel disease (chap-
ter 2.4). We found that homocysteine levels greater than 14 µmol/L were associated with 
decreased information processing speed. However, white matter lesions and cerebral inf-
arcts on MRI did not explain this association.
Cerebral small vessel disease increases the risk of dementia
We prospectively studied the association of cerebral white matter lesions and asymptomatic 
brain infarcts and the risk of dementia. For each standard deviation increase in periven-
tricular white matter lesion severity, the risk of dementia increased by 70% (chapter 2.3). 
Furthermore, marked progression of white mater lesions in either the periventricular or 
subcortical region increased the risk of dementia, which was partly explained by the occur-
rence of stroke during follow-up (chapter 4.3). The presence of silent brain infarcts at base-
line more than doubled the risk of dementia (chapter 2.2). The majority of dementia cases 
in our studies were of the Alzheimer’s type, and the associations of periventricular white 
matter lesions and silent brain infarcts with dementia remained after analyses were limited 
to Alzheimer’s disease. 
Cerebral small vessel disease is associated with depression
We found that people with either symptomatic or asymptomatic brain infarcts on MRI had 
a three-fold increased risk of chronic depressive disorders. Severe subcortical white matter 
lesions at baseline more than doubled the risk of incident depressive disorders (chapter 3). 
Subsequently, marked progression of white matter lesions increased the risk of depressive 
symptoms (chapter 4.3). Our ﬁ ndings support the ‘vascular depression’ hypothesis, which 
implies that there is a subtype of depression arising in later life that is characterized by a 
distinct clinical presentation and an association with cerebrovascular disease.3 
Progression of cerebral white matter lesions increases the risk of stroke, dementia and 
depression
We evaluated the concordance of a volumetric method for measuring white matter lesion 
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change with several visual rating scales, and found that commonly used visual rating scales 
are not well suited for measuring change in white matter lesion severity. A new simple vis-
ual rating scale that we designed to measure white matter lesion change proved to be more 
accurate and precise (chapter 4.1). We used this new scale to assess change in white matter 
lesions in participants from the Rotterdam Scan Study. Approximately one-third of elderly 
people had progression of white matter lesions over a 3-year period. Risk factors for pro-
gression included higher white matter lesion severity at baseline, increasing age, female sex, 
elevated blood pressure and current cigarette smoking (chapter 4.2). WML progression in-
creased the risk of stroke more than three-fold. People with white matter lesion progression 
showed a steeper decline in global cognitive function and information processing speed. 
Marked progression increased the risk of dementia and depressive symptoms, which was 
partly explained by the occurrence of new brain infarcts on MRI and clinical stroke during 
follow-up (chapter 4.3). 
METHODOLOGICAL ISSUES
For an overview of the general principles related to the quality of epidemiological research 
I refer to standard texts.4,5 This paragraph concerns several speciﬁ c methodological issues 
related to the studies in this thesis. I ﬁ rst address the advantages and disadvantages of our 
study design. Next, I discuss the problem of attrition in relation to repeated assessments 
of cognitive function and mood in population-based studies. The third methodological is-
sue that I will focus on is the question whether or not to adjust for white matter severity at 
baseline.
The studies that I described in this thesis were performed in the context of a large pro-
spective population-based cohort study. One of the strengths of such a design is that, pro-
vided that the response is high enough and loss to follow-up is minimized, selection bias is 
limited. This holds for our analyses regarding incident dementia and depression (chapter 
2.2 and 2.3). Another clear advantage of our design is that the results can be directly gener-
alized to the general population. Furthermore, the prospective nature made it possible to 
establish temporal relationships between small vessel disease and clinical outcomes, which 
can provide arguments for causality. In general, a large sample size is the primary way 
to increase precision in an epidemiological study. However, precision also relates to the 
efﬁ ciency of a study, and despite the large size of the study, the number of people who de-
veloped incident dementia and incident depression was modest.4 Therefore, precision was 
a concern in our study, particularly regarding the analyses on progression of white matter 
lesions and the risk of dementia (chapter 4.3). 
Attrition is a problem in repeated measurements of cognitive function or mood in a 
population-based MRI study. People with cognitive impairment or depressive symptoms 
as well as those who are generally less healthy, are more likely to drop out of the study and 
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thus not participate in a follow-up neuropsychological examination or psychiatric inter-
view.6,7 In our study this was illustrated by a higher rate of dementia in people without a 
second examination (chapter 2.1). This selection will have resulted in an underestimation of 
cognitive decline and incident depressive symptoms. Furthermore, it might have led to an 
underestimation of the strength of the association between small vessel disease and cogni-
tive decline and incident depressive symptoms. This may be considered as the paradox of 
measuring cognitive decline with sensitive neuropsychological tests: people who can be 
tested repeatedly and reliably are the same ones who are least likely to decline. Learning 
effects induced by repeated testing also result in an underestimation of cognitive decline in 
the study population. In order to measure substantial cognitive decline in population-based 
studies, follow-up should be sufﬁ ciently long, alternative versions of tests should be used in 
order to reduce learning effects, and the response rate should be kept as high as possible. 
A methodological issue that is important for the interpretation of our ﬁ ndings on pro-
gression of white matter lesions involves the adjustment for white matter lesion severity 
at baseline. We presented our estimates for the association between progression of white 
matter lesions and outcomes both unadjusted and adjusted for white matter lesion sever-
ity at baseline. One reason for adjusting for baseline is that white matter lesion severity at 
baseline can be considered a confounder in the relation between progression of white mat-
ter lesions and outcome. Theoretically, adjustment for baseline may induce bias due to the 
phenomenon of regression towards the mean.8,9 However, we judge this effect to be small 
in our study because we used a change scale to measure progression instead of calculating 
the difference between two repeated measurements.10 It is important to realize that white 
matter severity at baseline and progression of white matter lesions are both parameters of 
the same pathofysiological process, and progression can be considered an intermediate in 
the relationship between white matter severity and outcome.11 Adjusting for baseline may 
therefore be considered overadjusting and can lead to an underestimation of the association 
of interest.
CEREBRAL WHITE MATTER LESIONS AND BRAIN INFARCTS ON MRI
In this thesis I refer to white matter lesions and lacunar brain infarcts on MRI as measures of 
cerebral small vessel disease. However, the pathofysiology of these lesions is still not com-
pletely understood. The histological abnormalities associated with white matter lesions in 
elderly people can be considered nonspeciﬁ c.12 The most consistent histological substrates 
of white matter lesions are a diffuse myelin rarefaction sparing the U ﬁ bers, astrogliosis, 
spongiosis, axonal loss, and widened perivascular spaces.13 Important risk factors for the 
development of white matter lesions in our study are increasing age, presence of arterial hy-
pertension and cardiovascular disease.14,15 Arteriolosclerosis and hyaline wall thickening of 
the long penetrating arterioles in combination with impaired autoregulation may result in 
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hypoxia and ischemia of the white matter. Ischemic injury to the blood-brain-barrier perme-
ability may lead to leakage of macromolecules and ensuing activation of astrocytes.12 Other 
mechanisms have also been suggested. Deposits of amyloid β in the media and adventitia 
of meningocortical arteries and arterioles may lead to obliteration of vessel luminae and 
loss of vascular smooth muscle cells necessary to cerebral autoregulation.16,17 Collagenous 
thickening and occlusion of deep periventricular-draining veins has been postulated to be 
another factor in the production of deep hemispheric white matter lesions.18 In degenerative 
dementia, white matter lesions may be attributed to wallerian degeneration.19 A number of 
conditions require consideration in the differential diagnosis of white matter changes on 
MRI.20 Cerebral white matter changes are present in multiple sclerosis, leukodystrophies, 
mitochondrial encephalopathies, certain infections, and after cerebral anoxia from cardiac 
arrest or carbon monoxide poisoning. However, in elderly people they can rarely be at-
tributed to these conditions.21 Furthermore, white matter lesions are a prominent feature in 
some hereditary cerebrovascular condition such as cerebral autosomal dominant arteriopa-
thy with subcortical infarcts and leukoencephalopathy and hereditary cerebral hemorrhage 
with amyloidosis.22-24 These hereditary conditions are rare, and are characterized by an onset 
of clinical manifestations around the age of 50, which makes them unlikely to be present in 
our study population. 
In our study the vast majority of brain infarcts were of the lacunar type and asymp-
tomatic.25 The term lacune refers to a small cavity located deep within the brain. Lacunar 
infarcts vary in maximal diameter from 3-20 mm, and are most commonly found in the 
putamen, caudate, thalamus, pons, internal capsule and cerebral white matter.26 Tradition-
ally, lacunes are classiﬁ ed into type I and type II lacunes.27 Type I lacunes consist of irregular 
cavities up to 20 mm in size, and are the most frequent. Type II lacunes are characterized 
by numerous haemosiderin laden macrophages, and are assumed to represent old, small 
hemorrhages.27 These microbleeds may be a signiﬁ cant risk factor for primary intracerebral 
hemorrhage.28 In our study we were not able to assess these types of lacunes, since speciﬁ c 
MRI acquisitions (gradient echo T2) are needed to visualize these lesions. The most com-
mon cause of lacunar infarcts is small vessel atherosclerosis and ﬁ brinoid necrosis (lipohy-
alinosis). Risk factors for asymptomatic infarcts in our study were increasing age, arterial 
hypertension and increased total plasma homocysteine concentration.2,25 Atherosclerosis 
may be present in the proximal perforating arteries, at their origin, or in the parent artery of 
the circle of Willis, while lipohyalinosis is thought to be responsible for smaller (40-300 µm) 
perforating vessels that result in occlusion of lenticulostriate, thalamoperforating and long 
penetrating arteries.26,29 Apart from the pathology underlying small vessel stroke described 
above, many other causes have been described as rare causes of lacunar infarcts such as 
infective and immune vasculitis, cardiac and large vessel embolism, arterial dissection, and 
microaneurysm. I consider it unlikely that these rare causes have contributed in an impor-
tant way to our results.
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ASSESSMENT OF COGNITIVE DECLINE, DEMENTIA AND DEPRESSION
We assessed cognitive function with a number of neuropsychological tests that were consid-
ered as being sensitive and suitable for use in the elderly population. The question remains 
how decline in cognitive function relates to the development of dementia. A diagnosis of 
dementia is often preceded by a preclinical phase of many years, and it has been shown that 
during this phase, people already have a decreased performance on psychometric tests.30-32 
At the time that the ﬁ rst clinical changes in cognitive functioning and behavior start to in-
terfere with daily living a sharp change in psychometric performance is observed.33 Cogni-
tive decline in elderly people can therefore be considered as a trajectory. Depending on the 
progression of underlying pathologies that are responsible for this decline, and the summed 
effect of cognitive impairment in multiple domains, people may eventually cross the line of 
clinical dementia.
In our study, since necropsy data was not available, we used clinical diagnoses of de-
mentia and its subtypes according to standardized criteria. The value of such a clinical dis-
tinction between Alzheimer’s disease and vascular dementia can be challenged. Necropsy 
conﬁ rmed clinical diagnostic accuracy for Alzheimer’s disease is reported to be as high as 
87%.34,35 However, it has been argued that such ﬁ gures contain two fallacies; they include 
cases in which Alzheimer’s disease exists with other diseases affecting cognition and the 
studies that report these ﬁ gures excluded cases without necropsy (veriﬁ cation bias). When 
these two fallacies are taken into account, the positive predictive value of a diagnosis of 
pure Alzheimer’s disease is reported to be no more than 38%.36 Evidence has been accumu-
lating that most elderly people with dementia have mixed disease.37-39 As a result, current 
clinical distinctions into dementia subtypes are both imprecise and arbitrary, and may be of 
little use in etiologic research.
We assessed depressive symptoms with the Center for Epidemiologic Studies Depres-
sion scale (CES-D), a validated depression scale, and used a cut-off that indicates clinically 
relevant depressive symptoms (chapter 3 and 4.3).40 To ascertain a Diagnostic and Statistical 
Manual of Mental Disorders-Fourth Edition (DSM-IV)41 diagnosis of depression, a psy-
chiatrist interviewed screen positives with a semi-structured psychiatric interview, a Dutch 
version of the Present State Examination.42 Secondly, we monitored the medical records of 
all participants at the general practitioner’s ofﬁ ces and the Regional Institute for Ambula-
tory Mental Health for depressive episodes (chapter 3). In the analyses on depressive dis-
orders, we combined the diagnostic categories of major depression, dysthymia, and minor 
depression. In the elderly, these syndromes have similar prognosis and consequences for 
well-being and disability.43 Furthermore, these syndromes are difﬁ cult to delineate in eld-
erly people.44 
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IMPLICATIONS
The impact of cerebral small vessel disease on cognitive function has long been a matter of 
debate fuelled by equivocal results from cross-sectional studies.45-48 Results from prospec-
tive studies, including ours, provide strong evidence that small vessel disease causes cog-
nitive decline, and in particular decline in information processing speed.49-51 Small vessel 
disease may directly interrupt prefrontal subcortical loops.52 Our data suggest that small 
vessel disease also indirectly leads to cognitive decline through the development of stroke.53 
A third mechanism may be through interaction with Alzheimer pathology.37,39,54 
There is widespread belief that cerebral small vessel disease plays a role in the aetiology 
of dementia. However, there is hardly any evidence from prospective population based 
studies on the association of white matter lesions and asymptomatic brain infarcts with 
the risk of dementia and Alzheimer’s disease. We found that both white matter lesions and 
brain infarcts strongly increased the risk of dementia, including clinical Alzheimer’s disease. 
Furthermore, our study is the ﬁ rst to relate progression of white matter lesions to cognitive 
decline and dementia. This temporality provides strong evidence for a causal relationship 
between cerebral white matter lesions and cognitive decline and dementia. Observations 
from epidemiological studies including ours, and from pathology studies challenge the 
conventional distinction between Alzheimer’s disease and vascular dementia on the basis 
of diagnostic criteria. Vascular amyloid angiopathy is commonly reported in Alzheimer’s 
disease, and risk factors for vascular disease and stroke such as hypertension, diabetes mel-
litus, cholesterol, atrial ﬁ brillation, and increased homocysteine have been associated with 
an increased risk of Alzheimer’s disease.39,54 In a community-based neuropathology study 
Alzheimer-type and vascular pathology were the major pathological correlates of dementia 
in elderly people, although most patients had mixed disease. There were no clear thresholds 
of these features that predicted dementia status.37 All of these ﬁ ndings strongly suggest that 
dementia in elderly people is mostly a heterogeneous disorder in which different patholo-
gies contribute to the clinical syndrome of dementia.  
We found that patients with small vessel disease had a higher risk for depressive dis-
orders. Patients with vascular depression are reported to experience greater cognitive dys-
function, disability, and retardation, but less agitation and guilt feelings than patients with 
non vascular depression.55 What could be the neuroanatomical substrate to explain this dif-
ference in clinical phenotype? A possible explanation comes from a recent model for depres-
sion involving dysfunctional coordination of limbic-cortical pathways. In this model, a dor-
sal compartment composed of superior limbic structures is thought to regulate attentional 
and cognitive symptoms of depression such as apathy, psychomotor retardation, impaired 
attention, and executive dysfunction. A ventral compartment formed of limbic, paralimbic 
and subcortical structures is proposed to mediate the vegetative and somatic aspects of 
depression, such as sleep, appetite and endocrine disturbances. The rostral cingulate area 
has a regulatory role for the interactions between the two compartments. Dysfunction in 
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this coordinating area is suggested to result in disintegrated mood, cognitive, somatic and 
autonomic responses.56,57 According to this model, it can be hypothesized that in vascular 
depression there is a differential involvement of superior limbic structures. This may occur 
either via strategically placed lesions or as a result of an overall burden.3 Our observation 
that people who developed depression had a higher severity of subcortical white matter 
lesions in the frontal lobes is compatible with this view. In summary, small vessel disease 
may contribute to the development of depression by ischemic damage of prefrontal cortical 
and striatal systems leading to disruption of neurotransmitter circuitry involved in mood 
regulation.
FUTURE DIRECTIONS
This thesis has provided some answers on the role of small vessel disease in the aetiology of 
dementia and depression. However, at the same time it has generated many more questions. 
What is the next step we should take in neuroimaging studies on brain changes in relation 
to dementia and depression? Do we need new diagnostic criteria for dementia? What are 
the possibilities for primary and secondary prevention of cerebral small vessel disease and 
its consequences? 
We showed that the location of small vessel disease is important in relation to the de-
velopment of dementia and depression. However, the way we deﬁ ned and assessed lesion 
location can be considered rather crude. Future imaging studies in the general population 
as well as in patient populations may use volumetric MRI and automatic lesion assess-
ments, which will provide precise information on extent and localization of lesions. This 
will result in increased statistical power to further elucidate the interaction between small 
vessel disease and other brain pathologies at old age, such as atrophy of medial temporal 
lobe structures. Higher ﬁ eld strength increases the resolution of MRI images, and will pro-
vide more detailed anatomical information. Diffusion tensor magnetic resonance imaging 
can provide important information about the anatomy of white matter tracts, which can be 
related to function. Techniques for the in vivo visualization of amyloid β are in progress.58 
Future neuroimaging studies may take both small vessel disease and Alzheimer pathology 
into account when studying risk factors for the development of dementia and depression. 
As mentioned previously, there are strong suggestions that dementia in elderly peo-
ple is mostly a heterogeneous disorder. As a result, the conventional distinction between 
Alzheimer’s disease and vascular dementia is being challenged. This leads to the question 
whether there is a need for new clinical criteria for dementia. In the clinical setting, criteria 
are useful to enhance agreement and communication among clinicians. For this purpose, 
present clinical criteria may be sufﬁ cient. According to the DSM IV for example, mixed 
forms of dementia can be classiﬁ ed as “Dementia due to multiple etiologies”.41 In the set-
ting of aetiological research, one should really question whether clinical criteria, in which 
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notions about the aetiology are incorporated, are of any use and whether they not only lead 
to circularity. In the setting of clinical trials, clinical criteria may be useful to reduce hetero-
geneity, thereby increasing the power of a trial. For vascular dementia, Erkinjuntti and col-
leagues have summarized the characteristics that new criteria need to fulﬁ ll.59,60 Constructs 
should be based on homogeneity in the aetiology, brain changes, and clinical syndrome. 
Criteria for the more homogeneous subtype of subcortical vascular dementia have already 
been proposed.59
In order to prevent small vessel disease, subjects at risk should be identiﬁ ed and risk fac-
tors should be treated. Hypertension is the main risk factor and can be effectively control-
led. In the double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, 
active treatment of elderly people with systolic hypertension with nitrendipine with the 
possible addition of enalapril and hydrochlorothiazide, reduced the incidence of dementia 
by 50% compared with placebo.61 An unhealthy blood lipid proﬁ le should be treated with 
statins to reduce the risk of ischemic heart disease and stroke.62 People should optimize their 
cardiovascular health, which means they should avoid obesity and smoking. 
There is little evidence regarding secondary prevention in patients with small vessel 
disease. As discussed previously, lacunar infarcts and white matter lesions, apart from sub-
tle subependymal white matter lesions in the immediate vicinity of the ventricles that are 
probably non-pathological, are both indicators of small vessel disease.20,63 These structural 
brain changes can be used as (surrogate) endpoints in clinical trials. Blood pressure lower-
ing with perindopril and indapamide in patients with prior stroke or transient ischemic 
attack reduced the risk of dementia and cognitive decline associated with recurrent stroke 
in the PROGRESS study.64 The question remains whether these results can be generalized to 
patients with small vessel disease. Only two trials have reported on the effect of antiplatelet 
agents in patients presenting with lacunar infarcts. The AICLA trial showed that treatment 
with aspirin or aspirin with dypiradimole compared to placebo, reduced stroke recurrence 
in patients with lacunar stroke.65 A beneﬁ t of ticlopidine for stroke prevention in patients 
with lacunar stroke was shown by the CATS study.66 Even more than lacunes, white matter 
lesions have been neglected as a potential endpoint in clinical trials. For this reason, it is 
not known whether for instance antiplatelet agents are beneﬁ cial in patients with extensive 
white matter lesions. Future studies on secondary prevention of cerebral small vessel dis-
ease are needed. 
Promising results have been reported from treatment studies in patients with vascular 
dementia. A recent placebo-controlled trial of memantine, an antagonist of the N-methyl-d-
aspartate receptor, in patients with mild to moderate vascular dementia showed improved 
cognition, stabilization of global functioning and behavior, and good tolerance and safety.67 
Cholinesterase inhibitors have been approved for the treatment of Alzheimer’s disease and 
may also be of use in the treatment for vascular dementia. In two large trials of patients 
with vascular dementia, patients treated with donepezil showed improvement in cognitive 
scores (ADAS-cog, MMSE) and global scores (CIBIC-plus) compared with placebo.68 More 
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studies are needed to investigate the beneﬁ cial effects of these and other agents for demen-
tia patients with cerebral small vessel disease.
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SUMMARY
Cerebral small vessel disease may lead to the development of cerebral white matter lesions 
and brain infarcts. These structural brain changes are common in older people. The pres-
ence and severity of white matter lesions and infarcts increase with increasing age, and arte-
rial hypertension is considered as being the most important risk factor. It is a widespread 
belief that cerebral small vessel disease is involved in the aetiology of dementia. However, 
the evidence from prospective population based studies to support these notions is scarce. 
Cerebral small vessel disease may also be involved in the aetiology of depression in older 
people. Again, this relationship has barely been studied prospectively in the general popu-
lation. The objective of the research described in this thesis was to relate the presence and 
severity of small vessel disease on magnetic resonance imaging (MRI) with the development 
of dementia and depression in older people. The research was carried out within the context 
of the Rotterdam Scan Study, a prospective cohort-study in 1,077 people aged 60 years and 
older from the general population. All participants were free from dementia at the start of 
the study.
Chapter 1 is a general introduction to the topic of this thesis. In chapter 2.1 we relate the 
presence and severity of white matter lesions, infarcts, and generalized brain atrophy on 
MRI to cognitive decline. White matter lesions in the periventricular region, infarcts, and 
generalized atrophy were associated with cognitive decline, and particularly with decline in 
information processing speed. Furthermore, our results suggest that stroke may be an inter-
mediate in the association between white matter lesions, infarcts and cognitive decline. 
In older people, brain infarcts that have not resulted in stroke-like symptoms are fre-
quently observed on MRI. Chapter 2.2 describes a study that examined whether or not these 
asymptomatic infarcts are related to the risk of dementia and cognitive decline. Participants 
underwent an MRI of the brain both at baseline and on average three years later, and under-
went neuropsychological testing. Brain infarcts were assessed on MRI and were classiﬁ ed as 
either symptomatic or asymptomatic based on medical information. The presence of asymp-
tomatic infarcts at baseline doubled the risk of dementia. Older people who developed new 
infarcts declined steeper in cognition than contemporaries without such lesions. 
We examined the relationship between cerebral small vessel disease in speciﬁ c locations 
and the risk of dementia in chapter 2.3. We measured the severity of white matter lesions 
on MRI in the periventricular and subcortical region. All participants were followed over a 
ﬁ ve-year period for the development of dementia. During the study period, 45 participants 
became demented. Increasing severity of white matter lesions in the periventricular region 
increased the risk of dementia. Per standard deviation increase in periventricular white 
matter lesion severity the risk of dementia increased by 70 percent. This risk increase was 
independent of other risk factors for dementia, and partly independent of the presence of 
other structural brain changes on MRI. 
In chapter 2.4, we explore the association between the concentration of homocysteine in 
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blood plasma and cognitive function. We found that elderly people with an increased ho-
mocysteine concentration performed worse on cognitive tests, in particular tests that meas-
ure information processing speed. This association was not explained by structural brain 
changes on MRI, which may suggest that homocysteine affects cognitive function through 
a direct neurotoxic effect.  
Whether or not brain infarcts and white matter lesions increase the risk of depression 
is examined in chapter 3. We assessed brain infarcts and white matter lesions on MRI, and 
followed participants over a 3-year period for the development of depressive disorders. 
We made a distinction between incident and chronic depressive disorders. Brain infarcts 
tripled the risk of chronic depressive disorders, whereas severe white matter lesions in the 
subcortical region doubled the risk of incident depressive disorders. These ﬁ ndings support 
the vascular depression hypothesis, which implies that there is a subtype of depression oc-
curring in late life that is characterized by a distinct clinical presentation and an association 
with cerebrovascular disease.
Chapter 4.1 focuses on a method comparison study in which the concordance of several 
visual rating scales with volumetrics for measuring white matter lesion change is evaluated. 
For assessment of change in white matter lesions, the scales of Fazekas, of Scheltens, and the 
periventricular part of the Rotterdam Scan Study scale showed little correlation with volu-
metrics. A new visual scale, which we designed for measuring progression of white matter 
lesions, and the subcortical part of the Rotterdam Scan Study scale showed good correlation 
with volumetrics. After observers had become familiarized with the new scale, the measure-
ments with this scale also showed good interobserver agreement.
Although much is known about the frequency and risk factors of white matter lesions 
in the general population, there is only limited information available about the evolution of 
these lesions over time. The objective of the study in chapter 4.2 was to describe the rate of 
progression of white matter lesions in the general population, and to assess risk factors for 
this progression. Over a 3-year period, about one third of participants showed progression 
of white matter lesions. Risk factors for progression were the severity of white matter le-
sions at baseline, increasing age, female sex, hypertension and cigarette smoking. In chapter 
4.3, we consider whether progression of white matter lesions is related to the risk of stroke, 
cognitive decline, dementia and depression. Older people with progression of white matter 
lesions had a tripled risk of stroke, and declined steeper in global cognitive function and in-
formation processing speed. Severe progression increased the risk of dementia and depres-
sive symptoms, which was partly explained by the occurrence of clinical stroke. 
Finally, in chapter 5, we summarize our main ﬁ ndings, discuss methodological and con-
ceptual issues, and make reccomendations for future research.                   
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SAMENVATTING
Schade aan de kleine bloedvaten in de hersenen, of cerebrale microangiopathie, kan leiden 
tot het ontstaan van witte stof afwijkingen en infarcten. Deze afwijkingen komen veel voor 
bij ouderen. De aanwezigheid en ernst van witte stof afwijkingen en infarcten nemen toe met 
de leeftijd, en hoge bloeddruk wordt beschouwd als de belangrijkste risicofactor. Over het 
algemeen wordt verondersteld dat cerebrale microangiopathie een rol speelt bij de etiologie 
van dementie. Tegelijkertijd zijn er echter maar weinig studies die deze relatie prospectief 
hebben onderzocht in de algemene populatie. Microangiopathie speelt mogelijk ook  een 
rol bij het ontstaan van depressie op oudere leeftijd, maar ook voor deze relatie zijn weinig 
gegevens bekend uit prospectief bevolkingsonderzoek. Het doel van het in dit proefschrift 
beschreven onderzoek was om de aanwezigheid en ernst van cerebrale microangiopathie op 
“magnetic resonance imaging” (MRI) te relateren aan het ontstaan van dementie en depres-
sie bij ouderen. Het onderzoek werd verricht binnen de Rotterdam Scan Studie, een pros-
pectieve cohort-studie onder 1,077 personen van 60 jaar en ouder uit de algemene populatie. 
Alle deelnemers waren vrij van dementie aan het begin van de studie.
Hoofdstuk 1 is een inleiding over het onderwerp van dit proefschrift. In hoofdstuk 
2.1 relateren we de aanwezigheid en ernst van witte stof afwijkingen, infarcten en globale 
atroﬁ e op MRI aan achteruitgang in cognitief functioneren. Witte stof afwijkingen in de 
periventriculaire regio, infarcten en globale atroﬁ e waren geassocieerd met cognitieve 
achteruitgang, en speciﬁ ek met achteruitgang in snelheid van informatieverwerking. Onze 
resultaten suggereren verder dat een beroerte een tussenliggende stap kan zijn in de relatie 
tussen witte stof afwijkingen en infarcten enerzijds en cognitieve achteruitgang anderzijds. 
Op MRI scans van de hersenen worden bij ouderen vaak infarcten gezien die niet hebben 
geleid tot symptomen van een beroerte. Hoofdstuk 2.2 beschrijft een studie waarin wordt 
onderzocht of deze asymptomatische infarcten gerelateerd zijn aan het risico op dementie 
en cognitieve achteruitgang. Aan het begin van de studie, en gemiddeld drie jaar daarna, 
kregen de deelnemers een MRI scan van de hersenen en werden zij neuropsychologisch 
getest. Herseninfarcten werden beoordeeld op MRI en op basis van medische informatie 
onderverdeeld in symptomatische en asymptomatische infarcten. De aanwezigheid van 
asymptomatische infarcten aan het begin van de studie verdubbelde het risico op dementie. 
Ouderen die nieuwe asymptomatische infarcten doormaakten, gingen harder achteruit in 
cognitief functioneren dan ouderen zonder nieuwe asymptomatische infarcten. 
In hoofdstuk 2.3 bestuderen we de relatie tussen cerebrale witte stof afwijkingen in spe-
ciﬁ eke locaties en het risico op dementie. De ernst van cerebrale witte stof afwijkingen in 
de periventriculaire en subcorticale regio werd gemeten op MRI. Alle deelnemers werden 
over een periode van gemiddeld vijf jaar gevolgd met betrekking tot het ontwikkelen van 
dementie. Tijdens de studie-periode werden 45 deelnemers dement. Toenemende ernst van 
witte stof afwijkingen in de perivertriculaire regio verhoogde het risico op dementie. Voor 
elke standaard deviatie toename in ernst van periventriculaire witte stof afwijkingen nam 
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het risico op dementie toe met 70 procent. Dit verhoogde risico was onafhankelijk van an-
dere risicofactoren voor dementie en deels onafhankelijk van de aanwezigheid van andere 
structurele hersenafwijkingen op MRI. 
In hoofdstuk 2.4 beschrijven we de relatie tussen de concentratie van homocysteine in 
het bloed en cognitief functioneren. Wij vonden dat ouderen met een verhoogde homocys-
teine-concentratie slechter presteerden op cognitieve taken, met name op taken voor snel-
heid van informatieverwerking. Deze relatie werd niet verklaard door de aanwezigheid 
van structurele hersenafwijkingen op MRI. Dit suggereert mogelijk een direct neurotoxisch 
effect van homocysteine. 
Het verband tussen herseninfarcten, witte stof afwijkingen en depressie wordt beschre-
ven in hoofdstuk 3. Infarcten en witte stof afwijkingen werden gemeten op MRI en de deel-
nemers werden over een periode van drie jaar gevolgd met betrekking tot het ontwikkelen 
van een depressieve stoornis. Hierbij werd een onderscheid gemaakt  tussen incidente en 
chronische depressieve stoornissen. Herseninfarcten verdrievoudigden het risico op chroni-
sche depressieve stoornissen, terwijl ernstige witte stof afwijkingen in de subcorticale regio 
het risico op incidente depressieve stoornissen verdubbelden. Deze bevindingen ondersteu-
nen de vasculaire depressie hypothese, die veronderstelt dat er bij ouderen een subtype 
depressieve stoornis bestaat die gekenmerkt wordt door een speciﬁ eke klinische presentatie 
en een associatie met cerebrovasculaire ziekte.
Hoofdstuk 4.1 betreft een studie waarin verschillende visuele schalen werden verge-
leken met volumetrie voor het meten van progressie van witte stof afwijkingen. Voor het 
meten van progressie van witte stof afwijkingen bleken de schalen van Fazekas, Scheltens 
en het periventriculaire deel van de Rotterdam Scan Studie schaal niet goed overeen te ko-
men met volumetrie. Een nieuwe visuele schaal, speciﬁ ek ontworpen voor het meten van 
progressie van witte stof afwijkingen, en het subcorticale deel van de Rotterdam Scan Studie 
schaal vertoonden een goede correlatie met volumetrie. Nadat de beoordelaars vertrouwd 
waren geraakt met de nieuwe schaal, waren de progressie-metingen met deze schaal ook 
goed reproduceerbaar.
Hoewel er veel bekend is over de frequentie van en risicofactoren voor witte stof afwij-
kingen onder de algemene populatie, zijn er maar weinig gegevens over de verandering 
in witte stof afwijkingen over de tijd. Het doel van de in hoofdstuk 4.2 beschreven studie 
was om de mate van progressie van witte stof afwijkingen in de algemene populatie te be-
schrijven en om risicofactoren voor deze progressie te onderzoeken. In een periode van drie 
jaar vertoonde ongeveer een derde van de ouderen een toename van witte stof afwijkingen. 
Risicofactoren voor progressie van witte stof afwijkingen waren de ernst van witte stof af-
wijkingen aan het begin van de studie, hogere leeftijd, vrouwelijk geslacht, hoge bloeddruk 
en roken.
Het onderzoek in hoofdstuk 4.3 bestudeert de associatie tussen progressie van witte 
stof afwijkingen en het risico op beroerte, dementie en depressie. Ouderen met progressie 
van witte stof afwijkingen hadden een drie keer verhoogd risco op een beroerte en gingen 
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harder achteruit in globaal cognitief functioneren en snelheid van informatieverwerking. 
Ernstige progressie verhoogde het risico op dementie en depressieve symptomen, wat bij 
een deel van de ouderen werd verklaard door een doorgemaakte beroerte. 
In hoofdstuk 5 worden de belangrijkste bevindingen van de in dit  proefschrift beschre-
ven onderzoeken samengevat en wordt aandacht besteed aan een aantal methodologische 
en conceptuele kwesties. Tot slot worden  suggesties gedaan voor verder onderzoek.                   
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Dit proefschrift is het resultaat van drie en een half jaar onderzoek aan de afdeling Epidemi-
ologie & Biostatistiek van het Erasmus MC. Gedurende deze periode hebben veel mensen 
op de een of andere manier aan dit proefschrift bijgedragen. Nu het is voltooid, is het mo-
ment aangebroken om hen te bedanken.
In de eerste plaats wil ik de meer dan duizend deelnemers aan de Rotterdam Scan Studie 
bedanken. Dank ook aan alle huisartsen uit Rotterdam en Zoetermeer die bij onze studie 
betrokken waren, en verder aan de medewerkers van de BAVO RNO groep en Circuit 
Haagrand Parnassia voor hun coöperatie.
Vervolgens gaat mijn dank uit naar mijn promotoren Monique Breteler en Peter Koud-
staal. Monique Breteler bood mij de mogelijkheid binnen haar onderzoeksgroep te promo-
veren en gaf daarmee een beslissende wending aan mijn loopbaan. Onze gedeelde interesse 
voor hersenafwijkingen in relatie tot cognitie en stemming bleek een goede basis voor een 
vruchtbare samenwerking. Met haar recente benoeming als hoogleraar neuro-epidemiolo-
gie krijgt zij nu de erkenning die zij verdient.
Peter Koudstaal wist gedurende mijn promotieperiode een scherpe wetenschappelijke 
blik te combineren met een jaloersmakende efﬁ ciëntie. Naast zijn onmisbare bijdrage aan 
mijn onderzoek heeft hij mij gesteund in mijn ambitie voor een carrière in de klinische neu-
rologie. Ik kijk met genoegen uit naar de komende jaren waarin we onze samenwerking 
zullen continueren.
Ook Bert Hofman ben ik zeer erkentelijk. Als hoofd van de afdeling creëerde hij de voor-
waarden voor het in dit proefschrift beschreven onderzoek. Aan het begin van mijn aanstel-
ling gaf hij mijn project de juiste richting en ook gedurende de rest van mijn promotietijd 
wist hij mij steeds te inspireren.
Een aantal mensen wil ik bedanken voor hun bijdrage aan mijn proefschrift. Jelle Jolles 
maakte het neuropsychologisch onderzoek mogelijk en gaf waardevolle adviezen over de 
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analyse en interpretatie van de neuropsychologische gegevens. Matthijs Oudkerk super-
viseerde het MRI onderzoek. Robert Clarke was verantwoordelijk voor de homocysteine 
bepalingen en gaf waardevol advies bij de studie naar homocysteine en cognitie. Henning 
Tiemeier zijn commentaar en advies waren onmisbaar bij de analyse en interpretatie van 
de depressie-gegevens. Philip Scheltens, Frederik Barkhof en Ilse van Straaten hielpen bij 
het ontwikkelen en evalueren van een methode voor het meten van progressie van witte 
stof afwijkingen op MRI. Theo Stijnen gaf waardevolle adviezen met betrekking tot de data 
analyse. Ewoud van Dijk, Tom den Heijer en Sarah Vermeer speelden een grote rol bij de 
dataverzameling en de organisatie van de Rotterdam Scan Studie en voorzagen de manus-
cripten van waardevol commentaar. Bess Leroy las de manuscripten kritisch door op het 
gebruik van het Engels. Ingrid van Vuuren, Frank-Erik de Leeuw, Jan Cees de Groot, Frank 
van Rooij, Henri Vrooman en Rik Stokking speelden een belangrijke rol bij het verzamelen 
en of beheren van de gegevens van de Rotterdam Scan Studie.
Mijn dank gaat verder uit naar alle collega’s van de afdeling Epidemiologie & Biostatis-
tiek. Met name bedank ik Marti von Stein, Petra van Rikxoort en Marjolijn Kasi voor de 
uitstekende secretariële ondersteuning, en Nano Suwarno, Eric Neeleman, René Molhoek, 
René Vermeeren en Marcel Rond voor hun behulpzaamheid bij alle automatiseringsproble-
men. Mijn collega’s Ewoud van Dijk en Anna Schut namen de afgelopen jaren een bijzon-
dere plaats in. De zeer nauwe samenwerking met Ewoud groeide uit tot een vriendschap. 
Anna gaf mijn verblijf op de afdeling glans.
Tot slot bedank ik mijn ouders voor het onbegrensde vertrouwen dat zij altijd in mij 
hebben gesteld, en mijn zus Anna voor haar liefde en steun tijdens het schrijven van dit 
proefschrift.
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